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Abstract FimH 
 
Urinary tract infection (UTI) is one of the most common infections, with millions of people 
affected every year. Besides women, who bear a risk of 40 - 50% to experience at least one 
symptomatic UTI episode during a life-time, patients with diabetes, spinal cord injuries, and 
suppressed immune system are particularly at risk. Without treatment UTI may lead to 
bladder infection (cystitis) and, in a later infection state, to kidney infection (pyelonephritis). 
The initial and most fundamental step in the pathogenesis of UTIs is the type 1 pili-dependent 
adhesion of uropathogenic Escherichia coli (UPEC) to α-mannoside-containing glycoprotein 
receptors on the surface of uroepithelial cells, such as uroplakin Ia (UPIa). The bacterial 
adhesion is mediated by the lectin FimH, localized at the tip of type 1 pili, which recognizes 
mono- and oligomannosides. The adhesion triggers the bacterial cell invasion, resulting in the 
development of an infection. FimH antagonists such as α-D-mannopyranosides have been 
shown to interfere with the attachment of UPEC to their host cells, thus providing a novel 
therapeutic opportunity for the treatment and prevention of UTIs as an alternative to antibiotic 
treatment. 
A potent FimH antagonist has to fulfill several requirements to also achieve a high in vivo 
efficacy. Besides a high affinity for FimH (KD), slow off-rates and irreversibility of the 
antagonist-FimH interaction are beneficial for the in vivo efficacy, as prolonged occupancy of 
the target by the drug results in an extended duration of the pharmacological effect. 
Furthermore, target selectivity of FimH antagonists is a pivotal concern, since the reported 
FimH antagonists are α-D-mannopyranosides and therefore are potential ligands for mannose 
receptors of the human host system. Non-selective interactions of FimH antagonists with the 
various mannose receptors would have a profound impact on physiological processes and 
could cause severe side effects.  
This thesis adresses some major issues in the development and biological evaluation of FimH 
antagonists: 
- Development of a cell-based competition assay for the determination of IC50 values of 
FimH antagonists using flow cytometry. 
- Determination of kinetic properties and KD values of FimH antagonists by surface 
plasmon resonance. 
- Investigation of the selectivity of FimH antagonists towards human mannose binding 
receptors. 	
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FimH Introduction 
Microbial lectins 
Glycoconjugates on mammalian cell surfaces are often exploited as receptors for cell 
adhesion by pathogenic microorganisms, leading to tissue invasion and colonization.  This 
first and crucial step of an infection can either be mediated by bacterial adhesins or by viral 
hemagglutinins, which specifically bind to surface receptors on epithelial cells [1, 2]. Most 
adhesins are lectins that recognize complex carbohydrate structures located on membrane 
receptors such as glycoproteins, glycolipids, or proteoglycans [2]. Hemagglutinin from the 
influenza A virus was the first microbial lectin to be discovered in the 1950s [3, 4]. The name 
hemagglutinin derives from its ability to aggregate red blood cells, which it shares with many 
other microbial lectins. 
Bacterial lectins commonly form oligomers that assemble in filamentous, fiber-like, 
organelles, called fimbriae or pili, such as type 1 fimbriae [5, 6], P fimbriae [7, 8] and F17 
fimbriae [9, 10], which are important for Escherichia coli infections. The terminal subunit of 
each fimbriae functions as carbohydrate recognition domain (CRD), which recognizes distinct 
carbohydrate structures (subunit FimH on type 1 fimbriae [11], PapG on P-fimbriae [12], and 
F17G on F17 fimbriae [13]). The ligand specificity of these fimbrial lectins determines the 
tissue tropism of the microorganism. P-fimbriae favorably bind to galabiose (Galα1-4Galβ)-
structures, expressed in the upper part of the kidney [14], whereas type 1 fimbriae prefer high-
mannose containing glycoconjugates that are highly abundant on urothelial bladder cells [15, 
16]. The receptor interaction triggers signal transduction pathways in the host cells, which are 
often crucial for the host invasion and infection. Type 1 fimbriae bind to uroplakin protein 
complexes on the bladder urothelium, and thereby trigger the cytoskeletal reorganization that 
is critical for the internalization of the microorganism, as well as the activation of apoptosis 
cascades within the urothelial cells [17, 18].   
 
Type 1 fimbriae and urinary tract infections 
Type 1 fimbriae are abundantly expressed on invasive uropathogenic E.coli (UPECs), which 
are the etiological agent in more than 80% of the reported cases of urinary tract infections 
[19-21]. The lectin FimH being located on the tip of each pilus, allows the bacteria to adhere 
to oligomannosides of the glycoprotein uroplakin Ia (UPIa) on uroepithelial cells [15, 16]. 
This initial adhesion is the most crucial step during the entire infection process. It prevents the 
FimH Introduction 
	
   5	
  
rapid clearance of E. coli from the urinary tract by the bulk flow of urine and, at the same 
time, enables the invasion of the host cells [22, 23]. This finally leads to a urinary tract 
infection (UTI), one of the most common infections, with millions of people affected every 
year. Particularly affected beside women, who bear a 40 - 50% risk to experience at least one 
symptomatic UTI episode during a life-time [20], are patients with diabetes, spinal cord 
injuries, and suppressed immune system [24, 25]. An untreated UTI can lead to a bladder 
infection (cystitis) and in a later infection stage to kidney infection (pyelonephritis) [21], both 
serious infections. The adherence of UPEC to the urothelium activates the innate immune 
defense, triggering the exfoliation of infected bladder cells, the influx of neutrophils, and 
other inflammatory responses [18]. Nevertheless, UPEC can evade innate host defense 
mechanisms and invade deeper into the tissue. There they can adopt a quiescent state by 
forming intracellular bacterial communities (IBCs), in which the bacteria are well protected 
from exogenous influences and therefore are thought to be the cause for the high incidence of 
recurrence of UTIs [18] (Figure 1). Antibiotic treatment does not always eradicate UPEC, 
resulting in the emergence of microbial resistance [26]. Therefore, over 50% of all patients 
experience a relapse of the infection within 6 months [19, 21]. 
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Figure 1. Infection cycle of uropathogenic Escherichia coli (UPEC), taken from [27]. UPECs bind to 
urothelial bladder cells via type 1 pili. They invade the host cells, replicate, and form biofilm-like 
intracellular bacterial communities (IBCs). Protected from immune responses and antibiotic treatment 
UPECs can persist for months in this quiescent state. Bacteria can re-emerge from IBCs and can form 
long fibers of not divided cells, which facilitate the easy infection of neighboring cells. Furthermore, 
UPECs can penetrate deeper into the bladder tissue and infect the underlying cells.  
 
Assembly and expression of type 1 fimbriae 
Type 1 fimbriae are 1-3 µm long, filamentous organelles [5, 6]. These helical rods with a 
diameter of 7 nm consist of thousands of FimA subunits, forming the pili rod, followed by the 
subunits FimF, FimG, and FimH, forming the tip of the fimbrium. The adhesin FimH, which 
is located at the distal end of the linear fimbrium, contains the mannose-specific carbohydrate 
recognition domain (FimH-CRD) [11, 28, 29].  
Type 1 pili assembly takes place in the periplasmic space mediated by the chaperone/usher 
pathway [30] (Figure 2). This pathway is a conserved bacterial secretion system that is also 
used for the assembling of other fimbriae, e.g. for P fimbriae [31]. For the pilus biogenesis, 
the periplasmic chaperone FimC and the outer membrane assembly platform, the subunit 
FimD (termed the usher), are required [32]. FimD catalyzes the polymerization of the 
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subunits and provides the channel for the translocation of the assembled pili across the outer 
membrane. FimC guarantees the proper intracellular folding of the monomeric pili subunits 
and their delivery to the FimD platform. The subunits share similar structures, possessing an 
imperfect immunoglobulin (Ig)-like fold with one C-terminal β-strand missing. The 
periplasmic chaperone FimC interacts with each subunit by providing the missing β-strand to 
complete their Ig-like fold. Delivered to the FimD usher, an N-terminal extension strand (15-
20 bp) of the incoming subunit replaces the FimC donor strand of the previously incorporated 
subunit [33]. This donor-strand complementation mechanism accounts for the strong and 
kinetically stable intermolecular interactions between the subunits and therefore for the 
remarkable stability of type 1 pili [34, 35]. 
 
 
Figure 2. Schematic representation of the chaperone/usher pathway, taken from [35]. The fibrillum 
rod is composed of thousands of FimA subunits forming the pilus rod and the fibrillum tip consists of 
the subunits FimF, FimG, and the adhesin FimH. The chaperone FimC binds intracellular to each 
subunit, catalyzing folding of the subunits and delivery to the assembly platform FimD (usher) in the 
outer membrane. There, the donor β-strand of the previously incorporated subunit of the growing pilus 
replaces the donor strand of FimC. 
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The expression of type 1 pili is phase variable and switches between fimbriated and non-
fimbriated states in individual cells. The genes for type 1 fimbriae are organized on a fim gene 
cluster as depicted in Figure 3. 
 
Figure 3. Organization of the fim gene cluster. The cluster encode for the pili subunits FimA, FimF, 
FimF, and FimH, for the chaperone FimC, the assembly platform FimD (the usher) and for the 
recombinases FimB and FimE. The invertible element in the promoter region is located upstream of 
the fimA gene.  
 
The phase variation is under the control of an invertible promoter region (314 bp), which is 
located upstream of the fimA gene and promotes the transcription of the fimA, fimC, fimF, 
fimG, and fimH genes. Depending on the orientation of this promoter element, the pili 
expression of individual bacteria can either be in the on-phase, resulting in protein 
transcription or in the off-phase, where the transcription of the fim gene cluster is silenced 
[36, 37]. The inversion is regulated by the two recombinases FimB and FimE, which are 
encoded upstream of the invertible element within the fim gene cluster. It was shown that 
FimB promotes the switch in both directions (on-to-off and off-to-on), whereas FimE 
predominantly promotes the on-to-off switch [38, 39]. Several factors such as growth 
conditions [37, 40] (pH, osmolarity, temperature, shaking/static incubation) and the infection 
state [41, 42] influence the activity of the recombinases, though the underlying mechanism is 
not fully understood. However, it was shown that there is a cross talk between different 
adhesin gene clusters. For example, the activated P fimbriae gene switches the fim gene to 
phase-off orientation, thus preventing simultaneous type 1 pili expression. Expression of P 
fimbriae allows UPECs to ascent and infect the upper part of the urinary tract, the kidneys, 
resulting in a pyelonephritis. These results implicate a mutually exclusive expression of the 
two types of pili, depending on the infection status. This regulatory mechanism seems to be 
crucial for the survival and pathogenicity of the bacteria under changing environmental 
conditions [41].  
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FimH topology and catch bond behavior 
To date, six crystal structures of FimH are accessible [29, 43-47] (Figure 4). FimH is a 30 
kDa protein and consists in contrast to all other pili subunits of two immunoglobulin-like 
domains, the N-terminal lectin domain and the C-terminal pilin domain. The pilin domain 
connects FimH with the following FimG protein and is homologous to the other pili subunits. 
The lectin domain contains two β-sheets, one large and continuous, the other smaller and 
split. The mannose-binding site is located at the distal end of the β-sandwich, opposite to the 
region where the lectin domain is connected with the pilin domain.  
The ligand binding site is a deep pocket that is negatively charged (Figure 5). FimH selects 
the α-configuration around the free reducing anomeric oxygen of D-mannose. Hydrophilic 
side chains of the amino acids lining the binding pocket establish a perfect network of 
hydrogen bonds with the hydroxyl groups of an α-D-mannopyranoside. The hydroxyl groups 
of D-mannose interact with residues Phe1, Asn46, Asp47, Asp54, Gln133, Asn135, Asp140, 
and Phe142 via hydrogen bonds and hydrophobic interactions. In addition, the entrance of the 
binding pocket is formed by three hydrophobic amino acids (Tyr48, Ile52 and Tyr137), which 
form the so called “tyrosine gate” [28, 46]. 
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Figure 4. FimH lectin domain structure in the high-affinity (left side, PDB entry 1KLF) and low-
affinity (right side, PDB entry 3jwn) conformation. In the high-affinity state the lectin domain is 
elongated with a narrow mannose-binding site. In the low-affinity state the lectin domain interacts 
with the pilin domain at the interdomain region with the insertion-, swing-, and linker-loop. These 
interdomain interactions lead to a twist in the β-sandwich fold of the lectin domain, which results in an 
opening of the distal mannose-binding site [47] (modeled by Adam Zalewski, IMP, University of 
Basel).  
 
 
Figure 5. FimH mannose-binding site in complex with methyl-α-D-mannopyranoside (left, PDB entry 
1KLF) and the interacting protein residues with n-heptyl-α-D-mannopyranoside (left). The hydroxyl 
groups of D-mannose interact with residues Phe1, Asn46 (not depicted), Asp47, Asp54, Gln133, 
FimH Introduction 
	
   11	
  
Asn135, Asp140, and Phe142 (not depicted) via hydrogen bonds and hydrophobic interactions. Tyr48, 
Ile52 and Tyr137 form the tyrosine gate at the entrance of the binding site (modeled by Adam 
Zalewski, IMP, University of Basel). 
 
FimH mediates shear-dependent binding to mannosylated surfaces, facilitated via force-
enhanced allosteric catch bonds [48, 49]. The physiological function of catch bonds seems to 
be to facilitate sustained adhesion under flow conditions, as they are found in the urinary 
tract. FimH can adopt two conformational states, a low and a high affinity state. Recently, the 
crystal structure of the low affinity FimH conformation was resolved [47] (Figure 4). In the 
low-affinity state the pilin and the lectin domain of FimH interact with each other via several 
loops of the lectin domain, which are called insertion-, swing-, and linker- loop. These 
interdomain interactions trigger a twist in the β-sandwich fold of the lectin domain, resulting 
in an opening of the distal mannose-binding site. In the active high-affinity state, the lectin 
and pilin domain are separated and thus do not interact, which leads to an untwist of the pilin 
domain and a tightening of the mannose binding pocket [47]. Since the low-affinity 
conformation is stabilized by intramolecular interactions, this mechanism is also called 
allosteric autoinhibition. Applying a tensile force across the bond can induce the switch from 
the low-affinity state to the high-affinity state. This force-induced switch and enhanced 
affinity to a ligand are characteristic for catch bonds. For catch bonds, the lifetime of a bond 
becomes longer when a tensile force is applied, in contrast to slip bonds, where the lifetime is 
reduced under enhanced shear force (Figure 6). The catch bond behavior of FimH was 
demonstrated in flow chamber assays [50] and atomic force microscopy experiments (AFM) 
[51]. In AFM experiments, using purified fimbrial tips, most bonds broke up at low force 
(<60 pN of rupture force), whereas all bonds survived when higher forces (140–180 pN of 
rupture force) were applied [51].  
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Figure 6. Bond-lifetime profile of catch- and slip-bond. For catch bonds, the lifetime of a bond 
becomes longer when a tensile force is applied across this bond. In normal slip bonds the lifetime is 
reduced under enhanced shear force.  
 
Further studies showed that external factors, which keep the domains apart, force FimH into 
the high affinity conformation. This can be the complexation with the chaperone FimC, which 
wedges the two domains apart, or binding of an antibody to the interdomain region [50, 51]. 
Consequently, the isolated lectin domain exhibits the high-affinity state. Additionally, it was 
shown that the binding to a ligand and the tightening of the binding pocket around the ligand, 
transiently induced a switch from the twisted low-affinity to the untwisted high-affinity 
conformation [47].  
 
FimH variants 
Various FimH mutant strains are found in nature. Although the mutations reside outside of the 
highly conserved mannose-binding site, they often lead to an enhanced mannose binding 
affinity [52, 53]. It is presumed that these mutations disrupt the interdomain interaction, thus 
shifting the equilibrium from the low-affinity to a high-affinity state [50]. In a wide study, 
Tchesnokova et al. showed that FimH possesses a ligand induced binding site (LIBS) in the 
interdomain region, which is constitutively exposed in FimH mutant variants with a disrupted 
interdomain interaction [54]. An exposed LIBS epitope, measured by the binding of a specific 
antibody to the LIBS epitope, correlates with a high-affinity for mannose. These results 
proved the allosteric link between the high affinity state of the mannose-binding site and the 
FimH Introduction 
	
   13	
  
open conformation of the interdomain region. Aprikian et al. investigated several FimH point 
mutations by comparing the binding strength of the LIBS antibody [50]. The study showed 
that most of the naturally occurring point mutations, such as the S62A and the A27V, weaken 
the interaction between the lectin and the pilin domain, resulting in higher mannose affinities. 
These mutant FimH variants evolved under positive selection, benefiting from augmented 
mannose binding affinity even under the static conditions, as they are found in the upper 
urinary tract [55]. Nevertheless, it is presumed that the allosteric catch-bond behavior still has 
its physiological advantages, such as better transmission potency and resistance to soluble 
inhibitors like the Tamm-Horsfall protein, found in the urine [56-58].  
 
FimH antagonists and assay methods 
Due to increasing antibiotic resistance, efforts are made to identify novel, inexpensive, and 
orally available therapeutics, which inhibit bacterial adhesion with a low potential for 
generating resistance. FimH antagonists, such as α-D-mannopyranosides, were shown to 
interfere with the attachment of UPEC to their host cells, thus providing a novel therapeutic 
opportunity for the treatment and prevention of UTIs as an alternative to antibiotic treatment 
[59-61].  
For the evaluation of FimH antagonists, several in vitro assays have been reported. Most of 
them measure the effect of antagonists on the hemagglutination of erythrocytes [62-64] or the 
aggregation of yeast cells in the presence of UPECs [65-67]. In addition, FimH antagonists 
were evaluated with an ELISA-based assay [67, 68] and with bacterial adhesion assays using 
GFP tagged bacteria [69], radiolabeled mannose [44] or radiolabeled bacteria [70]. The 
inhibition of the binding of purified type 1 fimbriae to human granulocytes was investigated 
utilizing the flow cytometry technology [71]. In surface plasmon resonance (SPR) 
experiments, the binding of FimH to an anti-FimH blocking antibody, covalently linked to the 
sensor chip, enabled the determination of the affinity of antagonists [44]. Depending on the 
applied assay format, the reported inhibitory potencies can be different, for example IC50 
values of D-mannose and methyl α-D-mannopyranoside can vary between millimolar [62, 66] 
and micromolar values [44, 71]. These discrepancies can have various origins. As already 
discussed, FimH can adopt two different conformational states. FimH mediates weak binding 
at low shear stress, but shifts to strong binding at high shear [72]. The isolated CRD, which is 
often used in target-based assays, always adopts the high-affinity state and therefore mediates 
strong binding to mannose even under static conditions [50]. In cell-based assays FimH is in 
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its native conformation, which is usually the low affinity conformation when no shear force is 
applied. Furthermore, the choice of the E.coli strain can have a strong effect on the outcome 
of an assay, since strains with various FimH mutations and different binding properties exist 
[52].  
Mannose, methyl-α-D-mannopyranoside and mannan were the first ligands discovered in the 
70s, which inhibited yeast aggregation [73]. In the following years several reports on 
mannose oligosaccharides and multivalent mannose dendrimers with nanomolar affinities 
have been published [62, 65]. Additionally, mannosides with an aromatic aglycon, such as p-
nitrophenyl α-D-mannopyranoside (p-NPMan, 2) and derivatives thereof exhibited increased 
inhibitory potencies [66]. Nowadays, these findings can be rationalized based on crystal 
structures, such as the structure of the FimH/FimC complex, which was resolved in 1999 [29]. 
It was shown that aromatic aglycons interact with the so called “tyrosine gate” via π-π 
stacking interactions with Tyr48 and Tyr137 at the entrance of the mannose-binding site. This 
binding mode is termed the “in-mode binding”. Since then, three main FimH antagonist 
families have been described, alkyl α-D-mannosides [44], α-D-mannosides with aromatic 
aglycon [46], and α-D-mannosides with extended aromatic aglycons [46]. Bouckaert and co-
workers showed that the affinity of alkyl α-D-mannosides increases with the length of the 
aglycon alkyl chain [44]. Among these inhibitors n-heptyl α-D-mannopyranoside (1) 
exhibited the best affinity, showing a KD of 5 nM in SPR assays. In the group of α-D-
mannosides with an aromatic aglycon, it was shown that introduction of substituents in the 
ortho position of the aromatic ring (3) is superior to meta or para position [66, 68]. The third 
group, mannosides with extended aromatic aglycons, comprises the biphenyl substituted 
compounds with various ring substitutions [46, 74], and p-NPMan compounds substituted 
with a squaric acid moiety [68]. Extending p-NPMan with a phenyl group increased the 
inhibitory potency of the antagonists by a factor of 16 (4) [46]. Furthermore, the m-nitro 
substituted biphenyl compounds (5) exceeded the inhibitory potency of p-NPMan by a factor 
of 62. They displayed nanomolar affinities in target-based assays and micromolar affinities in 
cellular yeast disaggregation assays [46, 75].  
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Figure 7. Known alkyl 1 [44] and aryl 2-9 [46, 74] α-D-mannopyranoside FimH antagonists.  
 
Recently, an unexpected binding mode of a biphenyl-substituted compound (7) was observed 
in a published crystal structure [46] (Figure 8). The X-ray structure revealed that the biphenyl 
aglycon was not located within the tyrosine gate, but exclusively formed π-π interactions with 
the Tyr 48 and additional electrostatic interactions with the Arg 98/Glu 50 salt-bridge at the 
outer side of the CRD. This new binding mode is termed the “out-binding mode”.  
 
Figure 8. FimH mannose-binding site in complex with n-butyl α-D-mannopyranoside in the in-
binding mode (left, PDB entry ITR7), and in complex with the biphenyl derivative (7) in the out-
binding mode (right, PDB entry 3MCY) [46] (modeled by Adam Zalewski, IMP, University of Basel). 
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Up to now, the squaric acid derivative (6) is the best monomeric antagonist with a 223-fold 
higher binding affinity than pNPMan (2), as determined in an ELISA based assay [68].  
Furthermore, in vivo mouse infection studies were performed, where the antagonists were 
directly instilled into the bladder concomitantly with uropathogenic E. coli. Methyl α-D-
mannopyranoside [45, 75, 76] and n-heptyl α-D-mannopyranoside [45] exhibited a 
considerable potential to reduce bacterial infections.  
For the development of an orally available drug, good pharmacokinetic properties of FimH 
antagonists are a prerequisite. In regard to enhance the oral availability, an ester prodrug 
approach was explored in a UTI mouse model [74]. The ester (8) was expected to facilitate 
high intestinal absorption, since it increases the lipophilicity of the compounds. Ester 
hydrolysis, resulting in compound (9) by carboxyl esterases, expressed in enterocytes of the 
small intestine and liver, would restore the hydrophilicity and thus renal elimination of the 
compounds. In this approach, an orally available, low molecular weight FimH antagonist was 
identified with the potential to reduce the colony forming units (CFU) in the bladder by 4 
orders of magnitude. These results confirmed the great potential for the effective treatment of 
urinary tract infections with orally available anti-infectives. 
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ABSTRACT: Mannose-based FimH antagonists are consid-
ered new therapeutics for the treatment of urinary tract
infections (UTIs). They prevent the adhesion of uropatho-
genic Escherichia coli (UPEC) to urothelial cell surfaces
triggered by the lectin FimH, which is located at the tip of
bacterial type 1 pili. Because all reported FimH antagonists are
α-D-mannosides, they are also potential ligands of mannose
receptors of the human host system. We therefore investigated
the selectivity range of five FimH antagonists belonging to
different compound families by comparing their affinities for FimH and eight human mannose receptors. On the basis of the
detected selectivity range of approximately 5 orders of magnitude, no adverse side effects resulting from nonselective binding to
the human receptors have to be expected. FimH antagonists can therefore be further considered as potential therapeutics for the
treatment of UTI.
■ INTRODUCTION
Urinary tract infections (UTIs) are primarily caused by
uropathogenic Escherichia coli (UPEC) (70−95% of cases)
expressing type 1 pili.1 At the tip of these pili, the lectin FimH
is located. It enables the bacteria to adhere to oligomannosides
of the glycoprotein uroplakin Ia (UPIa), which is located on
uroepithelial cells.2 This initial adhesion is a prerequisite for the
infection to take place, because it prevents the rapid clearance
of E. coli from the urinary tract by the bulk flow of urine and at
the same time enables the invasion of the host cells.2a,b FimH
antagonists, such as α-D-mannopyranosides, have been shown
to interfere with the attachment of UPEC to their host cells,
thus providing a novel therapeutic opportunity for prevention
and treatment of UTIs as an alternative to antibiotics.3 To date,
several FimH antagonists have been investigated in vitro.4
Furthermore, in vivo studies with methyl α-D-mannopyranosi-
de,5a n-heptyl α-D-mannopyranoside (1, Figure 1),5b,d biphenyl
α-D-mannopyranosides such as 2 and 3,5c−f and indolinylphenyl
α-D-mannopyranosides like 55g exhibited a considerable
potential to reduce bacterial infections.
Target selectivity is of great concern in drug development
and should be evaluated in the early stages of preclinical
development.6 Because all reported FimH antagonists are α-D-
mannopyranosides and therefore also potential ligands for
mannose receptors of the human host system, target selectivity
of these FimH antagonists is a pivotal concern. Although
various antagonists were already tested in vivo,5 their target
selectivity was not verified so far. Mammalian mannose
receptors are present on many tissues throughout the whole
body and are involved in numerous biological processes, such
as cell−cell adhesion7 and serum glycoprotein homeostasis.8
They also intervene in the innate and the adaptive immune
response by recognizing molecular patterns on pathogens.7,9
Consequently, nonselective interactions of FimH antagonists
with these various mannose receptors would have a profound
impact on these processes and could cause severe side effects. A
high selectivity of FimH antagonists is therefore of importance
for a clinical application and should be evaluated in the early
stages of preclinical development.
The majority of human mannose-binding lectins belong to
the group of pathogen-recognition receptors (PRRs). Most
PRRs are members of the C-type lectin superfamily.10 They are
either secreted as soluble plasma proteins or expressed as
membrane-bound proteins on the surface of cells of the
immune system such as macrophages, dendritic cells, or
Langerhans cells. Secreted PRRs, such as the mannose binding
protein (MBL)11 and the lung surfactant protein D (SP-D),12
bind to pathogens and simultaneously associate with cell
surface receptors, triggering signaling pathways such as the
lectin complement activation pathway, which results in
enhanced phagocytosis of the pathogens as well as activation
of the host defense system.13 MBL and SP-D belong to the
collectin family and share a similar collagen-like domain
connected to the C-terminal C-type lectin domain, which
contains the carbohydrate recognition domain (CRD). They
consist of homotrimers, which oligomerize with 2−6 other
trimers, forming high molecular weight complexes.14 Trans-
membrane PRRs, which are classified into type I and type II C-
type lectins, are also involved in the phagocytosis of pathogens,
leading to their elimination or their processing for antigen
presentation.15 The type I C-type lectins such as the
macrophage mannose receptor (MMR)9 contain multiple
CRDs within a single polypeptide backbone. In contrast, the
type II C-type lectins such as langerin,16 DC-specific ICAM-3-
grabbing nonintegrin (DC-SIGN),17 DC-specific ICAM-3-
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grabbing nonintegrin related (DC-SIGNR),18 dectin-2,19 and
dendritic cell lectin (DLEC)20 exhibit only a single CRD.
However, by formation of homomultimers, type II C-type
lectins can greatly enhance their binding affinity. This was
shown for the trimeric langerin21 and tetrameric DC-SIGN and
DC-SIGNR.19 The multimeric arrangement of the CRDs
further supports the discrimination between innate and
extrinsic carbohydrate epitopes.22
For defense mechanisms against a broad range of micro-
organisms, human mannose-binding receptors require highly
specific binding. Thus, MMR exhibits a preference for branched
sugars with terminal D-mannose, L-fucose, or N-acetyl-D-
glucosamine moieties that are specifically expressed on
mycobacteria and fungi.9a Dectin-2 selectively binds to high
mannose structures predominantly expressed on the surfaces of
yeast and fungi,23 whereas DC-SIGN recognizes high mannose
oligosaccharides and Lewis blood group antigens such as Lewisx
or Lewisa, found on mycobacteria, some viruses (e.g., HIV), and
fungi.18,24
To ensure that FimH antagonists do not cause any adverse
side effects due to nonselective binding to human mannose
receptors, their selectivity profile to eight different PRRs was
established. Nonselective binding may also have a profound
impact on the serum half-life of FimH antagonists, since
binding to PRRs often triggers endocytosis and would result in
their elimination from circulation. To address this selectivity
issue, we tested five mannose-based FimH antagonists with
diverse aglycones (alkyl, biphenyl, squaric acid, and indolinyl-
phenyl derivatives) for their binding affinity to various
mannose-binding lectins (MBL, SP-D, MMR, DC-SIGN, DC-
SIGNR, langerin, dectin-2, and DLEC).
■ RESULTS AND DISCUSSION
With a competitive binding assay,4d five high-affinity FimH
antagonists belonging to different compound families (Figure 1,
1−54d,5d,g) were tested for their selectivity for eight human
mannose receptors.
Synthesis of FimH Antagonists. n-Heptyl α-D-mannopyr-
anoside (1),25 the biphenyl α-D-mannopyranosides 25d and 3,5d
and the indolylphenyl α-D-mannopyranoside 55g were synthe-
sized as previously reported. The synthesis of FimH antagonist
4 (Scheme 1) started from nitrophenyl mannoside 6, which is
easily available from peracetylated D-mannose.4c,26 Because the
reported procedure4c for the hydrogenation to aniline 7 using
palladium on charcoal as a catalyst resulted in a substantial loss
of the chloro substituent, platinum dioxide in the presence of
morpholine was applied.27 The mannosylated ethyl squarate 8
was then obtained in analogy to Sperling et al.4c Finally,
treatment of ester 8 with N-methylpiperazine yielded amide 4
in 90%, which was ready for biological testing.
Binding Assays. The cell-free competitive binding assay4d
is based on the interactions of a biotinylated polyacrylamide
(PAA) glycopolymer [Manα1−3(Manα1−6)Manβ1−
4GlcNAcβ1−4GlcNAcβ-PAA, TM-PAA] with the mannose
receptors. Complexation of the biotinylated glycopolymer with
streptavidin coupled to horseradish peroxidase allows for the
quantification of the binding potencies of the tested FimH
antagonists.
For our selectivity study, two parameters, the protein
concentration and the TM-PAA concentration, were optimized
to obtain comparable optical densities (ODs) for the different
lectins in the competitive binding assay (Figure 2 and Table 1).
Because of distinctive coating properties of the proteins,
different protein concentrations (2.5−20 μg/mL) were
Figure 1. FimH antagonists tested for their selectivities for various human mannose-binding lectins: n-heptyl α-D-mannopyranoside (1),4d biphenyl
α-D-mannopyranoside derivatives 2 and 3,5d squaric acid derivative 4, and indolylphenyl derivative 5.5g IC50 values for FimH were obtained by a
competitive binding assay.4d
Scheme 1a
aReagents and conditions: (a) H2 (1 atm), cat. PtO2, morpholine,
MeOH, 45 min. (b) Diethyl squarate, MeOH, 1 day, 61% (2 steps).4c
(c) N-Methylpiperazine, DIPEA, MeOH, 18 h, 90%.
Journal of Medicinal Chemistry Article
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necessary to obtain comparable levels of immobilization. The
TM-PAA concentration in turn required adaptation due to
different affinities of the various lectins. Because of the
multivalent oligosaccharide presentation, the affinity of the
polymer is expected to be higher than the affinity of the
corresponding free oligosaccharide. We therefore used low TM-
PAA concentrations between 0.5 and 5 μg/mL, which
correspond to 16−160 μM TM-PAA assuming a molecular
mass of approximately 30 kDa. As a representative example, the
results of this optimization process for the lectin SP-D are
summarized in Figure 2. Briefly, when 5 μg/mL SP-D was used
for the immobilization step, an OD415nm of approximately 2 was
obtained with 5 μg/mL TM-PAA. The protein and polymer
concentrations leading to comparable ODs for the other
investigated lectins are summarized in Table 1.
For the competitive binding assays, concentrations of 1 mM
antagonists and 50 mM D-mannose (positive control) were
used. The results are summarized in Figure 3. The ODs
obtained in the absence of an antagonist were set to 100% TM-
PAA binding, the background in the absence of the polymer to
0% TM-PAA binding. D-Mannose showed a strong inhibition of
binding for all proteins at a concentration of 50 mM (more
than 90% inhibition). As expected, at a concentration of 1 mM,
the antagonists 1−5 strongly inhibited binding of the polymer
to FimH, whereas none of the antagonists showed relevant
inhibition potencies for the tested human lectins. The highest
inhibition of TM-PAA binding was observed for the antagonists
3 (54%) and 5 (58%) to MMR, for compound 3 (63%) to
langerin, and for compound 2 (50%) to DLEC (indicated by
asterisks, Figure 3). On the basis of their ODs, the IC50 value
(concentration at 50% inhibition) of these antagonists can be
estimated to be in the order of 1 mM. As compared to the low
nanomolar FimH affinities of the five investigated antagonists
(Figure 1), the affinities for the human lectins are at least 5
orders of magnitude lower, indicating an excellent selectivity
margin for a therapeutic application of these FimH antagonists.
Infection studies in a mouse disease model, using compounds
1−3, were previously reported.5d In these studies, a high dose
of 50 mg/kg was applied, resulting in a substantial reduction of
the bacterial infection caused by UPEC UTI89 [reduction of
the colony-forming units (CFU) in the urine by 2 orders of
magnitude and in the bladder by 4 orders of magnitude].
Furthermore, the in vivo pharmacokinetic parameters were
determined, including the maximal plasma concentrations
(Cmax) of the FimH antagonists after iv application. Maximal
concentrations of 39 μg/mL for 1, 35 μg/mL for 2, and 39 μg/
mL for 3 were detected in blood samples, which correspond to
Cmax values of 144, 80, and 97 μM, respectively. Low binding to
mammalian mannose receptors is expected even at these
concentrations, since the IC50 values of the antagonists 1−3 for
the eight tested human mannose receptors are approximately
10-fold higher than the detected maximal blood concentrations
in treated mice. Furthermore, with improved antagonists like
indolylphenyl derivative 5,5g the dose of 50 mg/kg could be
reduced to 1 mg/kg, thus additionally increasing the selectivity
margin.
Binding affinities of various human mannose receptors to
monosaccharides, such as D-mannose, L-fucose, and D-galactose,
have already been characterized in previous studies. Mono-
valent sugars showed only weak binding affinities in the
millimolar range toward DC-SIGN,18 DC-SIGNR,28 dectin-2,23
langerin,21 or MMR.29 The functional affinity to carbohydrates
necessary for pathogen capturing is predominantly an effect of
avidity, caused by the combined strength of multiple
interactions with ligands. The presentation of multivalent
carbohydrates on the pathogen surface and the multimerization
and/or clustering of the receptors on the host cells greatly
support binding between the interaction partners. Therefore,
multivalent presentations of α-D-mannosidic antagonists4a,30
might be prone to cause severe side effects due to strong
binding to human mannose receptors.
■ CONCLUSION
On the basis of the presented data, adverse side effects resulting
from nonselective binding of monovalent FimH antagonists to
the investigated mannose-binding lectins are not considered to
be a critical issue for their potential therapeutic application to
treat UTI. Although this selection does not cover the entire
mammalian mannose-binding proteins, it represents the most
abundant and best-characterized receptors expressed in various
tissues. The 105-fold lower affinity for the tested human
receptors as compared to the bacterial FimH lectin confirms a
high selectivity safety range. This primarily results from the fact
that the investigated FimH antagonists were optimized by
introducing hydrophobic substituents at their reducing end,
enabling the interaction with the tyrosine gate, the entrance to
the ligand-binding site, which is a unique feature of FimH.31
Furthermore, because of the importance of multivalent ligand
presentation in nature, monovalent α-D-mannopyranosides in
general can be considered to exhibit only low affinities to
human mannose receptors.
■ EXPERIMENTAL SECTION
General Methods. Commercially available reagents were
purchased from Sigma-Aldrich or Acros. Methanol (MeOH) was
Figure 2. Assay development and optimization on the example of the
human lectin SP-D. Different concentrations of coated SP-D (1−10
μg/mL) in combination with various TM-PAA concentrations (0.5−5
μg/mL) were tested.
Table 1. Optimized Protein and TM-PAA Concentrations
Used in the Competition Assays for Each Individual Lectin
μg/mL
protein [protein] [TM-PAA] OD415 nm
FimH 20 0.25 2.20
MBP 10 5 1.82
SP-D 5 5 1.88
MMR 5 2 2.03
langerin 10 2 2.12
dectin-2 10 5 1.92
DLEC 10 5 1.93
DC-SIGN 2.5 1 2.15
DC-SIGNR 10 5 2.10
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dried by distillation from sodium methoxide. Optical rotation was
measured at 20 °C on a Perkin-Elmer 341 polarimeter. Nuclear
magnetic resonance (NMR) spectra were obtained on a Bruker
Avance 500 UltraShield spectrometer at 500.13 MHz (1H) or 125.76
MHz (13C). Chemical shifts are given in ppm and were calibrated on
residual solvent peaks. Assignment of the 1H and 13C NMR spectra
was achieved using 2D methods (COSY and HSQC). Electron spray
ionization mass spectra (ESI-MS) were recorded on a Waters
micromass ZQ instrument. High-resolution mass spectra (HR-MS)
were obtained on an ESI Bruker Daltonics micrOTOF spectrometer
equipped with a TOF hexapole detector. Reactions were monitored by
TLC using glass plates coated with silica gel 60 F254 and visualized by
Figure 3. Selectivity profile of FimH antagonists 1−5. Competitive binding assays with FimH, MBP, SP-D, MMR, langerin, dectin-2, DLEC, DC-
SIGN, and DC-SIGNR to evaluate the selectivity of compounds 1−5. Inhibitory capacities of the compounds were tested at a concentration of 1
mM. D-Mannose (Man) served as a positive control (50 mM). The binding signals of TM-PAA to the proteins in absence of antagonists were set to
100%, and background signals were set to 0%. Asterisks indicate inhibition of TM-PAA binding by 50% or more. The assays were performed in
triplicate.
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using UV light and/or by charring with a molybdate solution (a 0.02
M solution of ammonium cerium sulfate dihydrate and ammonium
molybdate tetrahydrate in aqueous 10% H2SO4) with heating to 150
°C for 5 min. MPLC separations were carried out on a CombiFlash Rf
from Teledyne Isco equipped with RP-18 reversed-phase flash
columns. LC-MS separations were done on a Waters system equipped
with a Waters SunFire C18 OBD (5 μm, 19 mm × 150 mm) column,
sample manager 2767, pump 2525, PDA 2525, and micromass ZQ
mass spectrometer.
Compound Purity. The test compounds 1−3 and 5 were purified
by reversed-phase chromatography (RP-18 column, gradient of MeOH
in H2O, compound 1−35d,25) or chromatography on silica (DCM/
MeOH/H2O, compound 5
5g) followed by Bio-Gel P2 (exclusion limit
1800 Da, Bio-Rad Laboratories) size exclusion chromatography
(elution with water containing up to 20% MeOH at 0.25 mL/min)
prior to HPLC, HR-MS, NMR, and activity testing. Compound 4 was
purified by preparative LC-MS (Waters SunFire C18 OBD column,
H2O/MeCN + 0.2% HCO2H). The purity of all test compounds was
determined by NMR and HPLC to be ≥95% [method A (compounds
2, 3, and 5): Beckman Coulter Gold, consisting of pump 126, DAD
168 (190−410 nm), and autosampler 508; column, Waters Atlantis T3
(3 μm, 2.1 mm × 100 mm); A, H2O + 0.1% TFA; B, MeCN + 0.1%
TFA; detection, 254 or 270 nm; gradient, 5% B → 95% B (22 min);
and flow rate, 0.5 mL/min. Method B (compounds 1 and 4): Agilent
1100/1200 with UV detector (190−410 nm) and ELSD; column,
Waters Atlantis T3 (3 μm, 2.1 mm × 100 mm); A, H2O + 0.1% TFA;
B, H2O/MeCN (90:10) + 0.1% TFA; gradient, 5% B (1 min), 5% B→
70% B (15 min), 70% B (1 min), 70% B → 5% B (3 min); flow rate,
0.5 mL/min; and detection, 254 nm or ELSD]. For the 1H NMR
spectrum and HPLC trace of compound 4, see the Supporting
Information.
4-Amino-2-chlorophenyl α-D-Mannopyranoside (7). A sus-
pension of 64c,26 (430 mg, 1.28 mmol), morpholine (30 μL), and PtO2
(50 mg) in MeOH (20 mL) was hydrogenated (1 atm H2) for 45 min.
Then, the mixture was filtered and concentrated in vacuo to give crude
7 (443 mg) as a colorless oil, which contained approximately 15%
morpholine and was used in the next step without further purification.
1H NMR (500 MHz, CD3OD): δ 3.71−3.81 (m, 3H, H-4, H-5, H-6a),
3.83 (dd, J = 1.7, 12.7 Hz, 1H, H-6b), 3.95 (dd, J = 3.4, 9.1 Hz, 1H, H-
3), 4.11 (dd, J = 1.8, 3.4 Hz, 1H, H-2), 5.27 (d, J = 1.7 Hz, 1H, H-1),
6.61 (dd, J = 2.7, 8.7 Hz, 1H, C6H3), 6.78 (d, J = 2.7 Hz, 1H, C6H3),
7.09 (d, J = 8.7 Hz, 1H, C6H3).
13C NMR (125 MHz, CD3OD): δ 62.6
(C-6), 68.4 (C-4), 71.9 (C-2), 72.3 (C-3), 75.7 (C-5), 102.1 (C-1),
115.7, 117.4, 121.2, 153.2 (6C, C6H3). ESI-MS: m/z calcd for
C12H17ClNO6 [M + H]
+, 306.1; found, 306.0.
2-Chloro-4-[(2-ethoxy-3,4-dioxocyclobuten-1-yl)amino]-
phenyl α-D-Mannopyranoside (8).4c To a solution of 7 (443 mg)
in MeOH (15 mL) was added diethyl squarate (379 μL, 2.56 mmol)
under argon, and the reaction mixture was stirred at rt for 1 d. Then,
the solvent was removed in vacuo, and the residue was purified by
MPLC on RP-18 (H2O/MeOH) to yield 8 (337 mg, 61% from 6) as a
yellow solid. 1H NMR (500 MHz, CD3OD): δ 1.47 (t, J = 7.1 Hz, 3H,
OCH2CH3), 3.66 (dt, J = 3.7, 9.9 Hz, 1H, H-5), 3.75 (d, J = 3.7 Hz,
2H, H-6), 3.79 (t, J = 9.8 Hz, 1H, H-4), 4.00 (dd, J = 3.4, 9.6 Hz, 1H,
H-3), 4.16 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 4.81 (q, J = 7.1 Hz, 2H,
OCH2CH3), 5.56 (d, J = 1.5 Hz, 1H, H-1), 7.23 (m, 1H, C6H3), 7.32
(d, J = 9.0 Hz, 1H, C6H3), 7.47 (s, 1H, C6H3).
13C NMR (125 MHz,
CD3OD): δ 15.7 (OCH2CH3), 61.4 (C-6), 67.2 (C-4), 70.8 (C-2),
71.4 (C-3), 71.6 (OCH2CH3), 74.9 (C-5), 100.0 (C-1), 119.2, 120.2,
122.4, 124.7, 134.6, 152.5 (C6H3), 168.9, 176.2 (CC), 183.3, 186.9
(2 CO). ESI-MS: m/z calcd for C18H21ClNO9 [M + H]
+, 430.1;
found, 430.1.
2-Chloro-4-[(2-(4-methylpiperazin-1-yl)-3,4-dioxocyclobut-
en-1-yl)amino]phenyl α-D-Mannopyranoside (4). Compound 8
(72.5 mg, 0.169 mmol) was dissolved in MeOH (7.5 mL) at 50 °C.
After it was cooled to rt, N-methylpiperazine (28.0 μL, 0.252 mmol)
and diisopropyl-ethylamine (DIPEA) (145 μL) were added, and the
reaction mixture was stirred for 18 h at rt. Then, the solvent was
removed in vacuo, and the residue was purified by LC-MS (RP-18,
H2O/MeCN + 0.2% HCO2H) to give 4 (73.9 mg, 90%) as a white
powder after a final lyophilization from H2O/dioxane. [α]D +74.5 (c
1.00, MeOH). 1H NMR (500 MHz, CD3OD): δ 2.47 (s, 3H, NCH3),
2.76 (m, 4H, 2 CH2), 3.66 (ddd, J = 2.1, 5.6, 9.8 Hz, 1H, H-5), 3.71
(dd, J = 5.6, 11.8 Hz, 2H, H-6a), 3.74 (t, J = 9.7 Hz, 1H, H-4), 3.79
(dd, J = 2.1, 11.8 Hz, 2H, H-6b), 3.88 (m, 4H, 2 CH2), 3.96 (dd, J =
3.4, 9.4 Hz, 1H, H-3), 4.09 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 5.48 (d, J =
1.4 Hz, 1H, H-1), 7.15 (dd, J = 2.7, 8.9 Hz, 1H, C6H3), 7.33 (d, J = 8.9
Hz, 1H, C6H3), 7.35 (d, J = 2.7 Hz, 1H, C6H3).
13C NMR (125 MHz,
CD3OD): δ 45.4 (NCH3), 47.4 (2C, 2 CH2), 55.0 (2C, 2 CH2), 62.7
(C-6), 68.2 (C-4), 71.8 (C-2), 72.3 (C-3), 76.0 (C-5), 101.2 (C-1),
119.0, 121.6, 123.8, 125.0, 135.1, 150.2 (C6H3), 164.9, 169.2 (CC),
183.3, 185.9 (2 CO). HR-MS: m/z calcd for C21H26ClN2NaO8 [M +
Na]+, 506.1306; found, 506.1303.
Expression and Purification of DC-SIGN CRD-Fc and DC-
SIGNR CRD-Fc. Plasmids containing the full-length cDNA of DC-
SIGN and DC-SIGNR were kindly provided by Daniel A. Mitchell,
Clinical Sciences Research Institute, Warwick Medical School
(Coventry, United Kingdom). Standard molecular techniques32 were
used for the cloning of the CRD of DC-SIGN (DC-SIGN CRD; aa
residues 250−404, GenBank accession no. M98457) and DC-SIGNR
(DC-SIGNR CRD; aa residue 262−398, GenBank accession no.
Q9H2x3). The DC-SIGN/DC-SIGNR CRD encoding inserts were
amplified by PCR using primers containing the restriction sites EcoRI
and NcoI, respectively. The insert was ligated into the corresponding
cloning site of the pFUSE-hIgG2-Fc2 expression vector (Invivogen,
Toulouse, France). The constructs were amplified in chemocompetent
DH5α E. coli (Novagen, Lucerne, Switzerland), and their correctness
was confirmed by DNA sequencing.
CHO-K1 cells (American Type Culture Collection No. CCL-61)
were cultivated in Ham's Nutrient Mixture F-12 supplemented with 2
mM L-glutamate (Invitrogen, Paisley, United Kingdom), 10% fetal calf
serum (FCS, Invitrogen), 100 U/mL penicillin, and 100 μg/mL
streptomycin (both Sigma-Aldrich, Basel, Switzerland). The CHO-K1
cells were transfected with the DC-SIGN CRD or DC-SIGNR CRD
expression vector using the FuGENE HD transfection reagent (Roche
Applied Science, Rotkreuz, Switzerland). Stably transfected CHO-K1
cells were selected by treatment with Zeocin (0.5 μg/mL, Invitrogen),
and single clones were obtained by limiting dilution. For protein
production, the cells were cultivated as described above, and the
culture medium containing the secreted DC-SIGN CRD-Fc and DC-
SIGN CRD-Fc chimera was harvested weekly. Purification of the
recombinant protein was achieved by applying conditioned medium
on a protein A-sepharose column (BioVision, Mountain View, CA)
attached to a fast protein liquid chromatography apparatus [BioLogic
(FPLC) system, BioRad, Reinach BL, Switzerland], with loading buffer
I [20 mM Tris/HCl, pH 7.6, 150 mM NaCl, and 0.05% (v/v) Tween-
20]. The protein was eluted with elution buffer I (0.5 M acetic acid/
ammonium acetate, pH 3.4). The collected protein was further
purified on a L-fucose-sepharose column (prepared in house) using
loading buffer II (20 mM Tris/HCl, pH 7.8, 0.5 M NaCl, and 25 mM
CaCl2) and elution buffer II (20 mM Tris/HCl, pH 7.8, 0.5 M NaCl,
and 2 mM EDTA). For long-term storage, the protein was stored at
−80 °C.
FimH, Human Langerin, DLEC, SP-D, Mannose Binding
Protein (MBP), Dectin-2, and MMR. The FimH CRD linked with a
thrombin cleavage site to a 6His-tag (FimH-CRD-Th-6His) was
expressed in E. coli strain HM125 and purified by affinity
chromatography as described in Rabbani et al.4d Human langerin,
DLEC, SP-D, MBP, dectin-2, and MMR were purchased from R&D
systems (Minneapolis, MN).
Competitive Binding Assay. Biotinylated trimannose (TM)-PAA
polymer (20 μL, 1 mg/mL, Lectinity, Moscow) was mixed with 80 μL
of assay buffer (20 mM HEPES, 150 mM NaCl, and 10 mM CaCl2,
pH 7.4), 20 μL of FCS, and 80 μL of streptavidin−horseradish
peroxidase conjugate (500 U/mL, Roche, Mannheim, Germany) and
incubated for 2 h at 37 °C. The complex was stable for several weeks
when stored at 4 °C.
For assay development FimH, DC-SIGN, DC-SIGNR, MBP,
langerin, DLEC, SP-D, dectin-2, and MMR were each diluted in
assay buffer (20 mM HEPES, pH 7.4, 150 mM NaCl, and 10 mM
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CaCl2) at concentrations of 1, 3, 5, and 10 μg/mL and were coated on
microtiter plates (F96 MaxiSorp, Nunc, Langenselbold, Germany)
with 100 μL/well overnight at 4 °C. The coating solution was
discarded, and the wells were blocked with 200 μL/well of a 3% bovine
serum albumin (BSA) solution in assay buffer for 2 h at 4 °C. After
three washing steps with assay buffer, the streptavidin−peroxidase-
coupled TM-PAA polymer (0.5−5 μg/mL) in assay buffer (50 μL/
well) was added to the wells. The plates were incubated for 3 h at 25
°C and 350 rpm and then washed four times with assay buffer. After
the addition of 100 μL/well of 2,2′-azino-bis-(3-ethylbenzthiazoline-6-
sulfonic acid) (ABTS) substrate (Invitrogen), the colorimetric reaction
was allowed to develop for 4 min and then stopped by adding 100 μL/
well of 2% aqueous oxalic acid. The OD was measured at 415 nm on a
microplate reader (Spectramax 190, Molecular Devices, CA).
For measuring the binding properties of FimH antagonists to the
mannose binding receptors, a mix (total volume 100 μL/well) of the
test compounds 1−5 (final concentration 1 mM) or α-D-mannose
(final concentration 50 mM) and the streptavidin−peroxidase-coupled
TM-PAA polymer in assay buffer (final concentration see Table 1) was
added to the protein-coated wells and developed as described above.
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Urinary tract infections (UTIs) are among the most prevalent 
infections and affect millions of people each year. In 70 - 95% of 
all cases, UTI is caused by uropathogenic Escherichia coli 
(UPEC).[1] These bacteria express type 1 pili with a terminally 
located adhesive protein called FimH. FimH-mediated adhesion 
to the surface of urothelial cells by binding to oligomannoside 
residues of the glycoprotein uroplakin Ia (UPIa)[2-5] is a 
prerequisite for the invasion of the host cells leading to UTI.[2,3] 
Therefore, efforts are made to identify orally available FimH 
antagonists to interfere with the attachment of UPEC to urothelial 
cells. From these studies α-D-mannopyranosides have emerged 
providing a novel therapeutic opportunity for prevention and 
treatment of UTI as an alternative to antibiotics.[6-8] To date, 
several mannose-based FimH antagonists have been validated in 
various in vitro and in in vivo studies.[9-20]  
 
As part of their pharmacodynamic characterization, not only 
equilibrium dissociation constants (KD) or half-maximal inhibitory 
concentrations (IC50) but also the kinetics of the binding process 
are studied.[21-23] One crucial factor for a sustained in vivo efficacy 
is the half-life (t1/2) of the drug-receptor complex, especially when 
drugs compete with endogenous ligands. 
The t1/2 of a drug-receptor complex depends on the 
dissociation rate (koff). Slow off-rates are beneficial for the in vivo 
efficacy, as prolonged occupancy of the target by the drug results 
in an extended duration of the pharmacological effect. 
Consequently, lower drug concentrations are required to obtain 
high efficacy, reducing the risk of off-target toxicity.[21-23] The 
importance of long target occupancy is reflected in the long half-
lives of many drugs reaching the market, such as the HIV-1 
protease inhibitor Darunavir (t1/2 > 240 h),[24] the CCR5 receptor 
antagonist Maraviroc (t1/2 = 10.5 h),[25] or the viral neuraminidase 
inhibitor Zanamivir, which was developed from a carbohydrate-
based lead structure (t1/2 > 33 min).[26] 
For carbohydrate-lectin interactions, only a few studies 
describing the kinetic properties are available. For the lectins 
myelin-associated glycoprotein (MAG),[27,28] E-, L- and P-
selectin,[29-31] galectin-1 and -3,[32] mannose-binding protein 
(MBP),[33] concanavalin A (ConA)[34] and calreticulin[35] surface 
plasmon resonance (SPR) experiments revealed fast association 
and dissociation kinetics with koff rates between 2.6 x 10-3 and > 
10 s-1, resulting in short half-lives ranging from 266 to 0.07 
seconds (Table 1). This fast binding kinetics typical for 
carbohydrate-lectin interactions strongly hamper the development 
of carbohydrate derived drugs. The determination of the kinetic 
parameters of FimH antagonists is therefore of utmost importance 
for a successful lead optimization. 
Table 1. Typical kinetic binding parameters of carbohydrate-protein 
interactions. 
Protein Ligand KD 
[µM] 
kon 
[M-1/s-1] 
koff 
[s-1] 
t1/2 
[s] 
Ref. 
L-selectin GlyCAM1 108 >105 >10 0.07 [30] 
E-selectin ESL 1 62 4 x 104 3.0 0.2 [29] 
P-selectin PSGL 1 0.3 4 x 106 1.4 0.5 [31] 
GSLA-2 mAB sialyl Lewisa 4.3 1.1 x 105 8 x 10-1 0.9 [36] 
Myelin-asso-
ciated glyco-
protein (MAG) 
D-Neu5Ac 
derivative  2.8 3.5 x 10
5 0.8 x 10-1 0.9 [27] 
Galectin-1 
D-Lactose 
derivative 1010 1.9 x 10
2 2.1 x 10-1 3.3 [32] 
Galectin-3 
D-Lactose 
derivative 280 7.3 x 10
2 2.0 x 10-1 3.4 [32] 
CG-1A (avian 
galectin) 
D-Lactose 
derivative 83.5 2.5 x 10
3 2.1 x 10-1 3.3 [32] 
Calreticulin 
Glc1Man9-
GlcNAc2 
2 3.9 x 104 8 x 10-2 8.6 [35] 
Concana- 
valin A 
D-Man 
derivative  65 1.43 x 10
2 9.4 x 10-3 73.7 [34] 
Mannose-
binding protein 
(MBP) 
D-Man16/ 
BSA 13.3 3.47 x 10
4 2.6 x 10-3 266.6 [33] 
Beside KD values, dissociation rates (koff) of the complex of 
FimH-antagonist with the target protein FimH are of special 
interest. To study these parameters, SPR is widely applied, 
including for carbohydrate-lectin[37] and carbohydrate-antibody[36] 
interactions. For the lectin domain of FimH different affinity states 
are known.[38] In this study, the lectin domain in the high-affinity 
state was used.[39] Immobilization attempts by standard amine 
coupling failed, presumably due to accessible amino groups in 
and close to the ligand-binding site. Thus, the N-terminal 
phenylalanine is part of the binding site. Immobilization via a C-
terminal His-tag onto a Ni-NTA chip or indirect coupling via an 
anti-His-tag antibody failed due to instability of the base line, 
resulting from a slow detachment of the non-covalently 
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immobilized FimH. Furthermore, harsh regenerating conditions 
(50 mM NaOH), necessary for the dissociation of the antagonist-
lectin complex, caused the inactivation of the protein. 
Consequently, we immobilized FimH antagonists functionalized 
with an amino- (1 & 2, Scheme 1) or N-hydroxy-succinimide (3a,b, 
Scheme 1) via an amine-coupling procedure on CM4 dextran 
sensor surface chips. 
OAcO
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OAc
OAc
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N
NO2
4[19]
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Scheme 1. Synthesis of the amino- or N-hydroxyl-succinimide functionalized 
FimH antagonists 1, 2, 3a and 3b. a) H2 (1 atm), PtO2, morpholine, 
EtOAc/MeOH (1:1) (97%); b) 8-(Fmoc-amino)-3,6-dioxa-octanoic acid, PyBOP, 
DIPEA, DMF, rt; c) NaOMe, MeOH, rt (47% over two steps); d) EBE, COMU, 
DIPEA, DMF, 0 °C to rt (20%); e) EDC, NHS, H2O, rt (3a: 98%); f) EDC, NHS, 
MES buffer (pH 5.6), rt (3b: 99%). 
Direct binding assay - Kinetics of FimH antagonists. To 
determine the kinetic parameters of the FimH-antagonist 
interaction, FimH was passed at concentrations between 0-200 
nM over the flow cells (CM4 chip) equipped with covalently linked 
antagonists (Figure 1a). A reference cell without antagonist but 
treated with NHS/EDC and ethanolamine (EA) was used to 
account for nonspecific binding of the protein to the dextran 
matrix. 
The kinetic parameters kon and koff were obtained by applying 
a global fit to the sensorgrams, using a 1:1 (Langmuir-type) 
binding-model (Scrubber 2.0c). The fitted sensorgrams of 
compounds 1, 2, 3a and 3b are shown in Figure 1b. 
 
Figure 1. a) Schematic representation of a direct binding assay format. FimH 
binds to 1, 2, 3a and 3b, which are immobilized on the chip. b) Sensorgrams 
obtained by kinetic fits of FimH binding to the immobilized antagonists 1, 2, 3a 
and 3b. FimH concentrations between 0-200 nM were passed over the surface. 
For the fitting of the sensorgrams Scrubber 2.0c was applied. 
Mass transfer limitations, which might occur when using 
proteins as analytes (MW of FimH: 18.6 kD), can falsify the 
measured kinetic parameters. They depend on the cell dimension, 
the flow rate, and the diffusion coefficient of the analyte. Proteins 
having smaller diffusion coefficients than low molecular weight 
compounds are prone to show mass transfer limitations. To rule 
out these limitations, we used high flow rates (20-30 µL/min) and 
a low surface antagonist density (usage of CM4 chips instead of 
CM5 chips). Furthermore, we immobilized antagonist 1 at three 
different immobilization levels (different ratios between 1 and EA 
used for the immobilization) on the same sensor chip. FimH was 
screened simultaneously on all three surfaces and the kinetic 
parameters and affinities were evaluated. Since all three surfaces 
showed similar kinetic rates and affinities, mass transfer effects 
are negligible. The obtained kinetic parameters are summarized 
in Table 2. 
 
Table 2. Kinetic binding parameters for the interaction of FimH with 
antagonists 1, 2 and 3a,b. 
Antagonist Molar ratio 
Ligand : EA[a] 
KD 
[nM] 
kon 
[104 M-1/s-1] 
koff 
[10-5s-1] 
t1/2 
[h] 
1:0 
(high density) 3.5 1.4 5.2 3.7 
1:10 
(middle density) 2.5 2.0 5.1 3.8 
1 
1:100 
(low density) 2.0 2.6 5.3 3.6 
2 1:0 0.7 4.8 3.5 5.5 
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3a 1:0 2.3 1.1 2.0 9.6 
3b 1:0 n.d.[b] 1.4 
≤ 10-6 
(out of 
limit) 
>19 
[a] EA: ethanolamine [b] n.d.: not determinable due to koff ≤ 10-6 s-1. 
Association rates (kon) between 1.4 x 104 and 4.8 x 104 M-1s-1 
were obtained and are in the expected range for low molecular 
weight compounds. The dissociation rates (koff) were 5.2 x 10-5 s-1 
for 1, 3.5 x 10-5 s-1 for 2, and 2.0 x 10-5 s-1 for 3a. For compound 
3b the detection limit of koff (below 10-6 s-1) was reached and 
consequently the KD value not determinable. The small 
dissociation constants resulted in half-lives between 3.6 h and > 
19 h, representing extraordinary long half-lives for carbohydrate-
lectin interactions, which are usually in the range of seconds (see 
Table 1). Consistent with the long half-lives, the equilibrium state 
of the interactions can only be reached after an extended period 
of time, conditions, which were not applicable to our SPR 
experiments. The affinity (KD) of the antagonists was therefore 
calculated from the kinetic parameters (KD = koff/kon) and not 
determined from steady state measurements. As expected,[12,19] 
affinities in the low nanomolar range (0.7 to 3.5 nM) were 
obtained. Furthermore, the three-fold higher affinity of compound 
2 compared to compound 3a is consistent with published data, 
confirming that a chloro-substituent in ortho-position of the 
aromatic ring adjacent to the anomeric center enhances binding 
affinity to FimH.[12] The off-rate of compound 2 was already close 
to the detection limit of the used method. Compound 3b, which 
differs from 2 only by a shorter linker length, did not reveal 
reliable kinetic data, due to its immeasurable koff value (≤10-6 s-1), 
indicating that the linker length presumably has a small effect on 
the binding affinity. 
FimH can exhibit two conformations, a low-affinity conformation  
and a high-affinity conformation. The switch from the low-affinity 
state to the high-affinity state can be triggered by applying a 
mechanical force along the molecule. This behaviour is 
characteristic for the catch-bond mechanism found for the FimH-
ligand interaction.[38] It enables the bacteria to firmly attach to 
oligomannosides on bladder epithelial cells, even under the harsh 
conditions of the urinary tract (flow of urine). In the high-affinity 
state, the binding site of FimH forms a deep, narrow, and 
negatively charged pocket, unlike mammalian lectins, often 
characterized by shallow and water accessible binding sites (see 
e.g. selectins,[40] galectins,[41] mannose-binding protein[42] or DC-
SIGN[43]). Hydrophilic side chains of the amino acids lining the 
FimH binding pocket, establish a perfect network of hydrogen 
bonds with the hydroxyl groups of α-D-mannopyranosides.[44] 
Consequently, the slow dissociation of the carbohydrate-FimH 
complex found in this study, can be explained by the binding 
mode of FimH ligands to the high-affinity FimH conformation. As 
the pathogenicity of the bacteria depends on the interaction 
between FimH and its physiological ligand on the urothelial 
surface, a long half-life of FimH antagonists is of utmost 
importance for a successful treatment. 
In solution affinity assay – KD values of FimH antagonists. 
Due to the high affinity of FimH antagonists and their small 
dissociation rate, in solution affinity experiments (as described in 
Durka et al.[45) can be applied to determine KD values of 
antagonists. For these experiments we used the CM4 sensor chip 
coated with compound 1 (Chip 1). For an accurate determination 
of KD values, a constant concentration of FimH (10-15 nM) in the 
range of the KD value to prevent stochiometric titration conditions 
was equilibrated with a dilution series of the antagonists 7b-13[46]. 
After equilibration, the unbound FimH, [FimHfree] binds to the 
immobilized antagonist 1 (Figure 2a) and can therefore be 
determined by SPR (Figure 2b) using a calibration curve (Figure 
2c). Finally, [FimHfree] was plotted versus the antagonist 
concentration and the curve was fitted with the in-solution-affinity-
fit-algorithm of the BiaEvaluation software (Figure 2d). The 
obtained KD values are summarized in Table 3. 
 
Figure 2. Results from the in solution affinity assay with n-heptyl α-D-
mannopyranoside 8 (see Table 3, entry 1). a) Schematic representation of the 
in solution affinity assay. FimHfree after equilibration binds to 1, which is 
immobilized on the chip; b) Sensorgrams obtained after passing over the 
equilibrated mixtures of compound 8 and FimH; c) FimH calibration curve (FimH 
0-120 nM) and d) KD determination by in-solution-affinity-fit-algorithm of the 
BiaEvaluation software. 
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Table 3. KD values of FimH antagonists[46] determined by the in solution 
affinity assay.  
Entry 
OHO
HO
OH
OH
R  
KD [nM][a] rKD[b] 
1 O
 
5.21 ± 1.6 1 
2 
O
Cl
O
ONa
 
0.71 ± 0.01 
0.5 ± 0.05[c] 
0.13 
0.10[c] 
3 
O
F
O
ONa
 
1.63 ± 0.9 0.32 
4 
O
OMe
O
ONa
 
1.08 ± 0.18 0.21 
5 
O
Me
O
ONa
 
0.44 ± 0.22 0.09 
6 
O
O
ONa
 
2.19 ± 0.1 0.42 
7 
O
CF 3
O
ONa
 
1.1 ± 0.34 0.21 
[a] Determined on Chip 1 (CM4 chip functionalized with compound 1). [b] 
The relative KDs (rKD) were calculated by dividing the KD of the antagonist of 
interest by the KD of n-heptyl α-D-mannopyranoside (8). [c] Determined on 
Chip 2 (CM4 chip functionalized with compound 2, n = 3.) 
n-Heptyl α-D-mannopyranoside 8 and the biphenyl-
substituted mannose antagonists 7b and 9-13 with different 
substitutions in ortho-position of the aromatic ring adjacent to the 
anomeric position showed affinities in the low nanomolar range, 
which is in good agreement with data obtained from isothermal 
titration calorimetry (ITC).[46] To further validate the assay, we 
additionally tested compound 7b on a chip functionalized with 
compound 2 (Chip 2), and obtained a similar KD value (0.5 vs. 0.7 
nM). Furthermore, the KD value of 7b determined by the in 
solution affinity approach is equal to the KD value of 2 found by 
the direct binding assay (Table 2) (KD = 0.7 nM). Compounds 2 
and 7b share identical structure with the only difference that 2 
was immobilized on the chip via a linker (for the direct binding 
approach) whereas the KD for 7b was determined by the in 
solution affinity assay. The comparable affinities of the two 
approaches confirm that the attachment of a linker and the 
immobilization process do not significantly influence the affinity of 
the antagonist. 
In conclusion, for most medical applications, half-lives (t1/2) of 
the drug/target complex of several tens of minutes or even hours 
are of utmost importance, since long half-lives translate into 
higher in vivo efficacies and reduced adverse side effects 
resulting from off-target toxicity.[21,22] However, carbohydrate-
lectin interactions often exhibit low affinities and fast off-rates, 
properties that hamper the development of carbohydrate-derived 
drugs. Therefore, as part of the preclinical development process 
of FimH antagonists, we examined their kinetic characteristics by 
surface plasmon resonance (SPR). In this study, the lectin 
domain of FimH in the high-affinity state was used. The 
surprisingly small dissociation rates for FimH-antagonist 
complexes resulting in long half-lives in the range of several 
hours (> 3.6 h) are indicators for high in vivo efficacy. This is a 
further indication that the corresponding ester prodrugs not only 
have a beneficial pharmacokinetic profile[46] but also fulfil the 
pharmacodynamic requirement for a therapeutic application, i.e. 
high affinity and long residence time. However, whether the 
investigated high-affinity state of FimH investigated in our study[39] 
is the only pathophysiologically relevant state remains to be 
demonstrated. Therefore, studies with FimH lectin in other affinity 
states are planned. 
Experimental Section 
Synthesis. For synthesis and spectroscopic details of antagonists 1, 
2 and 3a,b see Supporting Information. The synthesis and 
characterization of compounds 9-13 is described in ref.[46] 
FimH-CRD-6His protein expression. The FimH carbohydrate 
recognition domain (CRD) with a thrombin cleavage site linked to a 
6His-tag (FimH-CRD-Th-6His) was expressed in E. coli strain HM125 
and purified by affinity chromatography as described in Rabbani et 
al.[39] 
Surface plasmon resonance (SPR) analysis. The SPR 
measurements were performed on a Biacore 3000 surface plasmon 
resonance based optical biosensor (BiacoreTM, GE Healthcare, 
Uppsala). Sensor chips (CM4), immobilization kits, maintenance 
supply and HBS-P buffer were purchased from GE Healthcare 
(Uppsala). The amino-functionalized monovalent compounds 1 and 2 
were covalently attached to the activated dextrane matrix on CM4 
chips by the standard amine-coupling method (GE Healthcare, 
Uppsala). The surface was activated by N-hydroxysuccinimide (NHS) 
and N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride 
(EDC). To obtain different ligand densities on the chip, compound 1 (1 
mM in borate buffer) was mixed with ethanolamine (EA, 1 M) in 
different molar ratios prior to the coupling process (1:EA ratios: 1:0, 
1:10, and 1:100). Pure compound 2 (1 mM in borate buffer) was 
coupled to the chip. After coupling, the matrix was capped with 
ethanolamine. For the coupling of the N-hydroxy-succinimide-
functionalized compounds 3 and 4 the free carboxyl groups on the 
chip were activated with NHS and EDC and reacted with 1,2-
diaminoethane (0.1 M in borate buffer, pH 8.5) to give free amino 
groups. The next steps were followed as described above. A 
reference cell without immobilized ligand was prepared and the 
system equilibrated with HBS-P buffer (10 mM HEPES, 150 mM NaCl, 
0.005% P20, pH 7.4). The activity of the chips was confirmed by 
FimH binding at a constant concentration of 50 nM in HBS-P buffer. 
All binding experiments were performed at 25 °C at a flow rate of 20 
or 30 µL/min using HBS-P buffer. For kinetic studies a dilution series 
of FimH with concentrations ranging from 0-200 nM in HBS-P buffer 
was used. Contact time was 120 s and the dissociation time 1200 s. 
The surface was regenerated with a single injection of 50 mM NaOH 
for 120 s. Data processing as well as kon, koff, and KD determination 
were accomplished with the Scrubber software (BioLogic Software, 
Version 2.0c, Campbell, Australia). Double referencing (subtraction of 
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reference and blank injection) was applied to correct for bulk effects 
and other systematic artefacts. 
In solution affinity inhibition experiments. FimH (10-15 nM in 
HBS-P buffer) was inhibited with a series of increasing concentrations 
of test compounds (0-1 µM) over night at rt to allow the equilibration 
of the system. The mixtures were run over a sensor surface coated 
with compound 1 and the resonance units (RU) after an association 
time of 110 s were detected. The non-inhibited FimH concentration 
([FimH]free) in the protein-compound mixtures was determined by 
means of a FimH calibration curve using free FimH concentrations 
ranging from 0 to 120 nM. The KD values of the compounds were 
calculated by plotting [FimH]free versus [compound] and fitting the 
curve with the in solution affinity fit. 
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Meike Scharenberg, Xiaohua Jiang, Lijuan Pang, Giulio Navarra, Said Rabbani, Florian Binder, Oliver 
Schwardt, Beat Ernst* 
Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Switzerland 
  
Synthesis and spectroscopic details of antagonists 1, 2 and 3a,b 
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Scheme S1. Synthesis of the amino- or N-hydroxyl-succinimide functionalized FimH antagonists 1, 2, 3a and 3b. a) H2 (1 atm), 
PtO2, morpholine, EtOAc/MeOH (1:1) (97%); b) 8-(Fmoc-amino)-3,6-dioxa-octanoic acid, PyBOP, DIPEA, DMF, rt; c) 
NaOMe, MeOH, rt (47% over two steps); d) EBE, COMU, DIPEA, DMF, 0 °C to rt (20%); e) EDC, NHS, H2O, rt (3a: 98%); 
f) EDC, NHS, MES buffer (pH 5.6), rt (3b: 99%). 
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General methods. NMR spectra were recorded on a Bruker Avance DMX-500 (500 MHz) spectrometer. 
Assignment of 1H and 13C NMR spectra was achieved using 2D methods (COSY, HSQC, TOCSY). 
Chemical shifts are expressed in ppm using residual CHCl3, CHD2OD and HDO as references. Optical 
rotations were measured using Perkin-Elmer Polarimeter 341. Electron spray ionization mass spectra 
(ESI-MS) were obtained on a Waters micromass ZQ. HRMS analysis was carried out using a Bruker 
Daltonics micrOTOF spectrometer equipped with a TOF hexapole detector. Reactions were monitored by 
TLC using glass plates coated with silica gel 60 F254 (Merck) and visualized by using UV light and/or by 
heating to 150 °C for 5 min with a molybdate solution (a 0.02 M solution of ammonium cerium sulfate 
dihydrate and ammonium molybdate tetrahydrate in aqueous 10% H2SO4). Column chromatography was 
performed on a CombiFlash Companion (Teledyne-ISCO, Inc.) using RediSep® normal phase disposable 
flash columns (silica gel). Reversed phase chromatography was performed on LiChroprep®RP-18 (Merck, 
40-63 µm). Commercially available reagents were purchased from Fluka, Aldrich or Acros. Methanol 
(MeOH) was dried by refluxing with sodium methoxide and distilled immediately before use. 
Dichloromethane (DCM) and ethyl acetate (EtOAc) were dried by filtration over Al2O3 (Fluka, type 5016 
A basic). 
 
4-(5-Aminoindolin-1-yl)phenyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside (5). To a solution of 
4[S1] (47.8 mg, 0.08 mmol) in MeOH/EtOAc (1:1, 5 mL) PtO2 (5 mg) and morpholine (10 µL) were added. 
The reaction mixture was stirred at rt under hydrogen (1 atm) for 1 h, then filtrated through a pad of celite 
and the celite was washed thoroughly with EtOAc. The filtrate was concentrated in vacuo to give 5 (44 
mg, 97%) as off-white foam, which was used in the next step without further purification. 
 
2-(2-(2-Fmoc-aminoethoxy)ethoxy)-N-(4-(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyloxy)phenyl)-
indolin-5-yl)-acetamide (6). To a mixture of 5 (45 mg, 0.08 mmol), PyBoP (50 mg, 0.096 mmol) and 8-
(Fmoc-amino)-3,6-dioxa-octanoic acid (39 mg, 0.1 mmol) in dry DMF (1.5 mL) was added DIPEA (32 
µL, 0.19 mmol) at rt. The reaction mixture was stirred at rt overnight, then diluted with EtOAc, and 
washed with water and brine. The organic layer was dried over Na2SO4 and the solvent was removed 
under reduced pressure. The residue was purified by silica gel chromatography (DCM/MeOH 24:1) to 
provide crude 6 as black oil, which contained some DMF. 1H NMR (500 MHz, CDCl3): δ = 2.05, 2.06, 
2.08, 2.21 (4s, 12H, 4 OAc), 3.19 (t, J = 8.4 Hz, 2H, CH2), 3.42 (dd, J = 5.2, 10.4 Hz, 2H, CH2), 3.62 (t, J 
= 5.0 Hz, 2H, CH2), 3.70 (m, 2H, CH2), 3.80 (m, 2H, CH2), 4.08-4.16 (m, 4H, H-5, H-6a, CH2), 4.33 (d, J 
= 7.1 Hz, 2H, CH2), 4.29 (dd, J = 5.2, 12.2 Hz, 1H, H-6b), 5.15 (t, J = 5.3 Hz, 1H, NH), 5.37 (t, J = 10.0 
Hz, 1H, H-4), 5.44 (m, 2H, H-1, H-2), 5.56 (dd, J = 3.0, 10.0 Hz, 1H, H-3), 6.88 (d, J = 8.5 Hz, 1H), 
7.01-7.07 (m, 4H, Ar-H), 7.27 (m, 1H, Ar-H), 7.36 (m, 2H, Ar-H), 7.46 (s, 1H, Ar-H), 7.52 (d, J = 7.0 Hz, 
2H, Ar-H), 7.74 (d, J = 8.0 Hz, 2H, Ar-H), 8.47 (s, 1H, Ar-H); 13C NMR (125 MHz, CDCl3): δ 20.52, 
20.71, 20.89 (4C, 4 OAc), 28.12, 40.74, 47.12, 52.70 (4 CH2), 62.14 (C-6), 65.96 (C-4), 66.72 (CH2), 
68.90 (C-3), 68.99 (C-5), 69.43 (C-2), 70.02, 70.23, 70.61, 71.06 (CH2, CH), 96.35 (C-1), 107.29, 117.44, 
118.47, 119.15, 119.43, 119.93, 124.85, 125.01, 126.99, 127.65, 128.44, 131.83, 139.72, 141.23, 144.82, 
150.04, 156.40 (Ar-C), 167.63, 169.76, 169.97, 170.02, 170.57, 174.43 (6 CO); ESI-MS: m/z: Calcd for 
C28H31N2O12 [M+Na]+: 946.34, found 946.30. 
 
2-(2-(2-Aminoethoxy)ethoxy)-N-(4-(α-D-mannopyranosyloxy)phenyl)-indolin-5-yl)-acetamide (1). 
Crude 6 was dissolved in dry MeOH and treated at rt with 0.5 M NaOMe/MeOH (0.2 mL) until 
completion of the reaction. The reaction mixture was neutralized with Amberlyst-15 (H+) ion-exchange 
resin and filtered. The filtrate was concentrated and the residue was purified by silica gel chromatography 
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(DCM/MeOH/H2O 50:50:6) to afford amine 1 (20 mg, 47% over two steps from 5) as an off-white solid. 
[α]D20 +70.7 (c 0.095, MeOH); 1H NMR (500 MHz, CD3OD): δ = 2.84 (t, J = 5.5 Hz, 2H, CH2), 3.10 (t, J 
= 8.0 Hz, 2H, CH2), 3.59 (t, J = 5.5 Hz, 2H, CH2), 3.67 (m, 3H, H-5, CH2), 3.73 (m, 4H, H-4, H-6a, CH2), 
3.78 (m, 3H, H-6b, CH2), 3.89 (m, 3H, H-3, CH2), 4.01 (dd, J = 2.0, 3.5 Hz, 1H, H-2), 5.41 (d, J = 2.0 Hz, 
1H, H-1), 6.88 (d, J = 8.5 Hz, 1H, Ar-H), 7.12-7.18 (m, 5H, Ar-h), 7.39 (d, J = 1.5 Hz, 1H, Ar-H); 13C 
NMR (125 MHz, CD3OD): δ = 29.09, 41.87, 54.10 (3 CH2), 62.73 (C-6), 68.39 (C-4), 71.28 (C-2), 71.53, 
72.10 (2 CH2), 72.42 (C-3), 73.03 (CH2), 75.33 (C-5), 100.84 (C-1), 108.11, 118.90, 119.96, 120.88, 
121.28, 129.79, 132.90, 140.76, 146.81, 152.86 (Ar-C), 170.56 (CO); ESI-MS: m/z: Calcd for 
C21H20ClNO8 [M+H]+: 534.24, found 534.20. 
 
N-(2-(2-(2-Aminoethoxy)ethoxy)ethyl)-3'-chloro-4'-(α-D-mannopyranosyloxy)-biphenyl-4-
carboxamide (2). COMU was added at 0 °C to a mixture of 7b[S2] (20 mg, 0.05 mmol) and DIPEA (9 µL, 
0.05 mmol) in dry DMF (0.5 mL). The reaction mixture was activated for 5 min, then EBE (14 µL, 0.1 
mmol) and DIPEA (9 µL, 0.05 mmol) were added. The reaction mixture was stirred at 0 °C for 1 h and at 
rt overnight. Water (0.5 mL) was added to the mixture and stirring continued for 5 min. The reaction was 
concentrated under reduced pressure, then the yellow residue was loaded onto a RP-18 chromatography 
column and eluted with MeOH (0 to 100%) in 0.01 N aqueous ammonia to give 2 (5.0 mg, 20%). 1H 
NMR (500 MHz, CD3OD): δ = 3.42-3.68 (m, 16H, H-4, H-5, H-6a, H-6b, 6 CH2), 3.90 (dd, J = 3.4, 9.5 
Hz, 1H, H-3), 4.02 (dd, J = 1.8, 3.4 Hz, 1H, H-2), 5.50 (d, J = 1.6 Hz, 1H, H-1), 7.37 (d, J = 8.7 Hz, 1H, 
Ar-H), 7.49 (dd, J = 2.3, 8.6, Hz, 1H, Ar-H), 7.58-7.63 (m, 3H, Ar-H), 7.76-7.85 (m, 2H, Ar-H); ESI-MS: 
m/z: Calcd for C25H34ClN2O9+[M+H+]: 541.19, found: 541.24. 
 
2,5-Dioxopyrrolidin-1-yl 4'-(α-D-mannopyranosyloxy)-biphenyl-4-carboxylate (3a). Compound 
7a[S2] (3.0 mg, 7.5 mmol) was added to a stirred solution of NHS (4.3 mg, 37 mmol) and EDC (538 mg, 
2.8 mmol) in water (37.5 mL) resulting in the formation of a white precipitate. After stirring for 30 min, 
the reaction mixture was diluted with satd aq. NH4Cl, filtered (syringe filter) and the filter was washed 
with DCM (2 x 3 mL). The product was recovered from the filter by washing with MeOH several times. 
Evaporation of the volatiles under reduced pressure gave the activated acid 3a (3.5 mg, 98%) as a white 
solid. 1H NMR (500 MHz, CD3OD): δ = 2.92 (s, 4H, 2 CH2), 3.61 (ddd, J = 2.7, 5.0, 9.8 Hz, 1H, H-5), 
3.71-3.80 (m, 3H, H-4, H-6a, H-6b), 3.93 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 4.04 (dd, J = 1.8, 3.4 Hz, 1H, H-
2), 5.57 (d, J = 1.6 Hz, 1H, H-1), 7.26 (d, J = 8.8 Hz, 2H, Ar-H), 7.70 (d, J = 8.8 Hz, 2H, Ar-H), 7.83 (d, 
J = 8.5 Hz, 2H, Ar-H), 8.18 (d, J = 8.5 Hz, 2H, Ar-H); 13C NMR (125 MHz, CD3OD): δ = 26.55 (2 CH2), 
62.16 (C-6), 67.69 (C-4), 71.44 (C-2), 72.01 (C-3), 75.00 (C-5), 99.56 (C-1), 117.64, 127.64, 128.95, 
131.17 (Ar-C); ESI-MS: m/z: Calcd for C23H23NNaO10 [M+Na+]: 496.12, found: 496.16 [M+Na+]. 
 
2,5-Dioxopyrrolidin-1-yl 3'-chloro-4'-(α-D-mannopyranosyloxy)-biphenyl-4-carboxylate (3b). NHS 
(160 mg, 1.38 mmol) and EDC (532 mg, 2.77 mmol) were dissolved in 0.1 M MES buffer (pH 5.6, 10 
mL). After stirring for 10 min 7b[S2] (300 mg, 0.693 mmol) was added. The solution became turbid, then 
clear, and then a precipitate started to form. After 20 min the solid was collected by filtration on a 
frittered-glass G4 filter, and washed with satd aq. NH4Cl and DCM. The solid was recovered with MeOH, 
the solvent was evaporated, and the residue dried under high vacuum to yield 3b (350 mg, 99%) as a 
white solid. 1H NMR (500 MHz, CD3OD): δ = 2.94 (s, 4H, 2 CH2), 3.68-3.82 (m, 4H, H-4, H-5, H-6a, H-
6b), 4.03 (dd, J = 3.3, 9.3 Hz, 1H, H-3), 4.15 (dd, J = 1.3, 3.3 Hz, 1H, H-2), 5.66 (d, J = 1.6 Hz, 1H, H-1), 
7.53 (d, J = 10.0 Hz, 1H, Ar-H), 7.68 (dd, J = 10.5 Hz, 1H, Ar-H), 7.83-7.87 (m, 3H, Ar-H), 7.76 (m, 1H, 
Ar-H), 8.21 (m, 1H, Ar-H); 13C NMR (125 MHz, CD3OD): δ = 26.63 (2 CH2), 62.64 (C-6), 68.21 (C-4), 
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71.83 (C-2), 72.41 (C-3), 76.06 (C-5), 100.70 (C-1), 118.61, 128.01, 128.30, 129.96, 132.03 (Ar-C), 
171.88 (CO); ESI-MS: m/z: Calcd for C23H22ClNNaO10 [M+Na+]: 530.09, found: 530.00 [M+Na+]. 
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Introduction
Urinary tract infections (UTIs), the most prevalent series of in-
fectious diseases worldwide, affect millions of people and ac-
count for significant morbidity as well as high medical costs.[1]
The primary cause of UTIs are strains of uropathogenic Escheri-
chia coli (UPEC), which make up 70–95% of reported cases.[1a,2]
UTIs are treated with antibiotics; however, recurrent infections
by UPEC with subsequent antibiotic exposure can lead to the
emergence of antimicrobial resistance.[3]
Adhesion to host cells is the initial step of microbial infec-
tion. To gain an initial foothold within the bladder, UPEC strains
encode filamentous surface-adhesive organelles called type 1
pili (fimbriae).[4] They mediate bacterial attachment to uropla-
kin Ia, a glycoprotein located on urothelial cells. This initial
step prevents the clearance of E. coli by the bulk flow of urine
and facilitates the invasion of host cells.[1b,5] A bacterial lectin
known as FimH is located at the tips of type 1 pili. The carbo-
hydrate recognition domain (CRD) of this lectin is responsible
for binding to the complementary carbohydrate epitope of the
host tissue. Blocking this lectin by a carbohydrate or a glycomi-
metic thereof offers a potential therapeutic approach for pre-
vention and/or treatment of UTIs.[6]
More than two decades ago, Sharon and co-workers ex-
plored various mannosides and oligomannosides as potential
antagonists for type 1 pili-mediated bacterial adhesion and ob-
served interactions in the micro- to millimolar range.[7] The first
crystal structure of FimH was solved in 1999,[8] and since then,
numerous crystallographic studies have been reported, greatly
facilitating the design of high-affinity ligands.[9] In summary,
the reported affinities can be rationalized on the basis of the
structure of FimH: First, the binding pocket accommodates the
mannose with the hydroxy groups forming an extended hy-
drogen bond network. Second, the entrance to the binding
site, referred to as the “tyrosine gate”, is formed by three hy-
drophobic amino acids (Tyr48, Tyr137, and Ile52)[9a] and can
host aliphatic and aromatic aglycones.
As a consequence of hydrophobic contacts of the alkyl agly-
cone, n-heptyl a-d-mannopyranoside (1) exhibits nanomolar
affinity.[9b] With aromatic aglycones such as 2–5 (Figure 1), fur-
ther improvements in affinity were observed.[10] To explore the
binding mode and to improve affinity as well as ADME proper-
ties, a series of biphenyl FimH antagonists were synthesized.
Results and Discussion
An unexpected docking mode was discovered upon co-crystal-
lization of biphenyl mannoside 3 with the FimH CRD.[10d]
Whereas the alkyl aglycone of n-butyl a-d-mannopyranoside[9b]
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[+] These authors contributed equally to this work.
Supporting information for this article is available on the WWW under
http://dx.doi.org/10.1002/cmdc.201200125.
Urinary tract infections (UTIs) are caused primarily by uropa-
thogenic Escherichia coli (UPEC), which encode filamentous sur-
face-adhesive organelles called type 1 pili. FimH is located at
the tips of these pili. The initial attachment of UPEC to host
cells is mediated by the interaction of the carbohydrate recog-
nition domain (CRD) of FimH with oligomannosides on urothe-
lial cells. Blocking these lectins with carbohydrates or ana-
logues thereof prevents bacterial adhesion to host cells and
therefore offers a potential therapeutic approach for preven-
tion and/or treatment of UTIs. Although numerous FimH an-
tagonists have been developed so far, few of them meet the
requirement for clinical application due to poor pharmacoki-
netics. Additionally, the binding mode of an antagonist to the
CRD of FimH can switch from an in-docking mode to an out-
docking mode, depending on the structure of the antagonist.
In this communication, biphenyl a-d-mannosides were modi-
fied to improve their binding affinity, to explore their binding
mode, and to optimize their pharmacokinetic properties. The
inhibitory potential of the FimH antagonists was measured in
a cell-free competitive binding assay, a cell-based flow cytome-
try assay, and by isothermal titration calorimetry. Furthermore,
pharmacokinetic properties such as logD, solubility, and mem-
brane permeation were analyzed. As a result, a structure–activi-
ty and structure–property relationships were established for
a series of biphenyl a-d-mannosides.
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interacts with both Tyr48 and Tyr137 of the tyrosine gate (in-
docking mode),[10f] the biphenyl aglycone adopts the out-dock-
ing mode; that is, it interacts only with Tyr48 (Figure 2A), prob-
ably due to insufficient flexibility; p–p stacking of the outer ar-
omatic ring of the biphenyl aglycone (ring B) with Tyr48 is ef-
fected by induced fit : a substantial move of Tyr48. Moreover,
further stabilization of the protein–ligand complex by polar in-
teraction between the ester in the meta position of 3 and the
side chain of Arg98 was proposed.[10d]
In silico docking studies with biphenyl derivative 4a[10e] sug-
gested a similar out-docking mode (Figure 2B). A close inspec-
tion revealed empty space between the ortho position of the
aromatic ring adjacent to the anomeric center (ring A) and the
protein surface. Indeed, with an ortho-chloro substituent (!
5a, Figure 1), affinity was substantially improved. Further stud-
ies with FimH antagonists that exhibit enhanced flexibility
(e.g. , compound 6; Figure 2C and Figure 3) indicated a switch
from the out-docking mode to the in-docking mode. However,
whether an optimal p–p stacking within the tyrosine gate can
be realized remains to be determined. Finally, docking studies
also indicated that elongation of the carboxylate-bearing para
substituent enables a polar interaction between the carboxyl-
ate and Arg98 (e.g. , compound 7; Figure 2D and Figure 3).
Starting from antagonist 4, we explored three types of
modifications (Figure 3):
1) For optimizing the van der Waals contact between the
ortho position of ring A and the binding pocket, a series of
substituents — F, CH3, CF3, OCH3, cyclopropyl, and CN —
were introduced as depicted in Scheme 1.
2) To determine whether the out-docking mode reported for
3[10d] results from insufficient flexibility, we increased the
aglycone flexibility by introducing a methylene spacer be-
tween the anomeric oxygen and ring A of the biphenyl
moiety (Scheme 2). This should decrease the conformation-
al constraints to allow an optimized spatial arrangement of
the aglycone in the tyrosine gate (!6, Figure 2C); at the
same time, water solubility
should be improved as
a result of the decreased
stacking tendency derived
from disruption of the sym-
metry of the aglycone.[15]
3) To enable a polar interaction
between the carboxylate
substituent on ring B with
Arg98 of FimH, we extended
the para substituent of 4,
that is, we replaced it with
either a flexible methyl etha-
nolate or a rigid methyl cy-
clopropanecarboxylate
(Scheme 3). Biphenyl a-d-
mannoside 24[10d] shows
a three- to eightfold lower af-
finity for FimH than its coun-
terparts with a methoxycar-
bonyl substituent at the
meta (!3)[10d] or para posi-
tions (!4)[10e] of ring B
(Table 1). Han et al. assigned
the increased affinity of com-
pound 3 to a polar interac-
tion of the ester with Arg98
of FimH.[10d] Because for spa-
tial reasons the ester in the
Figure 1. FimH antagonists : n-heptyl a-d-mannopyranoside (1) is used as
reference compound; the squaric acid derivative 2 and biphenyl derivatives
3–5 exhibit nanomolar affinities.
Figure 2. A) Crystal structure of biphenyl 3 (PDB ID: 3MCY)[10d] bound to the FimH CRD. B–D) In silico docking
studies obtained with flexible docking (Glide software package)[11] to the same FimH CRD structure; top-scored
binding mode of B) 4a, C) 6, and D) 7.
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para-substituted derivative 4 cannot establish a similar in-
teraction with Arg98, the substantial improvement in affini-
ty may result from solvation effects.
Synthesis
Optimization of ortho substituents (Scheme 1)
Mannosylation of phenols 9a–f with mannosyl fluoride 8 and
BF3·OEt2 as promoter yielded a-mannosides 10a–f stereospe-
cifically.[12] Whereas the phenols 9a–d and 9 f are commercially
available, the cyclopropyl derivative 9e was prepared via
tandem carbolithiation/1,3-elimination according to Ocasio
and Scanlan.[13] In a palladium-catalyzed Miyaura–Suzuki cou-
pling[14] of 10a–f with 4-methoxycarbonylphenylboronic acid
(11), biphenyls 12a–f were obtained in good to excellent
yields. Deacetylation using Zempl!n conditions (!13a–f) fol-
lowed by saponification of the methyl esters gave the test
compounds 14a–e. Owing to the instability of the cyano
group under aqueous basic conditions, 14 f was synthesized
by coupling 10 f with 4-carboxyphenylboronic acid pinacol
ester (15) followed by transesterification under Zempl!n condi-
tions to avoid the final saponification with aqueous sodium hy-
droxide.
Increase in aglycone flexibility (Scheme 2)
Benzyl alcohols 16a–c were first mannosylated with donor 8[12]
to yield the benzyl mannosides 17a–c. Subsequent cross-cou-
pling with 4-methoxycarbonylphenylboronic acid (11) afforded
acetates 18a,b and 21. Deacetylation of the mannose moiety
(!19a,b and 22) followed by
saponification of the methyl
esters gave compounds 6, 20,
and 23.
Elongation of the carboxylate-
bearing para substituent
(Scheme 3)
Peracetylated mannose 25 was
treated with 4-iodophenol in the
presence of BF3·Et2O. The result-
ing iodide 26 was transformed
into boronic acid pinacol ester
27, which was coupled with 4-
bromophenylacetic acid methyl
ester (28) and 4-bromophenylcy-
clopropylcarboxylic acid methyl
ester (32) under Miyaura–Suzuki
coupling conditions[14] to yield
biphenyls 29 and 33. Deacetyla-
tion with sodium methoxide (!
30 and 34) followed by saponification of the methyl ester
yielded the sodium salts 31 and 35.
Figure 3. Modifications to the aglycone of FimH antagonists by 1) optimization of the ortho substituent, 2) an in-
crease in the flexibility of the aglycone, and 3) elongation of the carboxylate-bearing para substituent.
Scheme 1. Reagents and conditions: a) BF3·Et2O, CH2Cl2, 0 8C, 3 h (10a–f, 73-
86%); b) Pd(Cl2)dppf·CH2Cl2, K3PO4, DMF, 80 8C, overnight (12a–f, 55–91%);
c) NaOMe, MeOH, RT, 4 h (13a–e, 14 f, 52–73%); d) 1. 0.2n NaOH(aq), MeOH,
RT, overnight; 2. Dowex (Na+), size-exclusion chromatography (P-2 gel)
(14a–e, 15–74%).
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Binding affinity and activity
The biphenyl a-d-mannosides with varying ortho substituents
(5a–b, 13a–f, 14a–f), increased aglycone flexibility (6, 19, 20,
22, 23), and elongated carboxylate-bearing para substituents
(30, 31, 34, 35) were evaluated in vitro by two competitive
assay formats (Table 1). All antagonists were tested in a cell-
free competitive binding assay.[16] Subsequently, the best candi-
dates were investigated in a cell-based flow cytometry assay.[17]
The cell-free competitive binding assay is based on the inter-
action of a biotinylated polyacrylamide glycopolymer as com-
petitor with the isolated CRD of FimH. In contrast, the cell-
based flow cytometry assay involves the infection of human
urinary bladder epithelial carcinoma cells with GFP-labeled
UPECs expressing the complete type 1 pili (see the Experimen-
tal Section below for details). The competitors in the former
assay are thus polymer-bound trimannosides, whereas in the
latter the antagonists compete with more potent high-man-
nose oligosaccharides present on uroplakin Ia, which is located
on the surface of human urinary bladder cells.[18,19] The interac-
tion is further affected by the presence of high- and low-affini-
ty states of the CRD of FimH. Aprikian et al. experimentally
demonstrated that in full-length fimbriae, the pilin domain sta-
bilizes the CRD domain in the low-affinity state, whereas the
CRD domain alone adopts the high-affinity state.[20] Further-
more, it was recently shown that shear stress can induce a con-
formational switch (twist in the b-sandwich fold of the CRD
domain), resulting in improved affinity.[21] Therefore, differing
affinities were expected in the cell-based flow cytometry assay,
in which full-length fimbriae are present, relative to the cell-
free competitive binding assay.
Cell-free competitive binding assays[16]
These assays were performed twice for every com-
pound with each concentration in duplicate. To
ensure comparability between various antagonists,
the reference compound n-heptyl a-d-mannopyrano-
side 1[22] was tested each time in parallel. The affini-
ties are reported relative to 1 as rIC50 in Table 1. A
comparison of the affinities of compounds 4a and
4b with the ortho-substituted analogues 5a, 13a–f
and 5b, 14a–f clearly demonstrates that ortho sub-
stituents on ring A indeed improve binding. However,
the differences between the various substituted
FimH antagonists are small. For a better understand-
ing of these results, a more detailed analysis of the
thermodynamic profile by isothermal titration calo-
rimetry (ITC) was performed (see below). By increas-
ing the flexibility of the aglycone, we expected
a switch from the out-docking mode as present for
antagonists 3 and 4 (Figure 2A,B) to the in-docking
mode (represented by antagonist 6 in Figure 2C).[10f]
However, affinities for all six representatives with in-
creased spacer length between carbohydrate and
aglycone (Table 1: 6—, 19, 20, 22, and 23) were dra-
matically decreased. A similar tendency was observed
Scheme 2. Reagents and conditions: a) BF3·Et2O, CH2Cl2, 0 8C, 3 h (17a–c, 34–
48%); b) 4-methoxycarbonylphenylboronic acid (11), Pd(Cl2)dppf·CH2Cl2,
K3PO4, DMF, 80 8C, overnight (18a,b and 21, 73–94%); c) NaOMe, MeOH, RT,
4 h (19a,b and 22, 47–90%); d) 1. 0.2n NaOH(aq), MeOH, RT, overnight;
2. Dowex (Na+), size-exclusion chromatography (P-2 gel) (6, 20 and 23, 10–
96%).
Scheme 3. Reagents and conditions: a) 4-iodophenol, BF3·Et2O, CH2Cl2, 40 8C, overnight
(70%); b) bis(pinacolato)diborone, Pd(Cl2)dppf·CH2Cl2, KOAc, DMF, MW 120 8C, 2 h (50%);
c) Pd(Cl2)dppf·CH2Cl2, K3PO4, DMF, 80 8C, overnight (34–56%); d) NaOMe, MeOH, RT, 4 h
(33–95%); e) 1. 0.2n NaOH(aq), MeOH, RT, overnight; 2. Dowex (Na
+), size-exclusion chro-
matography (P-2 gel) (31: 40%; 35 : 23%).
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Table 1. Pharmacodynamic parameters of FimH antagonists.
Compd Binding assay Flow cytometry
R IC50 [nm]
[a] rIC50
[b] IC50 [mm]
[a,c]
1[10e] 73!7.9 1 3.9!1.6
24[10d] 84.9 1.47 n.d.
3[10d] 28.6 0.55 n.d.
4a[10e] 10.4!1.2 0.14 n.d.
4b[10e] 17.1!2.2 0.15 n.d.
5a 4.8!1.2 0.06 n.d.
5b 6.7!2.1 0.09 0.33!0.05
13a 8.0 0.14 n.d.
14a 33.5 0.58 1.54!0.31
13b 23.3 0.40 n.d.
14b 9.2 0.16 1.83!0.14
13c 2.6 0.04 n.d.
14c 8.9 0.15 0.89!0.10
Table 1. (Continued)
Compd Binding assay Flow cytometry
R IC50 [nm]
[a] rIC50
[b] IC50 [mm]
[a,c]
13d 3.5 0.06 n.d.
14d 4.8 0.08 1.95!0.36
13e 31.7 0.55 n.d.
14e 63.0 1.09 4.85!0.79
13 f 22.5 0.39 n.d.
14 f 33.9 0.58 n.d.
19a 56.1 0.97 n.d.
6 107.9 1.87 n.d.
19b 98.9 1.7 n.d.
20 142.2 2.44 n.d.
22 85.8 1.49 n.d.
23 642.0 11.14 n.d.
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for the biphenyls with an elongated carboxylate-bearing para
substituent (Table 1: 30, 31, 34, and 35). It was previously de-
scribed that the ester of 3 is placed within hydrogen bonding
distance to form a polar interaction with Arg98 and Glu50.[10d]
However, an improvement of affinity provided by a similar
polar interaction between Arg98 and the antagonists 31 and
35 could not be achieved, probably due to the high desolva-
tion penalty of Arg98. Finally, it is important to note that the
free acids (sodium salt) of the antagonists in general showed
slightly lower affinities than their methyl ester counterparts,
with the only exceptions of 13b and 14b (Table 1). However,
because the esters are thought to act as prodrugs and to be
rapidly cleaved after oral application,[10e] the affinities of the
carboxylates are relevant with regard to the therapeutic poten-
tial of the present FimH antagonists.
Cell-based flow cytometry assay[17]
These assays were performed in duplicate/triplicate, and n-
heptyl a-d-mannopyranoside 1 was used as reference com-
pound with an IC50 value of 3.9!1.6 mm. The most potent an-
tagonists 5b and 14c (Table 1) showed respective IC50 values
of 0.33!0.05 and 0.89!0.10 mm. In general, the activities ob-
tained from the flow cytometry assay were ~50-fold lower
than the affinities determined in the target-based competitive
assay (see above).
Isothermal titration calorimetry
Because the biological in vitro evaluation only revealed small
differences between affinities, ITC experiments were carried
out to study the thermodynamic profile of the variously ortho-
substituted biphenyl compounds 5b and 14a–f in binding to
FimH. ITC directly measures the heat of interaction (change in
enthalpy, DH) at a constant temperature on titrating two com-
pounds of known concentration that form an equilibrium com-
plex.[23] It includes contributions from all equilibria that occur
as the interacting molecules go from the free to the bound
state, including those associated with solvent interactions and
macromolecular conformational changes. The noncovalent in-
teraction between a protein and a ligand can be quantified by
the change in free energy (DG), consisting of the change in en-
thalpy (DH) and change in entropy (DS) [Eq. (1)] .[24] The bind-
ing energy under standard conditions (DG8), in which all reac-
tants and products are at a concentration of 1m, can be calcu-
lated from the dissociation constant, KD [Eq. (2)] . With ITC, KD
and DH can be measured directly, whereas DG and the entro-
py term TDS are calculated according to Equations (1) and (2).
DG ¼ DH#TDS ð1Þ
DG ¼ RT lnKD ð2Þ
A favorable enthalpy term DH is associated with hydrogen
bond formation, electrostatic, and dipole–dipole interactions at
the overcompensation of the desolvation penalty.[25] The entro-
py term DS reflects the overall change in the degrees of free-
dom of a system. It can be dissected into translational and
rigid body rotational entropy,[26] solvation entropy,[27] and en-
tropy costs related to conformational changes of protein and
ligand [Eq. (3)] .[28] Whereas the formation of a protein–ligand
complex is always associated with a decrease in translational
and rotational freedom and therefore with entropy costs, the
entropic contribution involving changes in solvation (DSsolv)
and changes in rotational and vibrational entropy due to the
loss of conformational flexibility (DSconf) can differ both in sign
and magnitude.[29]
DS ¼ DSsolv þ DStrans=rot þ DSconf ð3Þ
The FimH CRD was used for the ITC experiments. It was pre-
pared from FimH-CRD-Th-His6 (see Competitive binding assay,
Experimental Section below) by incubation with thrombin, as
described earlier.[16]
The thermodynamic fingerprints of the various biphenyl de-
rivatives (Table 2, Figure 4) reveal a significant improvement in
the enthalpic term (DDH #4.3 to #11.2 kJmol#1) for all substi-
tuted biphenyls (5b, 14a–f) in comparison with the unsubsti-
tuted derivative 4b. The largest enthalpy improvement was
observed for the trifluoromethyl group (14c ; Table 2). Interest-
ingly, these largely improved enthalpic contributions are
mostly compensated by entropic penalties (#TDDS +3.2 to
+7.5 kJmol#1), resulting in only marginally improved KD values.
In the best case, the trifluoromethyl derivative 14c, a fourfold
improvement in KD was measured. Similar, but less pronounced
Table 1. (Continued)
Compd Binding assay Flow cytometry
R IC50 [nm]
[a] rIC50
[b] IC50 [mm]
[a,c]
30 63.2 1.09 n.d.
31 70.5 1.21 n.d.
34 49.5 0.85 n.d.
35 62.5 1.07 n.d.
[a] IC50 values were determined in a cell-free competitive binding assay.
[16]
[b] The rIC50 values were calculated by dividing the IC50 of the compound
of interest by that of reference compound 1; this leads to rIC50 values <1
for derivatives that bind better than reference 1, and rIC50 values >1 for
compounds with lower affinity than 1. [c] The anti-adhesion potential to
human epithelial bladder cells was determined in the flow cytometry
assay;[17] n.d.=not determined.
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effects were observed for most other ortho substituents. This
trend was broken only by the cyclopropyl derivative 14e (DDH
+0.7 kJmol!1, !TDDS !2.4 kJmol!1; Table 2).
The influence of the ortho substituent on binding can be at-
tributed to three factors. First, ortho substituents of appropri-
ate volume establish an improved shape complementarity
within the binding pocket, leading to a better van der Waals
(vdW) contact and therefore an improvement in the enthalpy
term DH. The improvement in enthalpy (DDH) correlates well
with increasing vdW volumes of spherical ortho substituents
(5b, 14a–c ; Figure 5). For non-spherical substituents (OMe,
14d ; cyclopropyl, 14e ; and CN, 14 f), the shape complemen-
tarity is not optimal, leading to only a decreased enthalpy con-
tribution. However, better vdW contacts also lead to decreased
conformational flexibility and therefore an entropic compensa-
tion by a less favorable DSconf value. A second parameter is the
desolvation enthalpy, which depends on the polarity of a spe-
cific ortho substituent and varies
between !2.39 kJmol!1 for CH3
and 19.31 kJmol!1 for CN.[25] Fi-
nally, depending on the surface
area of the ortho substituent,
the entropy of solvation may
change. In summary, the various
effects are superimposed and of
opposing contributions to the
free binding energy DG.
Physicochemical and in vitro
pharmacokinetic characteriza-
tion
To estimate the oral bioavailabil-
ity and renal elimination of acids
4b, 5b, 6, 14a–f, 20, 23, 31, 35,
and the methyl esters 4a, 5a,
13a–f, 19a–b, 22, 30 and 34, several physicochemical parame-
ters (lipophilicity, solubility) as well as permeability through an
artificial membrane and a cell monolayer were determined
(Table 3). The free acids of the antagonists assessed in this
study (4b, 5b, 6, 14a–f, 20, 23, 31, and 35) are generally hy-
drophilic and soluble at pH values >5. All acids showed
logD7.4 values below zero and are therefore thought to under-
go considerable renal clearance,[32] a prerequisite for FimH an-
tagonists to reach their target in the urinary bladder. Permea-
tion studies through an artificial membrane (PAMPA[33]) indicat-
ed for all acids except 14a effective permeation values (logPe)
below !6.7, suggesting low absorption in the small intestine
by passive permeation.[34] However, the high absorption poten-
tial of the fluoro-substituted biphenyl 14a predicted by
Table 2. Binding thermodynamics of FimH antagonists determined by ITC.
Compd R KD [nm] DG8 [kJmol
!1] DH8 [kJmol!1] !TDS8 [kJmol!1] N[a] VvdW [!3][b]
4b H 14.1 !44.8 !47.3 +2.5 1.00 7.2
5b Cl 3.7 !48.1 !55.5 +7.4 1.01 22.4
14a F 9.2 !45.9 !51.6 +5.7 1.00 13.3
14b Me 4.8 !47.5 !56.2 +8.7 1.01 26.7
14c CF3 3.2 !48.5 !58.5 +10.0 1.02 41.4
14d OMe 7.7 !46.3 !52.5 +6.2 1.02 34.8
14e cPr 6.9 !46.6 !46.7 +0.1 1.01 52.5
14 f CN 7.4 !46.4 !55.0 +8.6 1.01 29.7
[a] Molar ratio of protein/ligand. [b] van der Waals volumes (VvdW) of the ortho substituent were calculated with
the Phase volCalc utility.[30]
Figure 4. Enthalpy–entropy compensation, a property often reported for car-
bohydrate–lectin interactions,[31] for ortho-substituted biphenyl a-d-manno-
pyranosides; DDG, DDH, and TDDS values for 5b and 14a–f are plotted rel-
ative to the unsubstituted derivative 4b.
Figure 5. Correlation of DDH (relative to antagonist 4b) with the van der
Waals volumes[30] of ortho substituents.
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Table 3. Physicochemical and in vitro pharmacokinetic parameters of FimH antagonists.
Compd PAMPA logPe [log10
!6 cms!1]/pH[a] Caco-2 Papp [10
!6 cms!1][b] logD7.4
[c] Solubility [mgmL!1]/pH[d]
a!b b!a (b!a)/(a!b)
1 !4.9 7.0"0.6 9.4"0.2 1.3 1.7 >3000/6.5
24 !5.0"0.1/5.0
!4.9"0.1/6.2
!4.7"0.1/7.4
10.0"0.9 19.0"1.2 1.9 2.1"0.1 22"0/3.0
22"1/5.0
21"1/7.4
3 !4.9"0.0/5.0
!4.9"0.0/6.2
!4.9"0.0/7.4
2.2"0.2 17.6"0.4 8.0 2.0"0.0 >150/3.0
>150/5.0
>150/7.4
4a !4.7 1.5"0.0 6.4"0.4 4.3 2.1 14"1/3.0
13"1/5.0
12"1/7.4
4b n.p. n.d. n.d. n.d. <!1.5 >3000/6.6
5a !4.6 5.3"0.6 17.5"1.3 3.3 2.3 16"2/3.0
15"0/5.0
17"2/7.4
5b n.p. 0.2"0.0 0.4"0.0 1.6 !0.8 >3000/6.5
13a !4.8"0.0/5.0
!4.8"0.0/6.2
!4.8"0.0/7.4
5.6"0.7 22.0"0.6 4.0 2.7"0.1 22"1/3.0
24"3/5.0
17"6/7.4
14a !5.8"0.1/5.0
!6.3"0.1/6.2
!7.4"0.1/7.4
0.2"0.1 0.2"0.0 0.8 <!1.5 30"3/3.0
>100/5.0
>100/7.4
13b !4.5"0.1/5.0
!4.5"0.0/6.2
!4.6"0.1/7.4
6.2"1.3 22.7"1.2 3.6 2.4"0.2 7"0/3.0
7"0/5.0
7"0/7.4
14b !8.6"1.7/5.0
!8.8"1.4/6.2
!8.7"1.5/7.4
n.d. n.d. n.d. !0.6"0.1 34"3/3.0
>200/5.0
>200/7.4
13c !4.4"0.0/5.0
!4.4"0.0/6.2
!4.5"0.1/7.4
9.2"0.1 16.9"1.5 1.8 2.8"0.1 17"1/3.0
15"1/5.0
16"1/7.4
14c !8.4"1.3/5.0
!9.3"1.4/6.2
!8.6"1.6/7.4
n.d. n.d. n.d. !0.8"0.1 15"1/3.0
140"6/5.0
>200/7.4
13d !5.4"0.0/5.0
!5.4"0.0/6.2
!5.4"0.0/7.4
4.2"0.7 16.4"1.2 3.9 1.8"0.1 24"0/3.0
24"1/5.0
26"1/7.4
14d !8.5"0.6/5.0
!9.1"0.2/6.2
!9.2"0.4/7.4
n.d. n.d. n.d. <!1.5 127"4/3.0
>200/5.0
>200/7.4
13e !4.5"0.2/5.0
!4.4"0.0/6.2
!4.4"0.1/7.4
6.1"0.6 17.9"1.2 3.0 2.9"0.1 14"2/3.0
13"0/5.0
14"1/7.4
14e !9.3"1.3/5.0
!8.7"1.5/6.2
!8.7"1.5/7.4
n.d. n.d. n.d. !0.8"0.1 31"2/3.0
>200/5.0
>200/7.4
13 f !6.5"0.0/5.0
!6.5"0.1/6.2
!6.3"0.1/7.4
0.9"0.7 18.1"0.6 19.7 1.7"0.0 22"2/3.0
24"1/5.0
23"1/7.4
14 f !8.5"1.7/5.0
!7.3"0.3/6.2
!7.8"1.5/7.4
n.d. n.d. n.d. <!1.5 35"11/3.0
>200/5.0
>200/7.4
19a !4.9"0.0/5.0
!4.9"0.0/6.2
!4.9"0.1/7.4
4.4"0.1 18.8"1.7 4.3 1.9"0.1 103"8/3.0
100"6/5.0
95"5/7.4
6 !8.6"1.6/5.0
!9.3"1.4/6.2
!8.7"1.5/7.4
n.d. n.d. n.d. <!1.5 >130/3.0
>130/5.0
>130/7.4
19b !5.3"0.1/5.0
!5.6"0.1/6.2
!5.1"0.2/7.4
n.d. n.d. n.d. 2.4"0.1 30"0/3.0
29"1/5.0
31"1/7.4
20 !8.6"1.6/5.0
!9.3"1.4/6.2
!10/7.4
n.d. n.d. n.d. !1.2"0.2 >130/3.0
>130/5.0
>130/7.4
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PAMPA could not be confirmed by the colorectal adenocarci-
noma (Caco-2) cell permeation assay. In contrast, the methyl
esters (3, 4a, 5a, 13a–f, 19a–b, 22, 30, and 34) showed
logD7.4 values >1.5, that is, they are more lipophilic and hence
more permeable than the corresponding acids, as shown by
the PAMPA and Caco-2 permeation assay. Despite this high ab-
sorption potential, the ratios between the apparent permeabil-
ity coefficients (Papp) in the basolateral-to-apical (b!a, secreto-
ry) and apical-to-basolateral (a!b, absorptive) directions re-
vealed active efflux processes as an additional issue of all the
assessed compounds. Moreover, the methyl esters must be
readily hydrolyzed after absorption to become more polar and
to be renally eliminated. Rapid metabolic turnover by the
enzyme carboxylesterase was previously shown for the methyl
esters 4a and 5a.[10e]
The different substituents at the ortho position of ring A (5a,
5b, 13a–f, 14a–f ; Table 3) only have a minor influence on the
physicochemical properties. The addition of chloro, fluoro,
methyl, trifluoromethyl, or cyclopropyl substituents slightly in-
creases the lipophilicity of the respective acids and methyl
esters, whereas methoxy and cyano substituents render the
compounds more hydrophilic and less permeable. Moreover,
the substituents at the ortho position have negligible effects
on the low aqueous solubility, which is a major drawback of all
methyl esters.[35] In contrast, the modifications with increased
spacer length between carbohydrate and aglycone (6, 19a–b,
20, 22, and 23 ; Table 3) show higher aqueous solubility. Ex-
tending the spacer and linking it at the ortho or meta positions
of the biaryl moiety disrupts the symmetry of the molecular
structure, leading to increased solubility.[15,36] However, an addi-
tional chloro substituent at the 4-position (19b, 20 ; Table 3) re-
stores the symmetrical character of the structure, which in turn
lowers the solubility of the compound. Disrupted structural
symmetry might also hold true for the enhanced solubility of
the biphenyls with an elongated carboxylate-bearing para sub-
stituent (30, 31, 34, and 35 ; Table 3). The introduction of
a methylene or cyclopropylene group between the biphenyl
and the carboxylate moiety markedly improved the aqueous
solubility of the methyl esters, whereas the absorption poten-
tial was only slightly decreased.
Summary and Conclusions
In this study, we investigated the structure–affinity relationship
for ortho substituents on ring A of the biphenyl aglycone of
the FimH antagonists 13 and 14. The correlation between vdW
volumes of these substituents and the enthalpy term clearly in-
dicates the importance of shape complementary. This interpre-
tation is further supported by the fact that the electronic char-
acter of the substituent [Cl in 5a (Table 2), CF3 in 14c versus
CH3 in 14b] is less important. The correlation of enthalpic im-
provements (DDH) with vdW volumes offers a potent tool for
guiding further structural optimization.
The successful oral application using a prodrug approach
was recently demonstrated with the ester 5a.[10e] A major
drawback of the biphenyl methyl esters is their insufficient sol-
ubility, which is mostly in the range of 15–35 mgmL!1. As ex-
pected,[15] solubility could be substantially improved when the
symmetry of the aglycone was disrupted. Thus, the solubility
of 3 (>150 mgmL!1; Table 3), 19a (100 mgmL!1), and 22 (>
130 mgmL!1) was improved by a factor of ~10. However, for
these more flexible derivatives, the expected optimized fit
leading to improved affinities in the in-docking mode could
not be observed. In fact, the affinities for the members of this
Table 3. (Continued)
Compd PAMPA logPe [log10
!6 cms!1]/pH[a] Caco-2 Papp [10
!6 cms!1][b] logD7.4
[c] Solubility [mgmL!1]/pH[d]
a!b b!a (b!a)/(a!b)
22 !5.1"0.0/5.0
!5.1"0.0/6.2
!5.1"0.0/7.4
n.d. n.d. n.d. 1.7"0.1 >130/3.0
>130/5.0
>130/7.4
23 !7.3"1.8/5.0
!8.1"2.2/6.2
!10/7.4
n.d. n.d. n.d. <!1.5 >130/3.0
>130/5.0
>130/7.4
30 !5.5"0.0/5.0
!5.5"0.0/6.2
!5.4"0.1/7.4
n.d. n.d. n.d. 1.6"0.1 >130/3.0
>130/5.0
>130/7.4
31 !7.7"1.6/5.0
!8.1"1.3/6.2
!10/7.4
n.d. n.d. n.d. <!1.5 >130/3.0
>130/5.0
>130/7.4
34 !5.3"0.1/5.0
!5.6"0.0/6.2
!5.3"0.2/7.4
n.d. n.d. n.d. 2.2"0.1 >130/3.0
>130/5.0
>130/7.4
35 !8.0"1.3/5.0
!8.6"1.6/6.2
!10/7.4
n.d. n.d. n.d. n.d. 63"8/3.0
>130/5.0
>130/7.4
[a] Pe=effective permeation: passive permeation through an artificial membrane was determined by parallel artificial membrane permeation assay
(PAMPA); values represent the mean "SD of quadruplicate measurements taken at three pH values (pH 5.0, 6.2, and 7.4).[33] [b] Papp=apparent permeabili-
ty: permeation through cell monolayers was assessed by a Caco-2 assay in the absorptive (a!b) and secretory (b!a) directions in triplicate;[42] n.p.=no
permeation, n.d.=not determined. [c] Distribution coefficients (logD) were measured by a miniaturized shake-flask procedure at pH 7.4. [d] Kinetic solubili-
ty was measured in a 96-well format using the mSOL Explorer solubility analyzer at three pH values (pH 3.0, 5.0, and 7.4) in triplicate.
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family of compounds are drastically decreased, for example,
compounds 20 or 23 (Table 1).
Finally, the elongation of the ester-bearing para substituent
(Table 1; compounds 31 and 35) did not lead to the expected
additional polar interaction with Arg98. Instead, a five- to sev-
enfold decrease in affinity was observed. Clearly, the desolva-
tion penalty for the guanidinium group could not be matched
by the geometrically possible salt bridge with the carboxylate
of the antagonists 31 and 35.
In summary, our study confirms the earlier selection of the
FimH antagonists 5a for oral and 5b for intravenous applica-
tion. However, the methoxy derivative 13d (Table 1) shows
slightly improved pharmacokinetic properties and therefore
represents an additional candidate for future in vivo studies.
Experimental Section
General methods : NMR spectra were recorded on a Bruker Avance
DMX-500 (500.1 MHz) spectrometer. Assignment of 1H and 13C NMR
spectra was achieved using 2D methods (COSY, HSQC, HMBC).
Chemical shifts are expressed in ppm using residual CHCl3,
CHD2OD, or HDO as references. Optical rotations were measured
with a PerkinElmer Polarimeter 341. Electrospray ionization mass
spectrometry (ESI-MS) data were obtained on a Waters Micromass
ZQ instrument. LC–HRMS analyses were carried out using an Agi-
lent 1100 LC equipped with a photodiode array detector and a Mi-
cromass QTOF I equipped with a 4 GHz digital time converter. Mi-
crowave-assisted reactions were carried out with a CEM Discover
and Explorer. Reactions were monitored by TLC using glass plates
coated with silica gel 60 F254 (Merck) and visualized by UV light
and/or by charring with a molybdate solution (0.02m solution of
ammonium cerium sulfate dihydrate and ammonium molybdate
tetrahydrate in aqueous 10% H2SO4). MPLC separations were car-
ried out on a CombiFlash Companion or Rf from Teledyne Isco
equipped with RediSep normal-phase or RP-18 reversed-phase
flash columns. LC–MS separations were carried out on a Waters
system equipped with sample manager 2767, pump 2525, PDA
2525, and Micromass ZQ. Size-exclusion chromatography was per-
formed on Bio-Gel P-2 Gel (45–90 mm) from Bio-Rad (Reinach,
Switzerland). All compounds used for biological assays are at least
of 98% purity based on analytical HPLC results. Commercially avail-
able reagents were purchased from Fluka, Aldrich, Alfa Aesar or Iris
Biotech (Germany). Solvents were purchased from Sigma–Aldrich
(Buchs, Switzerland) or Acros Organics (Geel, Belgium) and were
dried prior to use where indicated. MeOH was dried by reflux with
sodium methoxide and distilled immediately before use. CH2Cl2
was dried by filtration over Al2O3 (Fluka, type 5016 A basic). Molec-
ular sieves (4 !) were activated in vacuo at 500 8C for 1 h immedi-
ately before use.
General procedure A for the synthesis of mannosides 10a–f and
17a–c : To an ice-cold suspension of 8[12] (200 mg, 0.57 mmol,
1.1 equiv), phenol 9a–f or benzyl alcohol 16a–c (0.52 mmol,
1.0 equiv), and molecular sieves (4 !, 600 mg) in dry CH2Cl2 (5 mL),
BF3·Et2O (0.3 mL, 2.44 mmol, 4.7 equiv) was added dropwise under
argon. The mixture was stirred at 0 8C for 3 h, and then at RT over-
night. The reaction mixture was filtered over Celite, and the filtrate
was diluted with CH2Cl2 (50 mL), extracted with 0.5n NaOH(aq)
(50 mL), H2O (50 mL), and brine (50 mL). The organic layer was
dried over Na2SO4 and concentrated in vacuo. The residue was pu-
rified by MPLC on silica gel (petroleum ether (PE)/EtOAc) to yield
10a–f or 17a–c.
General procedure B for the synthesis of mannosylated biphen-
yls : A Schlenk tube was charged with aryl bromide (1.0 equiv), bor-
onic acid or boronate (1.1 equiv), Pd(dppf)Cl2·CH2Cl2 (0.03 equiv),
K3PO4 (1.5 equiv) and a stirring bar. The tube was closed with
a rubber septum and was evacuated and flushed with argon. This
procedure was repeated once, then anhydrous DMF (2 mL) was
added under a stream of argon. The mixture was degassed in an
ultrasonic bath and flushed with argon for 5 min, and then stirred
at 80 8C overnight. The reaction mixture was cooled to RT, diluted
with EtOAc (50 mL), and washed with H2O (50 mL) and brine
(50 mL). The organic layer was dried over Na2SO4 and concentrated
in vacuo. The residue was purified by MPLC on silica gel (PE/EtOAc)
to afford biphenyls 12a–f, 18a,b, 21, 29 or 33.
General procedure C for deacetylation : To a solution of 12a–f,
18a,b, 21, 29 or 33 (1.0 equiv) in dry MeOH (5 mL) was added
freshly prepared 1m NaOMe/MeOH (0.1 equiv) under argon. The
mixture was stirred at RT until the reaction was complete (moni-
tored by TLC), then neutralized with Amberlyst-15 (H+) ion-ex-
change resin, filtered and concentrated in vacuo. The residue was
purified by MPLC on silica gel (CH2Cl2/MeOH, 10:1–8:1) to afford
13a–f, 19a,b, 22, 30 or 34 as white solids.
General procedure D for saponification : To a solution of 12a–e,
18a,b, 21, 29 or 33 (1.0 equiv) in MeOH (5 mL) was added 1m
NaOMe/MeOH (0.1 equiv) at RT. The reaction mixture was stirred at
RT for 4 h and concentrated. The residue was treated with 0.5m
NaOH(aq) (1 mL) for 24 h at RT. The solution was then adjusted to
pH 3–4 with Amberlyst-15 (H+), and the mixture was filtered and
concentrated. The crude product was transformed into the sodium
salt by passing through a small column of Dowex 50X8 (Na+ form)
ion-exchange resin. After concentration, the residue was purified
by MPLC (RP-18, H2O/MeOH, 1:0–2:1) followed by size-exclusion
chromatography (P-2 gel, H2O) to give 14a–e, 6, 20, 23, 31 or 35
as white solids after final lyophilization from H2O.
4-Bromo-2-fluorophenyl 2,3,4,6-tetra-O-acetyl-a-d-mannopyra-
noside (10a): Prepared according to general procedure A from
8[12] and 4-bromo-2-fluorophenol (9a). Yield: 220 mg (74%) as
white solid. Rf=0.48 (PE/EtOAc, 2:1) ; [a]
20
D +83.0 (c=0.70, EtOAc);
1H NMR (500 MHz, CDCl3): d=7.30 (dd, J=2.3, 10.1 Hz, 1H, Ar-H),
7.21 (dt, J=1.7, 8.8 Hz, 1H, Ar-H), 7.08 (t, J=8.6 Hz, 1H, Ar-H), 5.54
(dd, J=3.5, 10.0 Hz, 1H, H-3), 5.50 (dd, J=1.8, 3.4 Hz, 1H, H-2),
5.46 (d, J=1.5 Hz, 1H, H-1), 5.36 (t, J=10.0 Hz, 1H, H-4), 4.26 (dd,
J=5.5, 12.2 Hz, 1H, H-6a), 4.17 (ddd, J=2.1, 5.5, 10.0 Hz, 1H, H-5),
4.10 (dd, J=2.2, 12.2 Hz, 1H, H-6b), 2.20, 2.07, 2.05, 2.04 ppm (4 s,
12H, 4 OAc); 13C NMR (125 MHz, CDCl3): d=170.51, 169.95, 169.82,
169.76 (4 CO), 153.28 (d, J=251.4 Hz, Ar-C), 142.64 (d, J=11.1 Hz,
Ar-C), 127.58 (d, J=4.0 Hz, Ar-C), 120.4 (d, J=21.5 Hz, Ar-C), 120.28
(d, J=0.9 Hz, Ar-C), 115.73 (d, J=8.1 Hz, Ar-C), 97.49 (C-1), 69.76 (C-
5), 69.15 (C-2), 68.60 (C-3), 65.76 (C-4), 62.09 (C-6), 20.87, 20.71,
20.69, 20.67 ppm (4 COCH3); elemental analysis calcd (%) for
C20H22BrFO10: C 46.08, H 4.25, found: C 46.11, H 4.26.
4-Bromo-2-methylphenyl 2,3,4,6-tetra-O-acetyl-a-d-mannopyra-
noside (10b): Prepared according to general procedure A from
8[12] and 4-bromo-2-methylphenol (9b). Yield: 254 mg (86%) as
white solid. Rf=0.60 (PE/EtOAc, 2:1) ; [a]
20
D +61.8 (c=1.00, EtOAc);
1H NMR (500 MHz, CDCl3): d=7.31 (d, J=1.9 Hz, 1H, Ar-H), 7.24
(dd, J=2.3, 8.7 Hz, 1H, Ar-H), 6.97 (d, J=8.8 Hz, 1H, Ar-H), 5.53 (dd,
J=3.4, 10.0 Hz, 1H, H-3), 5.47 (d, J=1.7 Hz, 1H, H-1), 5.45 (dd, J=
2.0, 3.4 Hz, 1H, H-2), 5.37 (t, J=10.0 Hz, 1H, H-4), 4.28 (dd, J=5.6,
12.3 Hz, 1H, H-6a), 4.10–4.03 (m, 2H, H-5, H-6b), 2.27 (s, 3H, CH3),
2.20, 2.06, 2.05, 2.04 ppm (4 s, 12H, 4 OAc); 13C NMR (125 MHz,
CDCl3): d=170.53, 170.04, 169.96, 169.73 (4 CO), 152.96, 133.78,
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129.88, 129.61, 115.81, 115.23 (Ar-C), 95.91 (C-1), 69.39 (C-5), 69.38
(C-2), 68.88 (C-3), 65.76 (C-4), 62.12 (C-6), 20.88, 20.70, 20.68 (4C, 4
COCH3), 16.07 ppm (CH3); elemental analysis calcd (%) for
C21H25BrO10: C 48.76, H 4.87, found: C 48.84, H 4.91.
4-Bromo-2-trifluoromethyl-phenyl 2,3,4,6-tetra-O-acetyl-a-d-
mannopyranoside (10c): Prepared according to general procedure
A from 8[12] and 4-bromo-2-trifluoromethylphenol (9c). Yield:
260 mg (80%) as white solid. Rf=0.50 (PE/EtOAc, 2:1) ; [a]
20
D +64.6
(c=1.00, EtOAc); 1H NMR (500 MHz, CDCl3): d=7.74 (d, J=2.3 Hz,
1H, Ar-H), 7.61 (dd, J=2.4, 8.9 Hz, 1H, Ar-H), 7.15 (d, J=8.9 Hz, 1H,
Ar-H), 5.60 (d, J=1.6 Hz, 1H, H-1), 5.51 (dd, J=3.5, 10.1 Hz, 1H, H-
3), 5.45 (dd, J=2.0, 3.3 Hz, 1H, H-2), 5.39 (t, J=10.1 Hz, 1H, H-4),
4.27 (dd, J=5.3, 12.4 Hz, 1H, H-6a), 4.08–4.00 (m, 2H, H-5, H-6b),
2.21, 2.06, 2.05, 2.04 ppm (4 s, 12H, 4 OAc); 13C NMR (125 MHz,
CDCl3): d=170.41, 169.91, 169.74, 169.62 (4 CO), 152.16 (d, J=
1.7 Hz, Ar-C), 136.07 (Ar-C), 130.35 (t, J=5.3 Hz, Ar-C), 122.30 (d, J=
271.4 Hz, CF3), 121.72 (d, J=31.7 Hz, Ar-C), 117.08, 114.88 (Ar-C),
95.75 (C-1), 69.96 (C-5), 69.02 (C-2), 68.45 (C-3), 65.44 (C-4), 61.95
(C-6), 20.84, 20.70, 20.67, 20.63 ppm (4 COCH3); elemental analysis
calcd (%) for C21H22BrF3O10: C 44.15, H 3.88, found: C 44.10, H 3.88.
4-Bromo-2-methoxyphenyl 2,3,4,6-tetra-O-acetyl-a-d-mannopyr-
anoside (10d): Prepared according to general procedure A from
8[12] and 4-bromo-2-methoxyphenol (9d). Yield: 234 mg (77%) as
white solid. Rf=0.32 (PE/acetone, 4:1) ; [a]
20
D +70.3 (c=0.70,
EtOAc); 1H NMR (500 MHz, CDCl3): d=7.03–6.95 (m, 3H, Ar-H), 5.58
(dd, J=3.5, 10.0 Hz, 1H, H-3), 5.52 (dd, J=1.8, 3.4 Hz, 1H, H-2),
5.42 (d, J=1.8 Hz, 1H, H-1), 5.34 (t, J=10.0 Hz, 1H, H-4), 4.28–4.24
(m, 2H, H-5, H-6a), 4.10 (m, 1H, H-6b), 3.84 (s, 3H, OCH3), 2.19,
2.07, 2.05, 2.04 ppm (4 s, 12H, 4 OAc); 13C NMR (125 MHz, CDCl3):
d=170.58, 169.98, 169.89, 169.80 (4 CO), 151.52, 143.91, 123.49,
120.37, 116.69, 115.94 (Ar-C), 97.52 (C-1), 69.45 (C-5), 69.36 (C-2),
68.80 (C-3), 66.06 (C-4), 62.27 (C-6), 56.04 (OCH3), 20.91, 20.73,
20.71, 20.69 ppm (4 COCH3); elemental analysis calcd (%) for
C21H25BrO11: C 47.29, H 4.72, found: C 47.20, H 4.70.
4-Bromo-2-cyclopropylphenyl 2,3,4,6-tetra-O-acetyl-a-d-manno-
pyranoside (10e): Prepared according to general procedure A
from 8[12] and 4-bromo-2-cyclopropylphenol (9e). Yield: 235 mg
(76%) as white solid. Rf=0.30 (PE/EtOAc, 3:1) ; [a]
20
D +64.7 (c=0.40,
EtOAc); 1H NMR (500 MHz, CDCl3): d=7.20 (d, J=8.7 Hz, 1H, Ar-H),
7.00–6.69 (m, 2H, Ar-H), 5.58 (d, J=10.1 Hz, 1H, H-3), 5.50 (s, 2H,
H-1, H-2), 5.39 (t, J=10.1 Hz, 1H, H-4), 4.28 (dd, J=5.4, 12.2 Hz, 1H,
H-6a), 4.14–4.08 (m, 2H, H-5, H-6b), 2.21, 2.09, 2.04 (3 s, 12H, 4
OAc), 1.02 (d, J=8.1 Hz, 2H, CH2-cPr), 0.65 ppm (d, J=4.6 Hz, 2H,
CH2-cPr) ;
13C NMR (125 MHz, CDCl3): d=170.54, 170.03, 170.15,
169.75 (4 CO), 153.64, 135.64, 129.11, 128.94, 116.29, 115.79 (Ar-C),
96.15 (C-1), 69.46 (C-5), 69.39 (C-2), 68.93 (C-3), 65.78 (C-4), 62.16
(C-6), 21.07, 20.89, 20.70 (4C, 4COCH3), 9.73, 7.88, 7.82 ppm (cPr);
elemental analysis calcd (%) for C23H27BrFO10: C 50.84, H 5.01,
found: C 50.82, H 5.00.
4-Bromo-2-cyanophenyl 2,3,4,6-tetra-O-acetyl-a-d-mannopyra-
noside (10 f): Prepared according to general procedure A from 8[12]
and 4-bromo-2-cyanophenol (9 f). Yield: 220 mg (73%) as white
solid. Rf=0.51 (PE/EtOAc, 2:3) ; [a]
20
D +54.3 (c=0.60, EtOAc); IR
(KBr): n˜=2232 (s, C!N), 1749 cm"1 (vs, C=O); 1H NMR (500 MHz,
CDCl3): d=7.73 (d, J=2.5 Hz, 1H, Ar-H), 7.66 (dd, J=2.5, 9.0 Hz,
1H, Ar-H), 7.15 (d, J=9.0 Hz, 1H, Ar-H), 5.62 (d, J=1.7 Hz, 1H, H-1),
5.56 (dd, J=3.5, 10.0 Hz, 1H, H-3), 5.51 (dd, J=2.0, 3.4 Hz, 1H, H-
2), 5.41 (t, J=10.0 Hz, 1H, H-4), 4.28 (dd, J=4.9, 12.1 Hz, 1H, H-6a),
4.13–4.08 (m, 2H, H-5, H-6b), 2.21, 2.07, 2.05, 2.04 ppm (4 s, 12H, 4
OAc); 13C NMR (125 MHz, CDCl3): d=169.37, 168.93, 168.71, 168.48
(4CO), 155.18, 136.28, 135.00, 116.12, 114.41, 112.97, 104.62 (Ar-C,
CN), 95.68 (C-1), 69.26 (C-5), 68.02 (C-2), 67.35 (C-3), 64.38 (C-4),
60.85 (C-6), 19.81, 19.67, 19.64, 19.58 ppm (4 COCH3); elemental
analysis calcd (%) for C21H22BrNO10: C 47.74, H 4.02, N 2.65, found:
C 47.78, H 4.29, N 2.67.
Methyl 4’-(2,3,4,6-tetra-O-acetyl-a-d-mannopyranosyloxy)-3’-flu-
orobiphenyl-4-carboxylate (12a): Prepared according to general
procedure B from 10a (100 mg, 0.192 mmol), 4-methoxycarbonyl-
phenylboronic acid (11, 38.0 mg, 0.211 mmol), Pd(dppf)Cl2·CH2Cl2
(4.7 mg, 5.8 mmol) and K3PO4 (61.1 mg, 0.288 mmol). Yield: 83 mg
(75%) as white solid. Rf=0.26 (PE/EtOAc, 2:1) ; [a]
20
D +93.0 (c=0.60,
EtOAc); 1H NMR (500 MHz, CDCl3): d=8.03–8.02 (m, 2H, Ar-H),
7.53–7.52 (m, 2H, Ar-H), 7.33 (dd, J=2.1, 11.8 Hz, 1H, Ar-H), 7.27
(dd, J=1.5, 8.9 Hz, 1H, Ar-H), 7.20 (t, J=8.3 Hz, 1H, Ar-H), 5.53 (dd,
J=3.4, 10.0 Hz, 1H, H-3), 5.49–5.47 (m, 2H, H-1, H-2), 5.32 (t, J=
10.0 Hz, 1H, H-4), 4.22 (dd, J=5.4, 12.1 Hz, 1H, H-6a), 4.17 (m, 1H,
H-5), 4.05 (dd, J=1.8, 12.1 Hz, 1H, H-6b), 3.87 (s, 3H, OCH3), 2.15,
2.01, 1.98, 1.97 ppm (4 s, 12H, 4OAc); 13C NMR (125 MHz, CDCl3):
d=170.54, 170.00, 169.86, 169.79, 166.82 (5 CO), 153.50 (d, J=
247.0 Hz, Ar-C), 143.56 (d, J=1.8 Hz, Ar-C), 143.22 (d, J=11.2 Hz,
Ar-C), 136.48 (d, J=6.7 Hz, Ar-C), 130.27, 129.29, 126.75 (5C, Ar-C),
123.16 (d, J=3.4 Hz, Ar-C), 119.32 (Ar-C), 115.64 (d, J=19.4 Hz, Ar-
C), 97.42 (C-1), 69.71 (C-5), 69.26 (C-2), 68.70 (C-3), 65.83 (C-4),
62.10 (C-6), 52.24 (OMe), 20.91, 20.74, 20.72, 20.70 ppm (4 COCH3);
HRMS: m/z : calcd for C28H29FNaO12 [M+Na]
+ : 599.1535, found:
599.1536.
Methyl 4’-(2,3,4,6-tetra-O-acetyl-a-d-mannopyranosyloxy)-3’-
methylbiphenyl-4-carboxylate (12b): Prepared according to gen-
eral procedure B from 10b (100 mg, 0.193 mmol), 11 (38.2 mg,
0.212 mmol), Pd(dppf)Cl2·CH2Cl2 (4.7 mg, 5.8 mmol) and K3PO4
(61.5 mg, 0.290 mmol). Yield: 87 mg (79%) as white solid. Rf=0.41
(PE/EtOAc, 1:0.9) ; [a]20D +85.4 (c=0.80, EtOAc);
1H NMR (500 MHz,
CDCl3): d=8.09–8.07 (m, 2H, Ar-H), 7.61 (m, 2H, Ar-H), 7.46 (d, J=
1.8 Hz, 1H, Ar-H), 7.40 (dd, J=2.3, 8.5 Hz, 1H, Ar-H), 7.18 (d, J=
8.5 Hz, 1H, Ar-H), 5.61–5.58 (m, 2H, H-1, H-3), 5.50 (dd, J=2.0,
3.5 Hz, 1H, H-2), 5.41 (t, J=10.0 Hz, 1H, H-4), 4.31 (dd, J=5.9,
12.8 Hz, 1H, H-6a), 4.14–4.09 (m, 2H, H-5, H-6b), 3.94 (s, 3H, OCH3),
2.37 (s, 3H, CH3), 2.22, 2.08, 2.05, 2.04 ppm (4 s, 12H, 4 OAc);
13C NMR (125 MHz, CDCl3): d=170.55, 170.06, 169.98, 169.75,
167.00 (5 CO), 154.05, 144.94, 134.54, 130.10, 130.02, 128.54,
128.05, 126.66, 125.76, 114.46 (12C, Ar-C), 95.84 (C-1), 69.48 (C-5),
69.37 (C-2), 68.98 (C-3), 65.81 (C-4), 62.13 (C-6), 52.12 (OCH3), 21.06,
20.91, 20.72, 20.70 (4 COCH3), 16.40 ppm (CH3); HRMS: m/z : calcd
for C29H32NaO12 [M+Na]
+ : 595.1786, found: 595.1786; elemental
analysis calcd (%) for C29H32O12: C 60.84, H 5.63, found: C 60.76, H
5.80.
Methyl 4’-(2,3,4,6-tetra-O-acetyl-a-d-mannopyranosyloxy)-3’-tri-
fluoromethylbiphenyl-4-carboxylate (12c): Prepared according to
general procedure B from 10c (100 mg, 0.175 mmol), 11 (34.6 mg,
0.193 mmol), Pd(dppf)Cl2·CH2Cl2 (4.3 mg, 5.3 mmol) and K3PO4
(55.7 mg, 0.263 mmol). Yield: 100 mg (91%) as white solid. Rf=0.25
(PE/EtOAc, 2:1) ; [a]20D +43.3 (c=1.00, EtOAc);
1H NMR (500 MHz,
CDCl3): d=8.13–8.11 (m, 2H, Ar-H), 7.87 (d, J=2.1 Hz, 1H, Ar-H),
7.75 (dd, J=2.2, 8.7 Hz, 1H, Ar-H), 7.63–7.61 (m, 2H, Ar-H), 7.35 (d,
J=8.7 Hz, 1H, Ar-H), 5.70 (d, J=1.7 Hz, 1H, H-1), 5.57 (dd, J=3.5,
10.1 Hz, 1H, H-3), 5.50 (dd, J=2.0, 3.4 Hz, 1H, H-2), 5.43 (t, J=
10.0 Hz, 1H, H-4), 4.30 (dd, J=5.6, 12.8 Hz, 1H, H-6a), 4.11–4.08 (m,
2H, H-5, H-6b), 3.95 (s, 3H, OCH3), 2.24, 2.07, 2.06, 2.05 ppm (4 s,
12H, 4 OAc); 13C NMR (125 MHz, CDCl3): d=170.45, 169.96, 169.78,
169.65, 166.76 (5 CO), 152.94, 143.37, 134.59, 130.34, 129.40,
126.79, 126.14, 115.79 (12C, Ar-C), 95.67 (C-1), 69.91 (C-5), 69.15 (C-
2), 68.56 (C-3), 65.50 (C-4), 61.97 (C-6), 52.25 (OCH3), 20.88, 20.71,
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20.66 ppm (4C, 4 COCH3); HRMS: m/z : calcd for C29H29F3NaO12 [M+
Na]+ : 649.1503, found: 649.1503.
Methyl 4’-(2,3,4,6-tetra-O-acetyl-a-d-mannopyranosyloxy)-3’-me-
thoxybiphenyl-4-carboxylate (12d): Prepared according to gener-
al procedure B from 10d (100 mg, 0.188 mmol), 11 (37.1 mg,
0.206 mmol), Pd(dppf)Cl2·CH2Cl2 (4.6 mg, 5.6 mmol) and K3PO4
(59.9 mg, 0.282 mmol). Yield: 91 mg (83%) as white solid. Rf=0.25
(PE/EtOAc, 1:0.9) ; [a]20D +50.7 (c=1.40, EtOAc);
1H NMR (500 MHz,
CDCl3): d=8.10–8.08 (m, 2H, Ar-H), 7.62–7.60 (m, 2H, Ar-H), 7.19–
7.13 (m, 3H, Ar-H), 5.64 (dd, J=3.5, 10.0 Hz, 1H, H-3), 5.58 (dd, J=
1.8, 3.5 Hz, 1H, H-2), 5.53 (d, J=1.7 Hz, 1H, H-1), 5.38 (t, J=
10.0 Hz, 1H, H-4), 4.34–4.28 (m, 2H, H-5, H-6a), 4.12 (m, 1H, H-6b),
3.94 (2 s, 6H, 2 OCH3), 2.21, 2.08, 2.05, 2.04 ppm (4 s, 12H, 4 OAc);
13C NMR (125 MHz, CDCl3): d=170.61, 170.02, 169.92, 169.83,
166.94 (5 CO), 151.01, 145.06, 144.92, 136.51, 130.13, 128.86,
126.87, 119.72, 119.32, 111.60 (12C, Ar-C), 97.50 (C-1), 69.48 (C-5),
69.43 (C-2), 68.91 (C-3), 66.12 (C-4), 62.29 (C-6), 56.01 (OCH3), 52.18
(CO2CH3), 20.95, 20.76, 20.74, 20.72 ppm (4 COCH3); HRMS: m/z :
calcd for C29H32NaO13 [M+Na]
+ : 611.1735, found: 611.1736.
Methyl 4’-(2,3,4,6-tetra-O-acetyl-a-d-mannopyranosyloxy)-3’-cy-
clopropylbiphenyl-4-carboxylate (12e): Prepared according to
general procedure B from 10e (100 mg, 0.184 mmol), 11 (36.4 mg,
0.202 mmol), Pd(dppf)Cl2·CH2Cl2 (4.5 mg, 5.5 mmol) and K3PO4
(58.6 mg, 0.276 mmol). Yield: 60 mg (55%) as white solid. Rf=0.48
(PE/EtOAc, 2:1) ; [a]20D +53.0 (c=0.70, EtOAc);
1H NMR (500 MHz,
CDCl3): d=8.08–8.07 (m, 2H, Ar-H), 7.59–7.57 (m, 2H, Ar-H), 7.37
(dd, J=2.4, 8.5 Hz, 1H, Ar-H), 7.19–7.17 (m, 2H, Ar-H), 5.64 (dd, J=
3.5, 10.1 Hz, 1H, H-3), 5.61 (d, J=1.6 Hz, 1H, H-1), 5.54 (dd, J=1.9,
3.4 Hz, 1H, H-2), 5.42 (t, J=10.1 Hz, 1H, H-4), 4.31 (dd, J=5.3,
12.2 Hz, 1H, H-6a), 4.19–4.10 (m, 2H, H-5, H-6b), 3.94 (s, 3H, OCH3),
2.22 (s, 3H, OAc), 2.17 (m, 1H, H-cPr), 2.08–2.05 (m, 9H, 3 OAc),
1.06–1.05 (m, 2H, CH2-cPr), 0.74–0.73 ppm (m, 2H, CH2-cPr) ;
13C NMR (125 MHz, CDCl3): d=170.55, 170.06, 170.02, 169.75,
166.98 (5 CO), 154.76, 145.12, 134.83, 133.56, 130.08, 128.58,
126.71, 125.33, 125.06, 114.84 (12C, Ar-C), 96.04 (C-1), 69.49 (C-5),
69.42 (C-2), 69.02 (C-3), 65.81 (C-4), 62.15 (C-6), 52.12 (OCH3), 20.91,
20.71 (4C, 4 COCH3), 9.78, 7.58 ppm (3C, cPr) ; elemental analysis
calcd (%) for C29H32O12: C 62.20, H 5.72, found: C 62.00, H 5.86.
Methyl 4’-(2,3,4,6-tetra-O-acetyl-a-d-mannopyranosyloxy)-3’-cya-
nobiphenyl-4-carboxylate (12 f): Prepared according to general
procedure B from 10 f (100 mg, 0.189 mmol), 11 (37.5 mg,
0.208 mmol), Pd(dppf)Cl2·CH2Cl2 (4.6 mg, 5.7 mmol) and K3PO4
(60.2 mg, 0.284 mmol). Yield: 92 mg (84%) as white solid. Rf=0.18
(PE/EtOAc, 2:1) ; [a]20D +61.4 (c=0.80, EtOAc);
1H NMR (500 MHz,
CDCl3): d=8.06–8.05 (m, 2H, Ar-H), 7.80 (d, J=2.3 Hz, 1H, Ar-H),
7.72 (dd, J=2.3, 8.8 Hz, 1H, Ar-H), 7.53–7.51 (m, 2H, Ar-H), 7.28 (d,
J=8.8 Hz, 1H, Ar-H), 5.64 (d, J=1.7 Hz, 1H, H-1), 5.55 (dd, J=3.5,
10.0 Hz, 1H, H-3), 5.49 (dd, J=1.9, 3.4 Hz, 1H, H-2), 5.37 (t, J=
10.0 Hz, 1H, H-4), 4.24 (dd, J=5.0, 12.4 Hz, 1H, H-6a), 4.12 (ddd,
J=2.2, 4.9, 10.0 Hz, 1H, H-5), 4.05 (dd, J=2.2, 12.4 Hz, 1H, H-6b),
3.88 (s, 3H, OCH3), 2.16, 2.01, 1.99, 1.98 ppm (4 s, 12H, 4 OAc);
13C NMR (125 MHz, CDCl3): d=170.45, 170.01, 169.78, 169.54,
166.65 (5 CO), 156.84, 142.44, 135.67, 132.36, 129.77, 126.76,
115.99, 115.18, 104.47 (13C, Ar-C, CN), 96.63 (C-1), 70.24 (C-5), 69.17
(C-2), 68.49 (C-3), 65.48 (C-4), 60.85 (C-6), 20.88, 20.73, 20.71,
20.64 ppm (4 COCH3); HRMS: m/z : calcd for C29H29NNaO12 [M+
Na]+ : 606.1582, found: 606.1583.
Methyl 3’-fluoro-4’-(a-d-mannopyranosyloxy)biphenyl-4-carbox-
ylate (13a): Prepared according to general procedure C from 12a
(33 mg, 0.057 mmol). Yield: 15 mg (65%). [a]20D +114.3 (c=0.30,
MeOH); 1H NMR (500 MHz, CD3OD): d=7.98–7.97 (m, 2H, Ar-H),
7.63–7.61 (m, 2H, Ar-H), 7.42–7.36 (m, 3H, Ar-H), 5.45 (d, J=1.7 Hz,
1H, H-1), 3.99 (dd, J=1.9, 3.4 Hz, 1H, H-2), 3.82–3.84 (m, 4H, H-3,
OCH3), 3.71–3.56 ppm (m, 4H, H-4, H-5, H-6);
13C NMR (125 MHz,
CD3OD): d=168.34 (CO), 154.75 (d, J=243.8 Hz, Ar-C), 145.6 (2C,
Ar-C), 136.37 (d, J=6.9 Hz, Ar-C), 130.20, 129.20, 127.80, 124.33,
120.33 (7C, Ar-C), 116.00 (d, J=20.0 Hz, Ar-C), 101.40 (C-1), 75.97
(C-5), 72.31 (C-3), 71.82 (C-2), 68.18 (C-4), 62.65 (C-6), 52.65 ppm
(OCH3); HRMS: m/z : calcd for C20H21FNaO8 [M+Na]
+ : 431.1113,
found: 431.1112.
Methyl 4’-(a-d-mannopyranosyloxy)-3’-methylbiphenyl-4-carbox-
ylate (13b): Prepared according to general procedure C from 12b
(31 mg, 0.054 mmol). Yield: 16 mg (73%). [a]20D +110.5 (c=0.35,
MeOH); 1H NMR (500 MHz, CD3OD): d=7.96–7.94 (m, 2H, Ar-H),
7.60–7.58 (m, 2H, Ar-H), 7.40–7.37 (m, 2H, Ar-H), 7.22 (d, J=8.5 Hz,
1H, Ar-H), 5.47 (d, J=1.6 Hz, 1H, H-1), 3.97 (dd, J=1.9, 3.4 Hz, 1H,
H-2), 3.87 (dd, J=3.4, 9.5 Hz, 1H, H-3), 3.82 (s, 3H, OMe), 3.67–3.52
(m, 3H, H-4, H-6), 3.46 (m, 1H, H-5), 2.21 ppm (s, 3H, Me); 13C NMR
(125 MHz, CD3OD): d=168.56 (CO), 156.20, 146.86, 134.70, 131.07,
130.07, 130.54, 129.45, 128.92, 127.63, 126.85, 115.83 (12C, Ar-C),
99.76 (C-1), 75.55 (C-5), 72.64 (C-3), 72.11 (C-2), 68.31 (C-4), 62.68
(C-6), 52.59 ppm (OCH3), 16.54 (CH3); HRMS: m/z : calcd for
C21H24NaO8 [M+Na]
+ : 427.1363, found: 427.1370.
Methyl 3’-trifluoromethyl-4’-(a-d-mannopyranosyloxy)biphenyl-
4-carboxylate (13c): Prepared according to general procedure C
from 12c (30 mg, 0.048 mmol). Yield: 14 mg (64%). [a]20D +113.1
(c=0.40, MeOH); 1H NMR (500 MHz, CD3OD): d=8.11–8.10 (m, 2H,
Ar-H), 7.92–7.90 (m, 2H, Ar-H), 7.75–7.73 (m, 2H, Ar-H), 7.63 (d, J=
8.4 Hz, 1H, Ar-H), 5.69 (d, J=1.5 Hz, 1H, H-1), 4.09 (dd, J=1.8,
3.3 Hz, 1H, H-2), 3.98–3.94 (m, 4H, H-3, OMe), 3.79–3.73 (m, 3H, H-
4, H-6), 3.61 ppm (ddd, J=2.3, 5.7, 9.6 Hz, 1H, H-5); 13C NMR
(125 MHz, CD3OD): d=168.29 (CO), 155.54, 145.13, 134.74, 133.45,
131.36, 131.29, 130.32, 127.91, 127.85, 126.44, 117.80 (Ar-C), 100.27
(C-1), 76.13 (C-5), 72.24 (C-3), 71.74 (C-2), 68.09 (C-4), 62.67 ppm (C-
6), 52.69 (OMe); HRMS: m/z : calcd for C21H21F3NaO8 [M+Na]
+ :
481.1081, found: 481.1082.
Methyl 4’-(a-d-mannopyranosyloxy)-3’-methoxybiphenyl-4-car-
boxylate (13d): Prepared according to general procedure C from
12d (32 mg, 0.055 mmol). Yield: 12 mg (52%). [a]20D +133.1 (c=
0.20, MeOH); 1H NMR (500 MHz, CD3OD): d=7.97–7.96 (m, 2H, Ar-
H), 7.63–7.61 (m, 2H, Ar-H), 7.21–7.11 (m, 3H, Ar-H), 5.37 (d, J=
1.7 Hz, 1H, H-1), 4.00 (dd, J=1.8, 3.4 Hz, 1H, H-2), 3.86 (dd, J=3.5,
8.8 Hz, 1H, H-3), 3.82 (s, 6H, 2 CH3), 3.70–3.63 ppm (m, 4H, H-4, H-
5, H-6); 13C NMR (125 MHz, CD3OD): d=168.50 (CO), 152.33, 147.40,
146.83, 136.56, 131.08, 129.76, 127.87, 120.86, 120.10, 112.54 (Ar-C),
101.51 (C-1), 75.66 (C-5), 72.40 (C-2), 72.00 (C-3), 68.34 (C-4), 62.70
(C-6), 56.61 (OMe), 52.63 ppm (OMe); HRMS: m/z : calcd for
C21H24NaO9 [M+Na]
+ : 443.1313, found: 443.1315.
Methyl 3’-cyclopropyl-4’-(a-d-mannopyranosyloxy)biphenyl-4-
carboxylate (13e): Prepared according to general procedure C
from 12e (21 mg, 0.035 mmol). Yield: 10 mg (67%). [a]20D +101.6
(c=0.24, MeOH); 1H NMR (500 MHz, CD3OD): d=8.07–8.05 (m, 2H,
Ar-H), 7.68–7.67 (m, 2H, Ar-H), 7.46 (dd, J=2.4, 8.5 Hz, 1H, Ar-H),
7.33 (d, J=8.5 Hz, 1H, Ar-H), 7.21 (d, J=2.4 Hz, 1H, Ar-H), 5.60 (d,
J=1.7 Hz, 1H, H-1), 4.13 (dd, J=1.9, 3.3 Hz, 1H, H-2), 4.02 (dd, J=
3.4, 9.5 Hz, 1H, H-3), 3.93 (s, 3H, OMe), 3.81–3.74 (m, 3H, H-4, H-6),
3.69 (m, 1H, H-5), 2.19 (m, 1H, H-cPr), 1.01–0.99 (m, 2H, CH2-cPr),
0.76–0.74 ppm (m, 2H, CH2-cPr);
13C NMR (125 MHz, CD3OD): d=
168.54 (CO), 156.92, 146.98, 135.00, 134.59, 131.07, 127.34, 127.67,
126.39, 125.34, 116.29 (12C, Ar-C), 100.14 (C-1), 75.61 (C-5), 72.64
(C-3), 72.14 (C-2), 68.33 (C-4), 62.71 (C-6), 52.60 (OCH3), 10.93,
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8.06 ppm (3C, cPr) ; HRMS: m/z : calcd for C23H26NaO8 [M+Na]
+ :
453.1520, found: 453.1519.
Methyl 3’-cyano-4’-(a-d-mannopyranosyloxy)biphenyl-4-carbox-
ylate (13 f): Prepared according to general procedure C from 12 f
(37 mg, 0.063 mmol). Yield: 19 mg (73%). [a]20D +101.1 (c=0.30,
MeOH); 1H NMR (500 MHz, CD3OD): d=8.00–7.99 (m, 2H, Ar-H),
7.90–7.85 (m, 2H, Ar-H), 7.65–7.63 (m, 2H, Ar-H), 7.50 (d, J=8.8 Hz,
1H, Ar-H), 5.63 (s, 1H, H-1), 4.03 (m, 1H, H-2), 3.91 (dd, J=2.8,
9.4 Hz, 1H, H-3), 3.83 (s, 3H, OMe), 3.69–3.60 (m, 3H, H-4, H-6),
3.50 ppm (m, 1H, H-5); 13C NMR (125 MHz, CD3OD): d=168.22
(CO), 159.29, 144.38, 135.61, 134.50, 133.08, 131.31, 130.56, 127.87,
117.36, 116.75, 104.35 (13C, Ar-C, CN), 100.62 (C-1), 76.39 (C-5),
72.27 (C-2), 71.62 (C-3), 68.07 (C-4), 62.64 (C-6), 52.71 ppm (OMe);
HRMS: m/z : calcd for C21H21NNaO8 [M+Na]
+ : 438.1159, found:
438.1162.
Sodium 3’-fluoro-4’-(a-d-mannopyranosyloxy)biphenyl-4-carbox-
ylate (14a): Prepared according to general procedure D from 12a
(50 mg, 0.087 mmol). Yield: 21 mg (58%). [a]20D +112.7 (c=0.40,
MeOH); 1H NMR (500 MHz, D2O): d=7.78–7.77 (m, 2H, Ar-H), 7.46–
7.45 (m, 2H, Ar-H), 7.30–7.15 (m, 3H, Ar-H), 5.43 (s, 1H, H-1), 4.07
(s, 1H, H-2), 3.93 (d, J=3.3 Hz, 1H, H-3), 3.68–3.62 ppm (m, 4H, H-
4, H-5, H-6); 13C NMR (125 MHz, D2O): d=175.19 (CO), 153.02 (d,
J=242.6 Hz, Ar-C), 142.52 (d, J=10.8 Hz, Ar-C), 141.23 (Ar-C),
135.53 (d, J=6.4 Hz, Ar-C), 135.07, 129.43, 126.25, 126.01, 122.96,
119.13 (Ar-C), 114.83 (d, J=19.4 Hz, Ar-C), 99.32 (C-1), 73.65 (C-5),
70.23 (C-3), 69.67 (C-2), 66.35 (C-4), 60.52 ppm (C-6); HRMS: m/z :
calcd for C19H19FNaO8 [M+Na]
+ : 417.0956, found: 417.0957.
Sodium 4’-(a-d-mannopyranosyloxy)-3’-methylbiphenyl-4-car-
boxylate (14b): Prepared according to general procedure D from
12b (46 mg, 0.081 mmol). Yield: 5 mg (15%). [a]20D +85.7 (c=0.20,
MeOH); 1H NMR (500 MHz, D2O): d=7.78–7.76 (m, 2H, Ar-H), 7.53–
7.52 (m, 2H, Ar-H), 7.43–7.37 (m, 2H, Ar-H), 7.10 (d, J=8.6 Hz, 1H,
Ar-H), 5.52 (d, J=1.6 Hz, 1H, H-1), 4.07 (dd, J=1.9, 3.4 Hz, 1H, H-2),
3.95 (dd, J=3.5, 9.6 Hz, 1H, H-3), 3.63–3.50 (m, 4H, H-4, H-5, H-6),
2.14 ppm (s, 3H, CH3);
13C NMR (125 MHz, D2O): d=153.33, 142.57,
134.59, 133.97, 129.47, 128.42, 126.25, 125.43, 114.99 (12C, Ar-C),
97.46 (C-1), 73.39 (C-5), 70.54 (C-3), 69.88 (C-2), 66.53 (C-4), 60.60
(C-6), 15.31 ppm (CH3); HRMS: m/z : calcd for C20H22NaO8 [M+Na]
+ :
413.1207, found: 413.1209.
Sodium 3’-trifluoromethyl-4’-(a-d-mannopyranosyloxy)biphenyl-
4-carboxylate (14c): Prepared according to general procedure D
from 12c (45 mg, 0.072 mmol). Yield: 25 mg (74%). [a]20D +94.2
(c=0.30, MeOH); 1H NMR (500 MHz, D2O): d=7.83–7.81(m, 3H, Ar-
H), 7.75 (d, J=8.7 Hz, 1H, Ar-H), 7.57–7.55 (m, 2H, Ar-H), 7.31 (d,
J=8.8 Hz, 1H, Ar-H), 5.64 (s, 1H, H-1), 4.09 (d, J=1.5 Hz, 1H, H-2),
3.94 (dd, J=3.4, 9.7 Hz, 1H, H-3), 3.67–3.60 (m, 3H, H-4, H-6),
3.54 ppm (m, 1H, H-5); 13C NMR (125 MHz, D2O): d=175.25 (CO),
152.40, 141.31, 135.09, 133.53, 131.93, 129.46, 126.34, 125.59,
115.86 (12C, Ar-C), 97.20 (C-1), 73.68 (C-5), 70.19 (C-3), 69.58 (C-2),
66.36 (C-4), 60.55 ppm (C-6); HRMS: m/z : calcd for C20H19F3NaO8
[M+Na]+ : 467.0924, found: 467.0923.
Sodium 4’-(a-d-mannopyranosyloxy)-3’-methoxybiphenyl-4-car-
boxylate (14d): Prepared according to general procedure D from
12d (47 mg, 0.080 mmol). Yield: 10 mg (29%). [a]20D +115.1 (c=
0.30, MeOH); 1H NMR (500 MHz, D2O): d=7.81–7.79 (m, 2H, Ar-H),
7.54–7.53 (m, 2H, Ar-H), 7.19–7.11 (m, 3H, Ar-H), 5.43 (d, J=1.6 Hz,
1H, H-1), 4.10 (dd, J=1.8, 3.5 Hz, 1H, H-2), 3.96 (dd, J=3.5, 9.0 Hz,
1H, H-3), 3.78 (s, 3H, OCH3), 3.70–3.62 ppm (m, 4H, H-4, H-5, H-6);
13C NMR (125 MHz, D2O): d=175.24 (CO), 149.53, 144.24, 142.42,
135.59, 134.75, 129.40, 126.41, 119.86, 118.03, 111.44 (12C, Ar-C),
99.23 (C-1), 73.53 (C-5), 70.32 (C-3), 69.78 (C-2), 66.40 (C-4), 60.54
(C-6), 55.81 ppm (OCH3); HRMS: m/z : calcd for C20H22NaO9 [M+
Na]+ : 429.1156, found: 429.1154.
Sodium 3’-cyclopropyl-4’-(a-d-mannopyranosyloxy)biphenyl-4-
carboxylate (14e): Prepared according to general procedure D
from 12e (28 mg, 0.047 mmol). Yield: 6 mg (26%). [a]20D +149.8
(c=0.20, MeOH); 1H NMR (500 MHz, D2O): d=7.79–7.77 (m, 2H, Ar-
H), 7.48–7.46 (m, 2H, Ar-H), 7.30 (d, J=7.8 Hz, 1H, Ar-H), 7.07–7.05
(m, 2H, Ar-H), 5.52 (s, 1H, H-1), 4.10 (m, 1H, H-2), 3.98 (dd, J=3.4,
9.5 Hz, 1H, H-3), 3.69–3.62 (m, 4H, H-4, H-5, H-6), 1.99 (m, 1H, H-
cPr), 0.86–0.84 (m, 2H, CH2-cPr), 0.58–0.56 ppm (m, 2H, CH2-cPr);
13C NMR (125 MHz, D2O): d=175.34 (CO), 153.82, 142.58, 134.57,
134.34, 133.74, 129.38, 126.26, 125.01, 124.01, 115.47 (12C, Ar-C),
97.88 (C-1), 73.47 (C-5), 70.55 (C-3), 69.93 (C-2), 66.46 (C-4), 60.57
(C-6), 9.16, 7.26, 7.06 ppm (cPr); HRMS: m/z : calcd for C22H24ONaO8
[M+Na]+ : 439.1363, found: 439.1363.
Sodium 3’-cyano-4’-(a-d-mannopyranosyloxy)biphenyl-4-carbox-
ylate (14 f): A two-neck flask was charged with 10 f (150 mg,
0.28 mmol), 4-carboxybenzene boronic acid pinacol ester (15)
(77 mg, 0.31 mmol), Pd(dppf)Cl2· CH2Cl2 (7 mg, 0.008 mmol), K3PO4
(89 mg, 0.42 mmol) and a stirring bar. The flask was evacuated and
flushed with argon, then anhydrous DMF (2 mL) was added under
a stream of argon. The mixture was degassed in an ultrasonic bath
and flushed with argon for 5 min, and then stirred at 80 8C over-
night. The reaction mixture was cooled to RT, diluted with EtOAc
(50 mL), and washed with H2O (50 mL) and brine (50 mL). The or-
ganic layer was dried over Na2SO4 and concentrated in vacuo. The
residue was purified by MPLC on silica gel (CH2Cl2/MeOH, 10:1–8:1)
to afford the biphenyl intermediate (162 mg). The intermediate
was dissolved in dry MeOH (4 mL) and treated with freshly pre-
pared 1m NaOMe/MeOH (28 mL) for 4 h at RT. The reaction mixture
was neutralized with Amberlyst-15 (H+), filtered and concentrated.
The crude product was transformed into the sodium salt by pass-
ing through a small column of Dowex 50X8 (Na+ form) ion-ex-
change resin. After concentration the residue was purified by
MPLC (RP-18, H2O) followed by size-exclusion chromatography (P-2
gel, H2O) to give 14 f (19 mg, 17%) as a white solid after final lyo-
philization from H2O. [a]
20
D +75.3 (c=0.20, MeOH);
1H NMR
(500 MHz, D2O): d=7.86–7.79 (m, 4H, Ar-H), 7.53–7.52 (m, 2H, Ar-
H), 7.31 (d, J=8.9 Hz, 1H, Ar-H), 5.64 (d, J=1.9 Hz, 1H, H-1), 4.11
(dd, J=1.9, 3.4 Hz, 1H, H-2), 4.00 (dd, J=3.5, 9.7 Hz, 1H, H-3),
3.73–3.65 (m, 3H, H-4, H-6), 3.58 ppm (ddd, J=2.4, 5.5, 9.9 Hz, 1H,
H-5); 13C NMR (125 MHz, D2O): d=175.12 (CO), 156.82, 140.37,
134.39, 133.56, 131.83, 129.58, 126.25, 116.82, 115.78, 102.08 (13C,
Ar-C, CN), 98.09 (C-1), 73.97 (C-5), 70.29 (C-3), 69.54 (C-2), 66.36 (C-
4), 60.56 ppm (C-6); HRMS: m/z : calcd for C21H21NNaO8 [M+Na]
+ :
424.1003, found: 424.1003.
3-Bromobenzyl 2,3,4,6-tetra-O-acetyl-a-d-mannopyranoside
(17a): Prepared according to general procedure A from 8[12] and 3-
bromobenzyl alcohol (16a). Yield: 100 mg (34%) as colorless oil.
Rf=0.43 (PE/EtOAc, 2:1) ; [a]
20
D +42.0 (c=1.40, EtOAc);
1H NMR
(500 MHz, CDCl3): d=7.48–7.46, 7.30–7.24 (m, 4H, Ar-H), 5.37 (dd,
1H, J=3.4, 10.1 Hz, H-3), 5.33–5.29 (m, 2H, H-2, H-4), 4.88 (d, 1H,
J=1.3 Hz, H-1), 4.68, 4.54 (A, B of AB, J=12.1 Hz, 2H, CH2Ar), 4.29
(dd, 1H, J=5.2, 12.3 Hz, H-6a), 4.07 (dd, 1H, J=2.3, 12.3 Hz, H-6b),
3.99 (ddd, 1H, J=2.4, 5.2, 9.9 Hz, H-5), 2.15, 2.13, 2.05, 2.00 ppm
(4 s, 12H, 4 OAc); 13C NMR (125 MHz, CDCl3): d=170.59, 169.98,
169.87, 169.69 (4 CO), 138.49, 131.34, 131.09, 130.24, 126.66, 122.57
(Ar-C), 96.83 (C-1), 69.43, 69.02, 68.90, 68.78 (C-2, C-3, C-5, CH2Ar),
66.03 (C-4), 62.36 (C-6), 20.86, 20.76, 20.68 ppm (4C, COCH3); ESI-
MS: m/z : calcd for C21H25BrNaO10 [M+Na]
+ : 539.05, found: 539.14.
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5-Bromo-2-chlorobenzyl 2,3,4,6-tetra-O-acetyl-a-d-mannopyra-
noside (17b): Prepared according to general procedure A from
8[12] and 5-bromo-2-chlorobenzyl alcohol (16b). Yield: 152 mg
(48%) as a white solid. Rf=0.56 (PE/EtOAc, 2:1) ; [a]
20
D +48.0 (c=
1.50, EtOAc); 1H NMR (500 MHz, CDCl3): d=7.48 (t, J=1.8 Hz, 1H,
Ar-H), 7.38 (s, 1H, Ar-H), 7.35 (d, J=1.8 Hz, 1H, Ar), 5.33 (m, 3H, H-
2, H-3, H-4), 4.88 (d, J=1.5 Hz, 1H, H-1), 4.65, 4.51 (A, B of AB, J=
12.3 Hz, 2H, CH2Ar), 4.30 (dd, J=5.3, 12.3 Hz, 1H, H-6a), 4.09 (dd,
J=2.4, 12.3 Hz, 1H, H-6b), 3.98 (ddd, J=2.4, 5.2, 9.7 Hz, 1H, H-5),
2.16, 2.13, 2.05, 2.01 ppm (4 s, 12H, 4 OAc); 13C NMR (125 MHz,
CDCl3): d=170.58, 169.98, 169.89, 169.69 (4 CO), 139.77, 135.35,
129.25, 126.85, 122.91 (6C, Ar-C), 96.96 (C-1), 69.33, 68.93, 68.24
(4C, C-2, C-3, C-5, CH2Ar), 65.98 (C-4), 62.38 (C-6), 20.86, 20.77,
20.68 ppm (4C, 4COCH3); ESI-MS: m/z : calcd for C21H24BrClNaO10
[M+Na]+ : 573.01, found: 573.06.
2-Bromobenzyl 2,3,4,6-tetra-O-acetyl-a-d-mannopyranoside
(17c): Prepared according to general procedure A from 8[12] and 2-
bromobenzyl alcohol (16c). Yield: 140 mg (47%) as a white solid.
Rf=0.55 (petrol ether/EtOAc, 2:1) ; [a]
20
D +44.6 (c=2.10, EtOAc);
1H NMR (500 MHz, CDCl3): d=7.57 (dd, J=1.0, 8.0 Hz, 1H, Ar-H),
7.47 (dd, J=1.4, 7.6 Hz, 1H, Ar-H), 7.35 (td, J=1.1, 7.5 Hz, 1H, Ar-
H), 7.20 (td, J=1.7, 7.9 Hz, 1H, Ar-H), 5.41 (dd, J=3.5, 10.0 Hz, 1H,
H-3), 5.35 (dd, J=1.8, 3.5 Hz, 1H, H-2), 5.31 (t, J=9.9 Hz, 1H, H-4),
4.98 (d, J=1.6 Hz, 1H, H-1), 4.83, 4.61 (A, B of AB, J=12.7 Hz, 2H,
CH2Ar), 4.29 (dd, J=5.8, 12.6 Hz, 1H, H-6a), 4.10–4.06 (m, 2H, H-6b,
H-5), 2.17, 2.12, 2.04, 2.00 ppm (4 s, 12H, 4 OAc); 13C NMR
(125 MHz, CDCl3): d=170.64, 170.02, 169.88, 169.72 (4 CO), 135.77,
132.69, 129.58, 129.49, 127.64, 122.96 (Ar-C), 97.33 (C-1), 69.48,
69.30, 69.10, 68.84 (C-2, C-3, C-5, CH2Ar), 66.05 (C-4), 62.35 (C-6),
20.88, 20.76, 20.69 ppm (4C, 4COCH3); ESI-MS: m/z : calcd for
C21H25BrNaO10 [M+Na]
+ : 539.05, found: 539.14.
Methyl 3’-[(2,3,4,6-tetra-O-acetyl-a-d-mannopyranosyloxy)me-
thyl]biphenyl-4-carboxylate (18a): Prepared according to general
procedure B from 17a (87.0 mg, 0.167 mmol), 11 (33.1 mg,
0.184 mmol), Pd(dppf)Cl2·CH2Cl2 (4.1 mg, 5.0 mmol) and K3PO4
(53.2 mg, 0.251 mmol). Yield: 70 mg (73%) as colorless oil. Rf=0.30
(PE/EtOAc, 2:1) ; [a]20D +41.2 (c=1.00, EtOAc);
1H NMR (500 MHz,
CDCl3): d=8.13–8.11 (m, 2H, Ar-H), 7.68–7.67 (m, 2H, Ar-H), 7.60–
7.58 (m, 2H, Ar-H), 7.48 (t, J=4.7 Hz, 1H, Ar-H), 7.39 (d, J=7.7 Hz,
1H, Ar-H), 5.41 (dd, J=3.4, 10.0 Hz, 1H, H-3), 5.33–5.30 (m, 2H, H-2,
H-4), 4.94 (d, J=1.5 Hz, 1H, H-1), 4.79, 4.64 (A, B of AB, J=12.0 Hz,
2H, CH2Ar), 4.30 (dd, J=5.0, 12.1 Hz, 1H, H-6a), 4.09–4.03 (m, 2H,
H-6b, H-5), 3.94 (s, 3H, OMe), 2.15, 2.11, 2.04, 2.00 ppm (4 s, 12H, 4
OAc); 13C NMR (125 MHz, CDCl3): d=170.64, 170.03, 169.91, 169.73,
166.94 (5 CO), 145.11, 140.41, 136.97, 130.15, 129.27, 129.09,
127.94, 127.22, 127.11 (12C, Ar-C), 96.76 (C-1), 69.57, 69.09, 68.94,
66.12 (C-2, C-3, C-5, CH2Ar), 62.40 (C-4), 60.38 (C-6), 52.15 (OMe),
20.89, 20.77, 20.69 ppm (4C, 4COCH3); ESI-MS: m/z : calcd for
C29H32NaO12 [M+Na]
+ : 595.18, found: 595.21.
Methyl 3’-[(2,3,4,6-tetra-O-acetyl-a-d-mannopyranosyloxy)meth-
yl]-4’-chlorobiphenyl-4-carboxylate (18b): Prepared according to
general procedure B from 17b (143 mg, 0.260 mmol), 11 (51.5 mg,
0.286 mmol), Pd(dppf)Cl2·CH2Cl2 (6.4 mg, 7.8 mmol) and K3PO4
(82.8 mg, 0.390 mmol). Yield: 133 mg (84%) as colorless oil. Rf=
0.30 (PE/EtOAc, 2:1) ; [a]20D +45.9 (c=1.20, EtOAc);
1H NMR
(500 MHz, CDCl3): d=8.13–8.11 (m, 2H, Ar-H), 7.65–7.64 (m, 2H, Ar-
H), 7.57 (t, J=1.8 Hz, 1H, Ar-H), 7.47 (s, 1H, Ar-H), 7.37 (s, 1H, Ar-
H), 5.40 (dd, J=3.4, 10.1 Hz, 1H, H-3), 5.33–5.29 (m, 2H, H-2, H-4),
4.93 (d, J=1.4 Hz, 1H, H-1), 4.76, 4.61 (A, B of AB, J=12.1 Hz, 2H,
CH2Ar), 4.31 (dd, J=5.2, 12.3 Hz, 1H, H-6a), 4.11 (dd, J=2.3,
12.3 Hz, 1H, H-6b), 4.03 (ddd, J=2.4, 5.2, 9.9 Hz, 1H, H-5), 3.95 (s,
3H, OMe), 2.16, 2.12, 2.05, 2.00 ppm (4 s, 12H, 4OAc); 13C NMR
(125 MHz, CDCl3): d=170.61, 170.02, 169.90, 169.72, 166.75 (5 CO),
143.68, 142.16, 138.79, 135.11, 130.26, 129.68, 127.14, 125.14 (12C,
Ar-C), 96.85 (C-1), 68.99, 68.89, 68.85, 66.07 (C-2, C-3, C-5, CH2Ar),
62.42 (C-4), 60.39 (C-6), 52.23 (OMe), 20.89, 20.78, 20.71, 20.69 ppm
(4COCH3); ESI-MS: m/z : calcd for C29H31ClNaO12 [M+Na]
+ : 629.14,
found: 629.10.
Methyl 2’-[(2,3,4,6-tetra-O-acetyl-a-d-mannopyranosyloxy)me-
thyl]biphenyl-4-carboxylate (21): Prepared according to general
procedure B from 17c (115 mg, 0.223 mmol), 11 (44.1 mg,
0.245 mmol), Pd(dppf)Cl2·CH2Cl2 (5.5 mg, 6.7 mmol) and K3PO4
(71.0 mg, 0.335 mmol). Yield: 120 mg (94%) as colorless oil. Rf=
0.41 (PE/EtOAc, 2:1) ; [a]20D +38.3 (c=2.00, EtOAc);
1H NMR
(500 MHz, CDCl3): d=8.11–8.10 (m, 2H, Ar-H), 7.51–7.48 (m, 1H, Ar-
H), 7.45–7.41 (m, 4H, Ar-H), 7.29 (m, 1H, Ar-H), 5.27–5.21 (m, 2H,
H-3, H-4), 5.19 (dd, J=1.9, 3.3 Hz, 1H, H-2), 4.77 (d, J=1.4 Hz, 1H,
H-1), 4.67, 4.34 (A, B of AB, J=11.3 Hz, 2H, CH2Ar), 4.13 (dd, J=5.2,
12.5 Hz, 1H, H-6a), 3.94 (s, 3H, OMe), 3.90 (dd, J=2.2, 12.3 Hz, 1H,
H-6a), 3.52 (ddd, J=2.2, 5.1, 9.3 Hz, 1H, H-5), 2.13, 2.05, 2.04,
1.99 ppm (4 s, 12H, 4 OAc); 13C NMR (125 MHz, CDCl3): d=170.52,
169.95, 169.82, 169.74, 166.77 (5 CO), 145.48, 141.44, 133.46,
129.99, 129.91, 129.58, 129.22, 128.52, 128.21 (12C, Ar-C), 97.20 (C-
1), 69.47 (C-2), 68.98 (C-3), 68.48 (C-5), 68.13 (CH2Ar), 65.88 (C-4),
62.15 (C-6), 52.18 (OMe), 20.85, 20.66, 20.62 ppm (4C, 4COCH3);
ESI-MS: m/z : calcd for C29H32NaO12 [M+Na]
+ : 595.18, found:
595.21.
Methyl 3’-[(a-d-mannopyranosyloxy)methyl]biphenyl-4-carboxyl-
ate (19a): Prepared according to general procedure C from 18a
(24 mg, 0.042 mmol). Yield: 11 mg (65%). Rf=0.40 (CH2Cl2/MeOH,
8:1) ; [a]20D +68.0 (c=0.34, MeOH);
1H NMR (500 MHz, CD3OD): d=
8.11–8.09 (m, 2H, Ar-H), 7.77–7.75 (m, 2H, Ar-H), 7.70 (s, 1H, Ar-H),
7.63 (d, J=7.6 Hz, 1H, Ar-H), 7.49 (t, J=7.6 Hz, 1H, Ar-H), 7.45 (d,
J=7.6 Hz, 1H, Ar-H), 4.90 (d, J=1.8 Hz, 1H, H-1), 4.86, 4.63 (A, B of
AB, J=12.0 Hz, 2H, CH2Ar), 3.94 (s, 3H, OMe), 3.89–3.87 (m, 2H, H-
2, H-3), 3.79–3.73 (m, 2H, H-4, H-6a), 3.68–3.64 ppm (m, 2H, H-5, H-
6b); 13C NMR (125 MHz, CD3OD): d=168.42 (CO), 146.91, 141.31,
139.97, 131.13, 130.20, 129.07, 128.17, 127.91, 127.67 (12C, Ar-C),
100.76 (C-1), 75.02 (C-5), 72.65 (C-3), 72.22 (C-2), 69.73 (CH2Ar),
68.65 (C-4), 62.98 (C-6), 52.66 ppm (OMe); HRMS: m/z : calcd for
C21H24NaO8 [M+Na]
+ : 427.1363, found: 427.1361.
Methyl 4’-chloro-3’-[(a-d-mannopyranosyloxy)methyl]biphenyl-
4-carboxylate (19b): Prepared according to general procedure C
from 18b (40 mg, 0.066 mmol). Yield: 26 mg (90%). Rf=0.19
(CH2Cl2/MeOH, 8:1) ; [a]
20
D +101.8 (c=0.50, MeOH);
1H NMR
(500 MHz, CD3OD): d=8.06 (d, J=8.4 Hz, 2H, Ar-H), 7.69 (d, J=
8.4 Hz, 2H, Ar-H), 7.57–7.56 (m, 2H, Ar-H), 7.41 (s, 1H, Ar-H), 4.87 (s,
1H, H-1), 4.80, 4.58 (A, B of AB, J=12.3 Hz, 2H, CH2Ar), 3.91 (s, 3H,
OMe), 3.87–3.83 (m, 2H, H-2, H-3), 3.74–3.57 ppm (m, 4H, H-4, H-5,
H-6); 13C NMR (125 MHz, CD3OD): d=168.74 (CO), 145.78, 143.68,
142.71, 136.55, 131.75, 131.31, 129.02, 128.77, 127.95, 126.63 (12C,
Ar-C), 101.47 (C-1), 75.65 (C-5), 73.16 (C-3), 72.65 (C-2), 69.49
(CH2Ar), 69.13 (C-4), 63.49 (C-6), 53.26 ppm (OMe); HRMS: m/z :
calcd for C21H23ClNaO8 [M+Na]
+ : 461.0974, found: 461.0975.
Methyl 2’-[(a-d-mannopyranosyloxy)methyl]biphenyl-4-carboxyl-
ate (22): Prepared according to general procedure C from 21
(48 mg, 0.084 mmol). Yield: 16 mg (47%). Rf=0.42 (CH2Cl2/MeOH,
8:1) ; [a]20D +61.9 (c=0.90, MeOH);
1H NMR (500 MHz, CD3OD): d=
8.11–8.09 (m, 2H, Ar-H), 7.57 (m, 1H, Ar-H), 7.51–7.49 (m, 2H, Ar-H),
7.43–7.40 (m, 2H, Ar-H), 7.31 (m, 1H, Ar-H), 4.71 (A of AB, J=
11.4 Hz, 1H, CH2Ar), 4.70 (d, J=1.5 Hz, 1H, H-1), 4.38 (B of AB, J=
11.4 Hz, 1H, CH2Ar), 3.75–3.60 (m, 5H, H-2, H-3, H-4, H-6), 3.95 (s,
3H, OMe), 3.40 ppm (ddd, J=3.0, 5.6, 6.8 Hz, 1H, H-5); 13C NMR
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(125 MHz, CD3OD): d=168.42 (CO), 147.33, 142.66, 136.03, 130.83,
130.53, 130.47, 129.26, 129.15 (12C, Ar-C), 101.14 (C-1), 74.78 (C-5),
72.60 (C-3), 72.18 (C-2), 68.37 (2C, C-4, CH2Ar), 62.71 ppm (C-6),
52.69 (OMe); HRMS: m/z : calcd for C21H24NaO8Na [M+Na]
+ :
427.1363, found: 427.1367.
Sodium 3’-[(a-d-mannopyranosyloxy)methyl]biphenyl-4-carbox-
ylate (6): Prepared according to general procedure D from 18a
(35 mg, 0.061 mmol). Yield: 24 mg (96%). [a]20D +64.5 (c=0.30,
MeOH/H2O 1:1);
1H NMR (500 MHz, D2O): d=7.80–7.78 (m, 2H, Ar-
H), 7.50–7.43 (m, 4H, Ar-H), 7.31–7.24 (m, 2H, Ar-H), 4.82 (s, 1H, H-
1), 4.58, 4.40 (A, B of AB, J=11.5 Hz, 2H, CH2Ar), 3.82 (m, 1H, H-2),
3.75–3.50 ppm (m, 5H, H-3, H-4, H-5, H-6); 13C NMR (125 MHz, D2O):
d=175.14 (CO), 142.69, 140.05, 137.34, 135.01, 129.46, 129.28,
127.92, 126.87, 126.64 (12C, Ar-C), 99.40 (C-1), 72.84 (C-5), 70.51 (C-
3), 70.01 (C-2), 69.29 (CH2Ar), 66.61 (C-4), 60.71 ppm (C-6); HRMS:
m/z : calcd for C20H22NaO8 [M+Na]
+ : 413.1207, found: 413.1211.
Sodium 4’-chloro-3’-[(a-d-mannopyranosyloxy)methyl]biphenyl-
4-carboxylate (20): Prepared according to general procedure D
from 18b (54 mg, 0.089 mmol). Yield: 4 mg (10%). [a]20D +44.7 (c=
0.30, MeOH); 1H NMR (500 MHz, D2O): d=7.86 (d, J=7.8 Hz, 2H,
Ar-H), 7.58–7.56 (m, 3H, Ar-H), 7.46, 7.34 (2 s, 2H, Ar-H), 4.90 (s, 1H,
H-1), 4.58, 4.50 (A, B of AB, J=12.3 Hz, 2H, CH2Ar), 3.91 (s, 1H, H-
2), 3.78–3.75 (m, 2H, H-3, H-4), 3.71–3.59 ppm (m, 3H, H-5, H-6);
13C NMR (125 MHz, D2O): d=174.76 (CO), 141.82, 141.55, 139.40,
134.37, 129.56, 127.34, 126.74, 126.62, 125.15 (12C, Ar-C), 99.99 (C-
1), 72.96 (C-5), 70.55 (C-3), 70.04 (C-2), 68.72 (CH2Ar), 66.66 (C-4),
60.77 ppm (C-6); HRMS: m/z : calcd for C20H21ClNaO8 [M+Na]
+ :
447.0817, found: 447.0816.
Sodium 2’-[(a-d-mannopyranosyloxy)methyl]biphenyl-4-carbox-
ylate (23): Prepared according to general procedure D from 21
(78 mg, 0.137 mmol). Yield: 26 mg (46%). [a]20D +53.2 (c=0.40,
MeOH); 1H NMR (500 MHz, D2O): d=7.91–7.89 (m, 2H, Ar-H), 7.43–
7.34 (m, 5H, Ar-H), 7.26 (m, 1H, Ar-H), 4.68 (s, 1H, H-1), 4.57, 4.31
(A, B of AB, J=10.8 Hz, 2H, CH2Ar), 3.57 (m, 1H, H-2), 3.46–3.39 (m,
4H, H-3, H-4, H-6), 2.83 ppm (m, 1H, H-5); 13C NMR (125 MHz, D2O):
d=173.20 (CO), 144.48, 141.80, 133.47, 132.43, 130.69, 129.95,
129.27, 128.96, 128.32 (12C, Ar-C), 99.90 (C-1), 72.44 (C-5), 70.33 (C-
3), 69.82 (C-2), 68.14 (CH2Ar), 65.99 (C-4), 60.25 ppm (C-6); HRMS:
m/z : calcd for C20H22NaO8 [M+Na]
+ : 413.1207, found: 413.1208.
4-(4,4,5,5-Tetramethyl)-1,3,2-dioxaborolan-2-yl)phenyl 2,3,4,6-
tetra-O-acetyl-a-d-mannopyranoside (27): A microwave tube was
charged with 26[37] (240 mg, 0.55 mmol), KOAc (161 mg,
1.65 mmol), bis(pinacolato)diborone (152 mg, 0.60 mmol) and Pd-
(dppf)Cl2·CH2Cl2 (13 mg, 0.017 mmol). The tube was closed, evacu-
ated and flushed with argon. Then anhydrous DMF (1 mL) was
added under a stream of argon. The mixture was degassed in an
ultrasonic bath and flushed with argon for 5 min, and then heated
by microwave irradiation at 120 8C for 2 h. The reaction mixture
was cooled to RT and diluted with CH2Cl2/H2O (100 mL, 1:1). The
organic layer was washed with H2O (50 mL) and brine (50 mL),
dried over Na2SO4 and concentrated. The residue was purified by
MPLC (toluene/EtOAc, 4:1) to afford 27 (120 mg, 50%) as colorless
oil. [a]20D +58.1 (c=0.60, EtOAc);
1H NMR (500 MHz, CDCl3): d=7.76
(d, J=8.6 Hz, 2H, Ar-H), 7.08 (d, J=8.6 Hz, 2H, Ar-H), 5.58–5.55 (m,
2H, H-1, H-3), 5.45 (dd, J=1.9, 3.4 Hz, 1H, H-2), 5.37 (t, J=10.0 Hz,
1H, H-4), 4.28 (dd, J=5.0, 12.0 Hz, 1H. H-6a), 4.05–4.02 (m, 2H, H-
6b, H-5), 2.20, 2.05, 2.03 (3 s, 12H, 4 OAc), 1.33 ppm (s, 12H, 4
CH3);
13C NMR (125 MHz, CDCl3): d=170.55, 169.91, 169.74 (4C, 4
CO), 157.98, 136.62, 136.58, 115.67 (5C, Ar-C), 95.44 (C-1), 83.77 (Ar-
C), 69.37 (C-2), 69.21 (C-5), 68.87 (C-3), 65.92 (C-4), 62.06 (C-6),
24.86, 24.58 (4C, 4 CH3), 20.87, 20.69 ppm (4C, 4COCH3); ESI-MS:
m/z : calcd for C26H35BNaO12 [M+Na]
+ : 573.21, found: 573.32.
Methyl 2-[4’-(2,3,4,6-tetra-O-acetyl-a-d-mannopyranosyloxy)bi-
phenyl-4-yl]acetate (29): Prepared according to general procedure
B from methyl 2-(4-bromophenyl)acetate (28, 41.2 mg,
0.180 mmol), 27 (109 mg, 0.198 mmol), Pd(dppf)Cl2·CH2Cl2 (4.4 mg,
5.4 mmol) and K3PO4 (57.3 mg, 0.270 mmol). Yield: 35 mg (34%) as
yellow oil. Rf=0.25 (petrol ether/EtOAc 2:1); [a]
20
D +75.09 (c=0.8,
EtOAc); 1H NMR (500 MHz, CDCl3): d=7.52–7.49 (m, 4H, Ar-H),
7.35–7.33 (m, 2H, Ar-H), 7.17–7.14 (m, 2H, Ar-H), 5.60–5.56 (m, 2H,
H-1, H-3), 5.47 (dd, J=1.8, 3.5 Hz, 1H, H-2), 5.38 (t, J=10.0 Hz, 1H,
H-4), 4.29 (dd, J=5.0, 11.9 Hz, 1H, H-6a), 4.15–4.08 (m, 2H, H-6b, H-
5), 3.71 (s, 3H, OMe), 3.66 (s, 2H, ArCH2), 2.21, 2.06, 2.05, 2.03 ppm
(4 s, 12H, 4 OAc); 13C NMR (125 MHz, CDCl3): d=171.99, 170.53,
169.99, 169.95, 169.76 (5 CO), 155.09, 139.26, 135.72, 132.83,
129.73, 128.21, 127.03, 116.82 (12C, Ar-C), 95.87 (C-1), 69.43 (C-2),
69.23 (C-5), 68.91 (C-3), 65.99 (C-4), 62.15 (C-6), 52.11 (OMe), 40.78
(ArCH2), 20.88, 20.71, 20.70, 20.67 ppm (4COCH3); ESI-MS: m/z :
calcd for C29H32NaO12 [M+Na]
+ : 595.18, found: 595.21.
Methyl 2-[4’-(2,3,4,6-tetra-O-acetyl-a-d-mannopyranosyloxy)bi-
phenyl-4-yl]cyclopropanecarboxylate (33): Prepared according to
general procedure B from methyl 1-(4-bromophenyl)cyclopropane-
carboxylate (32, 42.6 mg, 0.167 mmol), 27 (101 mg, 0.184 mmol),
Pd(dppf)Cl2·CH2Cl2 (4.1 mg, 5.0 mmol) and K3PO4 (53.2 mg,
0.251 mmol). Yield: 60 mg (56%) as colorless oil. Rf=0.31 (PE/
EtOAc, 2:1) ; [a]20D +70.2 (c=1.00, EtOAc);
1H NMR (500 MHz, CDCl3):
d=7.54–7.48 (m, 4H, Ar-H), 7.40–7.39 (m, 2H, Ar-H), 7.17–7.14 (m,
2H, Ar-H), 5.59 (dd, J=3.55, 10.1 Hz, 1H, H-3), 5.56 (d, J=1.6 Hz,
1H, H-1), 5.46 (dd, J=1.9, 3.5 Hz, 1H, H-2), 5.38 (t, J=10.0 Hz, 1H,
H-4), 4.29 (dd, J=5.1, 12.0 Hz, 1H, H-6a), 4.15–4.09 (m, 2H, H-6b,
H-5), 3.65 (s, 3H, OMe), 2.21, 2.06, 2.05, 2.03 (4 s, 12H, 4 OAc),
1.64–1.62 (m, 2H, cPr), 1.27–1.16 ppm (m, 2H, cPr); 13C NMR
(125 MHz, CDCl3): d=175.04, 170.53, 169.98, 169.95, 169.75 (5 CO),
155.10, 139.25, 138.43, 135.76, 130.94, 128.24, 126.61, 116.80 (12C,
Ar-C), 95.89 (C-1), 69.44 (C-5), 69.23 (C-2), 68.90 (C-3), 66.00 (C-4),
62.15 (C-6), 52.42 (OMe), 28.67 (cPr), 20.71, 20.68 (4C, 4COCH3),
16.75 ppm (cPr) ; ESI-MS: m/z : calcd for C31H34NaO12 [M+Na]
+ :
621.19, found: 621.26.
Methyl 2-[4’-(a-d-mannopyranosyloxy)biphenyl-4-yl]acetate (30):
Prepared according to general procedure C from 29 (30 mg,
0.052 mmol). Yield: 20 mg (95%). Rf=0.25 (CH2Cl2/MeOH, 8:1) ; [a]
20
D
+116.0 (c=0.50, MeOH); 1H NMR (500 MHz, CD3OD): d=7.57–7.53
(m, 4H, Ar-H), 7.34–7.33 (m, 2H, Ar-H), 7.22–7.20 (m, 2H, Ar-H),
5.54 (d, J=1.5 Hz, 1H, H-1), 4.05 (dd, J=1.8, 3.3 Hz, 1H, H-2), 3.95
(dd, J=3.4, 9.5 Hz, 1H, H-3), 3.82–3.74 (m, 3H, H-4, H-6), 3.71 (s,
3H, OMe), 3.66 (s, 2H, ArCH2), 3.65 ppm (ddd, J=2.5, 5.2, 9.7 Hz,
1H, H-5); 13C NMR (125 MHz, CD3OD): d=174.02 (CO), 157.50,
140.77, 136.22, 134.29, 130.81, 129.00, 127.77, 118.13 (12C, Ar-C),
100.23 (C-1), 75.42 (C-5), 72.45 (C-3), 72.03 (C-2), 68.38 (C-4), 62.70
(C-6), 52.49 (OMe), 41.34 ppm (ArCH2); HRMS: m/z : calcd for
C21H24NaO8 [M+Na]
+ : 427.1363, found: 427.1363.
Methyl 2-[4’-(a-d-mannopyranosyloxy)biphenyl-4-yl]cyclopropa-
necarboxylate (34): Prepared according to general procedure C
from 33 (38 mg, 0.063 mmol). Yield: 9 mg (33%). Rf=0.33 (CH2Cl2/
MeOH, 8:1) ; [a]20D +108.0 (c=0.30, MeOH);
1H NMR (500 MHz,
CD3OD): d=7.46–7.39 (m, 4H, Ar-H), 7.28–7.26 (m, 2H, Ar-H), 7.10–
7.07 (m, 2H, Ar-H), 5.42 (d, J=1.7 Hz, 1H, H-1), 3.93 (dd, J=1.9,
3.4 Hz, 1H, H-2), 3.82 (dd, J=3.4, 9.4 Hz, 1H, H-3), 3.69–3.61 (m,
3H, H-4, H-6), 3.53 (m, 4H, OMe, H-5), 1.49–1.47 (m, 2H, cPr), 1.14–
1.11 ppm (m, 2H, cPr); 13C NMR (125 MHz, CD3OD): d=157.50,
140.87, 139.51, 136.26, 132.03, 129.04, 127.43, 118.11 (12C, Ar-C),
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100.20 (C-1), 75.43 (C-5), 72.42 (C-3), 72.02 (C-2), 68.34 (C-4), 62.68
(C-6), 52.81 (OMe), 17.20 ppm (2C, cPr) ; HRMS: m/z : calcd for
C23H26NaO8 [M+Na]
+ : 453.1520, found: 453.1523.
Sodium 2-[4’-(a-d-mannopyranosyloxy)biphenyl-4-yl]acetate
(31): Prepared according to general procedure D from 29 (59 mg,
0.103 mmol). Yield: 17 mg (40%). [a]20D +94.0 (c=0.20, MeOH/H2O
1:1); 1H NMR (500 MHz, D2O): d=7.61 (d, J=8.6 Hz, 2H, Ar-H), 7.55
(d, J=8.0 Hz, 2H, Ar-H), 7.31 (d, J=8.0 Hz, 2H, Ar-H), 7.19 (d, J=
8.6 Hz, 2H, Ar-H), 5.60 (s, 1H, H-1), 4.13 (m, 1H, H-2), 4.00 (dd, J=
3.2, 8.5 Hz, 1H, H-3), 3.75–3.67 (m, 4H, H-4, H-5, H-6), 3.51 ppm (s,
2H, ArCH2);
13C NMR (125 MHz, D2O): d=154.94, 137.93, 136.29,
135.08, 129.76, 128.07, 126.72, 117.49 (12C, Ar-C), 98.20 (C-1), 73.37
(C-5), 70.40 (C-3), 69.89 (C-2), 66.58 (C-4), 60.65 (C-6), 43.89 ppm
(ArCH2); HRMS: m/z : calcd for C20H22NaO8 [M+Na]
+ : 413.1207,
found: 413.1208.
Sodium 2-[4’-(a-d-mannopyranosyloxy)biphenyl-4-yl]cyclopropa-
necarboxylate (35): Prepared according to general procedure D
from 33 (59 mg, 0.099 mmol). Yield: 10 mg (23%). [a]20D +95.0 (c=
0.20, dioxane/H2O 1:1);
1H NMR (500 MHz, D2O): d=7.62–7.60 (m,
2H, Ar-H), 7.54–7.53 (m, 2H, Ar-H), 7.38–7.19 (m, 4H, Ar-H), 5.60 (s,
1H, H-1), 4.13 (m, 1H, H-2), 4.00 (m, 1H, H-3), 3.75–3.67 (4H, H-4,
H-5, H-6), 1.33 (s, 2H, cPr), 1.01 ppm (s, 2H, cPr) ; 13C NMR
(125 MHz, D2O): d=128.67, 126.10, 124.37, 115.47 (12C, Ar-C), 96.18
(C-1), 71.35 (C-5), 68.38 (C-3), 67.87 (C-2), 64.56 (C-4), 58.62 (C-6),
12.66 ppm (2C, cPr); HRMS: m/z : calcd for C22H24NaO8 [M+Na]
+ :
439.1363, found: 439.1363.
Competitive binding assay
A recombinant protein consisting of the CRD of FimH linked with
a thrombin cleavage site (Th) to a His6-tag (FimH-CRD-Th-His6) was
expressed in E. coli strain HM125 and purified by affinity chroma-
tography.[16] To determine the affinity of the various FimH antago-
nists, a competitive binding assay described previously[16] was ap-
plied. Microtiter plates (F96 MaxiSorp, Nunc) were coated with
a 10 mgmL!1 solution of FimH-CRD-Th-His6 in 20 mm HEPES,
150 mm NaCl, and 1 mm CaCl2, pH 7.4 (assay buffer), 100 mL per
well, overnight at 4 8C. The coating solution was discarded, and the
wells were blocked with 3% BSA in assay buffer (150 mL per well)
for 2 h at 4 8C. After three washing steps with assay buffer (150 mL
per well), a fourfold serial dilution of the test compound (50 mL per
well) in assay buffer containing 5% DMSO and streptavidin-perox-
idase coupled Man-a(1–3)[Man-a(1–6)]-Man-b(1–4)-GlcNAc-b(1–4)-
GlcNAcb polyacrylamide (TM-PAA) polymer (50 mL per well of
a 0.5 mgmL!1 solution) were added. On each individual microtiter
plate, n-heptyl a-d-mannopyranoside (1) was tested in parallel. The
plates were incubated for 3 h at 25 8C and 350 rpm and then care-
fully washed four times with 150 mL per well assay buffer. After the
addition of 100 mL per well of 2,2’-azino-di-(3-ethylbenzthiazoline-
6-sulfonic acid) (ABTS) substrate, the colorimetric reaction was al-
lowed to develop for 4 min and then was stopped by the addition
of 2% aqueous oxalic acid before the optical density (OD) was
measured at 415 nm on a microplate reader (Spectramax 190, Mo-
lecular Devices, CA, USA). The IC50 values of the compounds tested
in duplicate were calculated with Prism software (GraphPad Soft-
ware Inc. , La Jolla, CA, USA). The IC50 defines the molar concentra-
tion of the test compound that decreases the maximal specific
binding of TM-PAA polymer to FimH-CRD by 50%. The relative IC50
(rIC50) is the ratio of the IC50 of the test compound to the IC50 of n-
heptyl a-d-mannopyranoside (1).
Cell-based flow cytometry assay
The assay was performed as described previously.[17] Briefly, 5637
cells (DSMZ, Braunschweig, Germany) were grown to confluence in
24-well plates. Before infection, a serial dilution of test compound
in 5% DMSO, PBS (Sigma–Aldrich) was prepared. GFP-labeled
UTI89 bacteria (200 mL) in RPMI 1640 medium (Invitrogen, Basel,
Switzerland) were pre-incubated with test compound (25 mL) for
10 min at RT. The bacteria–antagonist mixtures were then added
to the monolayers of 5637 cells. The multiplicity of infection (MOI)
was 1:50 (cell/bacteria). To homogenize the infection, plates were
centrifuged at RT for 3 min at 600 g. After an incubation time of
1.5 h at 37 8C, infected cells were washed four times with RPMI
1640 medium and suspended in ice-cold PBS for 5–20 min (treat-
ment with ice-cold PBS results in the detachment of the infected
cells). Cells were then kept in the dark until analysis. Samples were
measured with a CyAn ADP flow cytometer (Beckman–Coulter,
Brea, CA, USA) and analyzed by gating on the eukaryotic cells
based on forward (FSC) and side scatter (SSC), which excludes un-
bound labeled bacteria and debris from analysis. A total of 104
cells were measured per sample. Data were acquired in a linear
mode for the SSC and logarithmic mode for FSC and the green flu-
orescent channel FL1-H (GFP). The mean fluorescence intensity
(MFI) of GFP was counted as a surrogate marker for the adherence
of bacteria. Quantification of adhesion was evaluated with the
FlowJo software 9.0.1 (Tree Star Inc. , Ashland, OR, USA). IC50 values
were determined by plotting the concentration of the antagonist
in a logarithmic mode versus the MFI and by fitting the curve with
Prism software (GraphPad, inhibition curve, variable slope), (n=2–
3, in duplicate/triplicate).
Isothermal titration calorimetry (ITC)
For the ITC experiments, the His tag in FimH-CRD-Th-His6 was
cleaved.[16] Briefly, the protein (1 mg) was incubated with 10 U
thrombin (T-6884, Sigma–Aldrich) in 20 mm Tris·HCl, pH 8.4,
150 mm NaCl and 2.5 mm CaCl2 (cleavage buffer) at 20 8C for 16 h.
The mixture was then applied to a gel filtration column (Bio-Prep
SE100/17, Bio-Rad) attached to an FPLC system. The chromatogra-
phy was run with assay buffer and analyzed by SDS-PAGE. The frac-
tions containing FimH-CRD were pooled and concentrated by ul-
trafiltration (MWCO10, Sartorius AG, Tagelswangen, Switzerland).
The ITC experiments were performed using a VP-ITC instrument
from MicroCal Inc. (GE Healthcare, Northampton, MA, USA). The
measurements were performed at 25 8C. Prior to measurements,
the protein was dialyzed in assay buffer (10 mm HEPES, 150 mm
NaCl, 1 mm CaCl2, pH 7.4 (HBS-Ca). Injections of 3–5 mL ligand solu-
tions (150 mm) were added at an interval of 10 min into the sample
cell solution containing FimH-CRD (8–22 mm, sample cell volume
1.4523 mL) with stirring at 307 rpm. Protein concentration was de-
termined by HPLC-UV against a BSA standard.[38] The quantity c=
Mt(0) KD
!1, where Mt(0) is the initial macromolecule concentration,
is of importance in titration microcalorimetry. The c values ranged
between 300 and 3200. Because the smallest reliable volumes
were injected, sigmoidal curves were obtained. Control experi-
ments injecting ligand solution into buffer without protein showed
that the heat of dilution was small and constant. Baseline correc-
tion and peak integration were accomplished using Origin 7 as de-
scribed by the manufacturer (OriginLab, Northampton, MA, USA).
The first injection was always excluded from data analysis because
it usually suffers from sample loss during the mounting of the sy-
ringe and the equilibration preceding the actual titration. A three-
parameter (N (stoichiometry), KD (dissociation constant) and DH8
(change in enthalpy) nonlinear least-square data fitting was per-
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formed in a Microsoft Excel spreadsheet using the Solver add-in
(Frontline System)[39,40] according to binding isotherms published
by Ziegler and Seelig.[41]
Thermodynamics parameters were calculated from Equation (4).
DG ¼ DH"TDS ¼ RT lnKD ¼ "RT lnKA ð4Þ
where DG, DH, and DS are the changes in free energy, enthalpy,
and entropy of binding, respectively, T is the absolute temperature,
and R is the universal gas constant (8.314 Jmol"1 K"1).
Determination of pharmacokinetic parameters
Materials : Dimethyl sulfoxide (DMSO), 1-octanol, Dulbecco’s modi-
fied Eagle’s medium (DMEM) high glucose, l-glutamine solution,
penicillin–streptomycin solution, Dulbecco’s phosphate-buffered
saline (DPBS), and trypsin–EDTA solution were purchased from
Sigma–Aldrich. MEM nonessential amino acid (MEM-NEAA) solu-
tion, fetal bovine serum (FBS), and DMEM without sodium pyruvate
and phenol red were bought from Invitrogen. PAMPA System Solu-
tion, GIT-0 Lipid Solution, and Acceptor Sink Buffer were ordered
from pIon (Woburn, MA, USA). Acetonitrile (MeCN) was bought
from Acros Organics. The Caco-2 cells were kindly provided by
Prof. G. Imanidis, FHNW, Muttenz, Switzerland and originated from
the American Type Culture Collection (Rockville, MD, USA).
Parallel artificial membrane permeation assay (PAMPA)
Values of logPe were determined in a 96-well format with the
PAMPA[33] permeation assay. For each compound, measurements
were performed at three pH values (5.0, 6.2, 7.4) in quadruplicate.
For this purpose, 12 wells of a deep-well plate, i.e. , four wells per
pH value, were filled with 650 mL System Solution. Samples
(150 mL) were withdrawn from each well to determine the blank
spectra by UV spectroscopy (SpectraMax 190). Then, analyte dis-
solved in DMSO was added to the remaining System Solution to
yield 50 mm solutions. To exclude precipitation, the optical density
was measured at 650 nm, with 0.01 being the threshold value. Sol-
utions exceeding this threshold were filtered. Afterward, samples
(150 mL) were withdrawn to determine the reference spectra. Fur-
ther 200 mL were transferred to each well of the donor plate of the
PAMPA sandwich P/N 110 163 (pIon, Woburn MA, USA). The filter
membranes at the bottom of the acceptor plate were impregnated
with 5 mL of GIT-0 Lipid Solution, and 200 mL of Acceptor Sink
Buffer were filled into each acceptor well. The sandwich was as-
sembled, placed in the GutBox, and left undisturbed for 16 h. It
was then disassembled, and samples (150 mL) were transferred
from each donor and acceptor well to UV plates. Quantification
was performed by both UV spectroscopy and LC–MS; logPe values
were calculated with the aid of the PAMPA Explorer Software (pIon,
version 3.5).
Colorectal adenocarcinoma (Caco-2) cell permeation assay
Caco-2 cells were cultivated in tissue culture flasks (BD Biosciences,
Franklin Lakes, NJ, USA) with DMEM high-glucose medium contain-
ing l-glutamine (2 mm), nonessential amino acids (0.1 mm), penicil-
lin (100 UmL"1), streptomycin (100 mgmL"1), and FBS (10%). The
cells were kept at 37 8C in humidified air containing 5% CO2, and
the medium was changed every second day. When ~90% conflu-
ence was reached, the cells were split in a 1:10 ratio and distribut-
ed to new tissue culture flasks. At passage numbers between 60
and 65, they were seeded at a density of 5.3!105 cells per well to
Transwell 6-well plates (Corning Inc. , Corning, NY, USA) with 2.5 mL
culture medium in the basolateral and 1.8 mL in the apical com-
partment. The medium was renewed on alternate days. Permeation
experiments were performed between days 19 and 21 post-seed-
ing. Prior to the experiment, the integrity of the Caco-2 monolay-
ers was evaluated by measuring the transepithelial electrical resist-
ance (TEER) with an Endohm tissue resistance instrument (World
Precision Instruments Inc. , Sarasota, FL, USA). Only wells with TEER
values >300 Wcm2 were used. Experiments were performed in the
apical-to-basolateral (absorptive) and basolateral-to-apical (secreto-
ry) directions in triplicate. Transport medium (DMEM without
sodium pyruvate and phenol red) was withdrawn from the donor
compartments of three wells and replaced by the same volume of
compound stock solutions to reach an initial sample concentration
of 62.5 mm. The Transwell plate was then shaken (250 rpm) in the
incubator. Samples (40 mL) were withdrawn after 15, 30, and
60 min from the donor and acceptor compartments, and their con-
centrations were determined by LC–MS. Apparent permeability co-
efficients (Papp) were calculated according to the equation
Papp ¼ dQdt %
1
A% c0 ð5Þ
where dQ/dt is the permeability rate, A the surface area of the
monolayer, and c0 the initial concentration in the donor compart-
ment.[42] After the experiment, TEER values were assessed again for
each well and results from wells with values <300 Wcm2 were dis-
carded.
logD7.4 determination
The in silico prediction tool ALOGPS[43] was used to estimate the
logP values of the compounds. Depending on these values, the
compounds were classified into three categories: hydrophilic com-
pounds (logP<0), moderately lipophilic compounds (0& logP&1)
and lipophilic compounds (logP>1). For each category, two differ-
ent ratios (volume of 1-octanol to volume of buffer) were defined
as experimental parameters (Table 4).
Equal amounts of phosphate buffer (0.1m, pH 7.4) and 1-octanol
were mixed and shaken vigorously for 5 min to saturate the
phases. The mixture was left until separation of the two phases oc-
curred, and the buffer was retrieved. Stock solutions of the test
compounds were diluted with buffer to a concentration of 1 mm.
For each compound, six determinations, i.e. , three determinations
per 1-octanol/buffer ratio, were performed in different wells of
a 96-well plate. The respective volumes of buffer containing ana-
lyte (1 mm) were pipetted to the wells and covered by saturated 1-
octanol according to the chosen volume ratio. The plate was
sealed with aluminum foil, shaken (1350 rpm, 25 8C, 2 h) on a Hei-
doph Titramax 1000 plate shaker (Heidolph Instruments GmbH &
Co. KG, Schwabach, Germany) and centrifuged (2000 rpm, 25 8C,
Table 4. Compound classification based on estimated logP values.[43]
Compound type logP Ratio (1-octanol)/(buffer)
hydrophilic <0 30:140, 40:130
moderately lipophilic 0–1 70:110, 110:70
lipophilic >1 3:180, 4:180
1420 www.chemmedchem.org " 2012 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemMedChem 2012, 7, 1404 – 1422
MED B. Ernst et al.
FimH Publication 5  
	
   83	
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 min, 5804 R Eppendorf centrifuge, Hamburg, Germany). The
aqueous phase was transferred to a 96-well plate for analysis by
LC–MS.
logD7.4 was calculated from the 1-octanol/buffer ratio (o/b), the ini-
tial concentration of the analyte in buffer (1 mm), and the concen-
tration of the analyte in the aqueous phase (cB) with equation:
logD7:4 ¼ log 1mM" cBcB #
1
o : b
! "
ð6Þ
Solubility
Solubility was determined in a 96-well format using the mSOL Ex-
plorer solubility analyzer (pIon, version 3.4.0.5). For each com-
pound, measurements were performed at three pH values (3.0, 5.0,
7.4) in triplicates. For this purpose, nine wells of a deep-well plate,
that is, three wells per pH value, were filled with 300 mL of an
aqueous universal buffer solution. Aliquots (3 mL) of a compound
stock solution (10–50 mm in DMSO) were added and thoroughly
mixed. The final sample concentration was 0.1–0.5 mm, the residual
DMSO concentration was 1.0% (v/v) in the buffer solutions. After
15 h, the solutions were filtered (0.2 mm 96-well filter plates) using
a vacuum to collect manifold (Whatman Ltd. , Maidstone, UK) to
remove any precipitates. Equal amounts of filtrate and n-propanol
were mixed and transferred to a 96-well plate for UV detection
(190–500 nm). The amount of material dissolved was calculated by
comparison with UV spectra obtained from reference samples,
which were prepared by dissolving compound stock solution in
a 1:1 mixture of buffer and n-propanol (final concentrations 0.017–
0.083 mm).
LC–MS measurements
Analyses were performed using an 1100/1200 Series HPLC System
coupled to a 6410 Triple Quadrupole mass detector (Agilent Tech-
nologies, Inc. , Santa Clara, CA, USA) equipped with electrospray
ionization. The system was controlled with the Agilent MassHunter
Workstation Data Acquisition software (version B.01.04). The
column used was an Atlantis T3 C18 column (2.1!50 mm) with
a 3 mm particle size (Waters Corp., Milford, MA, USA). The mobile
phase consisted of two eluents: solvent A (H2O, containing 0.1%
formic acid, v/v) and solvent B (MeCN, containing 0.1% formic acid,
v/v), both delivered at 0.6 mLmin"1. The gradient was ramped
from 95% A/5% B to 5% A/95% B over 1 min, and then held at
5% A/95% B for 0.1 min. The system was then brought back to
95% A/5% B, resulting in a total duration of 4 min. MS parameters
such as fragmentor voltage, collision energy, and polarity were op-
timized individually for each analyte, and the molecular ion was
followed for each compound in the multiple reaction monitoring
mode. The concentrations of the analytes were quantified by the
Agilent Mass Hunter Quantitative Analysis software (version
B.01.04).
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Flow cytometry assay results 
 
Table 1. IC50 values obtained for OS compounds. 
FACS Inhibition Assay 
Compound Structure 
IC50 [µM]  rIC50 
n-heptyl α-D-manno-
pyranoside 
(reference)  
3.9 ± 1.6 1 
α-D-methyl mannoside 
 
249.2 ± 62.3 63.8 
pNpα  mannoside 
 
3.2 ± 0.69 0.82 
OS386 
 
1.06 ± 0.47 0.27 
OS394 
 
0.035 ± 0.008 0.009 
OS420 
 
 
0.13 ± 0.02 0.033 
OS421 
 
0.11± 0.2 0.028 
OS464 
 
0.12 ± 0.06 0.03 
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OS397 
 
0.09 ± 0.01 0.02 
OS452 
 
0.72 ± 0.003 0.19 
OS471 
 
0.61 ± 0.13 0.15 
OS487 
 
0.2 0.05 
	
  
Table 2. IC50 values obtained for JXH and Mha compounds.  
FACS Inhibition Assay 
Compound Structure 
IC50 [µM]  rIC50 
n-heptyl α-D-manno-
pyranoside 
(reference)  
3.9 ± 1.6 1 
JXH-224 
 
0.59 ± 0.045 0.15 
JXH-2431 
 
1.02 0.26 
MH17 
 
0.14 ± 0.05 0.04 
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Mh31? 
 
0.04 ± 0.02 0.01 
Mha31 
 
21.5 ± 1.49 5.5 
	
  
 
Table 3. IC50 values obtained for biphenyl compounds from JXH and TK.  
FACS Inhibition Assay 
Compound Structure 
IC50 [µM]  rIC50 
n-heptyl α-D-manno-
pyranoside 
(reference)  
3.9 ± 1.6 1 
JXH2372 
 
0.86 ± 0.56 0.22 
TK05 
 
0.33 ± 0.05 0.085 
TK15 
 
0.53 ± 0.06 0.135 
TK16 
 
0.24 ± 0.043 0.06 
TK18 
 
4.45 ± 1.9 1.14 
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TK20 
 
0.78 ± 0.16 0.2 
 
 
 
Table 4. IC50 values obtained for PLJ compounds.  
FACS Inhibition Assay 
Compound Structure 
IC50 [µM]  rIC50 
n-heptyl α-D-manno-
pyranoside 
(reference)  
3.9 ± 1.6 1 
PLJ01066A 
 
2.7 ± 0.26 0.69 
PLJ01076A 
 
0.83 ± 0.15 0.21 
PLJ01089A 
 
4.9 1.27 
PLJ01179B 
 
1.83 ± 0.14 0.47 
PLJ01178B 
 
1.95 ± 0.36 0.5 
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PLJ01181B 
 
4.85 ± 0.79 1.2 
PLJ01194B 
 
0.89 ± 0.1 0.23 
PLJ01175B 
 
1.54 ± 0.31 0.39 
 
Table 5. IC50 values obtained for KM compounds 
FACS Inhibition Assay 
Compound Structure 
IC50 [µM]  rIC50 
n-heptyl α-D-manno-
pyranoside 
(reference)  
3.9 ± 1.6 1 
KM FH58 
 
  
 
O
HO
HO
OH
O
OH
O
Cl
O
HO
HO
OH
OH
CN
Chemical Formula: C19H18ClNO6
Exact Mass: 391.08
Molecular Weight: 391.80
KM-FH-58
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Table 6. IC50 values obtained with Klebsiella pneumonia (C3091 strain) 
FACS Inhibition Assay 
Compound Structure 
IC50 [µM]  rIC50 
n-heptyl α-D-manno-
pyranoside 
(reference)  
7.82 ± 1.65 1 
MH17 
 
0.21 ± 0.11 0.027 
PLJ01178B 
 
0.33 ± 0.22 0.042 
OS421 
 
0.21 ± 0.08 0.027 
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Abstract DC-SIGN  
Dendritic cell-specific ICAM-3-grabbing non-integrin (DC-SIGN) is a pathogen recognition 
receptor (PRR) and abundantly expressed on immature dendritic cells (DCs). The binding of 
pathogens via PRRs mediates phagocytosis, DC maturation and migration from peripheral 
tissues to draining lymph nodes. After lysosomal degradation, the processed antigen particles 
are presented to naïve T-cells, resulting in the stimulation of adaptive immune responses. 
However, a variety of pathogens including HIV-1 use the interaction with DC-SIGN on DCs 
as initial entry port to their host. These pathogens are able to circumvent the intracellular 
degradation process and impair DC maturation. DC-SIGN recognizes mannose-containing 
glycoconjugates and fucose-containing blood-group antigens, such as Lewisx (Lex), Lewisa 
(Lea), and Lewisy (Ley), in the envelope of viruses and the membranes of parasites. DC-SIGN 
is therefore considered as a potential drug target for the treatment and prevention of a number 
of infectious diseases. Consequently, considerable efforts are made to develop DC-SIGN 
antagonists. These new anti-infectives would inhibit DC-SIGN-pathogen interaction and 
block the initial step of an infection, as well as the pathogen dissemination. 
This thesis addresses the issue of improving the recombinant expression of the carbohydrate 
recognition domain of DC-SIGN by investigating the effect of different signal peptides on the 
expression of recombinant protein in CHO-K1 cells. The usage of the luciferase signal 
peptide of the copepod Gaussia princeps led to a drastic improvement of the protein yield 
compared to the standard interleukin-2 signal peptide. The recombinant protein was used for 
the evaluation of binding potentials of novel FimH antagonists. A target-based binding assay 
was developed and a series of antagonists were measured, with the focus on Lewis type 
structures. Combination of binding assays, mutational analysis, STD NMR studies, and 
computational modeling revealed a new binding mode with improved affinity for phenyl 
group-substituted Lea compounds. Therefore these compounds display a novel class of 
potential anti-infectives. 
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DC-SIGN Introduction 
Pathogen recognition receptors on dendritic cells 
Dendritic cells (DCs) are specialized antigen presenting cells that play a major role in the 
initiation and differentiation of immune responses, operating at the interface between innate 
and adaptive immunity [1]. Immature DCs are abundantly found in peripheral tissues 
throughout the body, where they recognize invading microorganisms with pattern recognition 
receptors (PRRs) on their cell surfaces [2]. Antigen binding triggers pathogen uptake by 
receptor-mediated phagocytosis and antigen processing in lysosomal compartments. Binding 
also results in DC maturation and migration from the periphery to the lymphoid organs. Here 
the DCs present pathogenic peptides on major histocompatibility complex (MHC)-class I/II 
molecules on its surface to resting T cells. Transient interaction between the antigen-MHC 
complex and the T cell receptor leads to T cell activation and initiation of an adaptive immune 
response [3].  
Depending on their tissue localization and differentiation state, DCs express distinct patterns 
of PRRs and costimulatory molecules. PRRs recognize pathogen-associated molecular 
patterns (PAMPs) of microorganisms such as bacterial cell wall components or 
liposaccharides, as well as double stranded RNA of viruses. DCs are equipped with several 
different classes of PPRs, including Toll-like receptors (TLRs) [4], scavenger receptors [5], 
and C-type lectin receptors (CTLs) [6]. These receptors differ in their ligand specificity, and 
an activation of the DC triggers receptor-specific immune responses [7]. TLRs preferably 
bind to bacterial and viral lipopolysaccharides (LPS) [8], leading to the release of pro-
inflammatory cytokines (IFNs, IL12) and an up-regulation of costimulatory molecules 
important for T cell activation. Scavenger receptors recognize lipoproteins, while CTLs 
recognize carbohydrate structures, both leading to pathogen endocytosis and processing in 
lysosomal compartments [5, 9]. Furthermore, binding of CTLs to self-glycoproteins induces 
tolerance and maintenance of immune homeostasis, and also mediates cell-cell adhesion and 
migration processes. Since pathogens generally express several PAMPs, they can 
simultaneously stimulate multiple PRRs on a single cell.  This may result in an interplay of 
the PRRs and a cross talk between intracellular signaling pathways, tailoring the eliceted 
immune response [10-12]. 
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The C-type lectin DC-SIGN 
C-type lectin receptors share primary structural homology in their carbohydrate recognition 
domain (CRD) and most CTLs bind sugars in a calcium-dependent manner. The very large 
family of CTLs includes many endocytotic receptors, proteoglycans [13], as well as all 
selectins and collectins. The family can be divided in two subgroups, based on an amino-acid 
motif that is involved in the sugar binding. The CRD of mannose-type C-type lectins contains 
a Glu-Pro-Asn (EPN) motif, whereas the galactose-type lectins contain a Gln-Pro-Asp (QPD) 
sequence. EPN motif-containing lectins preferably bind to mannose- or fucose-terminated 
glycans, whereas QPD motif-containing lectins prefer galactose- or N-acetylgalactosamine-
terminated glycans [14]. Both types are involved in many immune system functions. They 
play crucial roles in inflammatory responses, are involved in innate immunity by pathogen 
recognition and their elimination, and in activation processes of cells of the adaptive 
immunity. One abundantly expressed EPN-type C-type lectin on dendritic cells and 
macrophage subpopulations [15] is DC-SIGN, which shapes the immune responses against 
various pathogens. DC-SIGN is mainly expressed on myeloid DCs, but also found on dermal 
DCs, interstitial DCs, and a subset of DCs in the blood [16, 17]. This receptor was first 
described in 1992 by Curtis et al. as a membrane associated PRR with a high affinity for the 
glycoprotein (gp120) on HIV-1 [18]. In 2000, Geijtenbeek and colleagues found the same 
molecule mediating intercellular interactions with ICAM-3 (intercellular adhesion molecule-
3) on resting T cells in the lymphatic tissue [19]. Since up to that time the interaction between 
DCs and T cells had only been attributed to integrins, they named the protein “DC-specific 
ICAM-3 grabbing non-integrin” or DC-SIGN.                                            
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Figure 1. Schematic representation of the type II transmembrane protein DC-SIGN. DC-SIGN 
consists of a cytoplasmic domain bearing the di-leucin motif, tri-acidic internalization motifs and the 
tyrosin residue, associated with signal transduction. The cytoplasmic domain connects to the 
transmembrane domain (TM) and the extracellular domain.  The extracellular domain is composed of 
the neck region, characterized by seven and a half repeats of 23 amino acids, and the carbohydrate 
recognition domain (CRD). DC-SIGN forms tetramers, facilitated by hydrophobic interactions 
between the neck regions of the monomers.  
 
DC-SIGN is a tetrameric type II transmembrane protein [20], consisting of an N-terminal 
cytoplasmic domain, connected via a short hydrophobic transmembrane domain to the 
extracellular domain (Figure 1). Certain amino acid motifs within the intracellular domain, as 
e.g. a di-leucin based motif and a tri-acidic cluster (Glu-Glu-Glu), regulate the internalization 
and the recycling of the receptor [17]. It also contains a YxxL motif that has been associated 
with intracellular signaling [21, 22]. The extracellular domain consists of a neck region and 
the carbohydrate recognition domain (CRD). The hydrophobic neck region bears seven 
complete and one incomplete tandem repeats of 23 amino acids and is crucial for the 
tetramerization of the lectin. The globular CRD is composed of 12 β-strands, two α-helices 
and three disulfide bridges, and is the ligand-binding part of the molecule [23]. It binds two 
Ca2+ ions, one being essential for the assembly of the tertiary structure, the other for the 
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binding of the ligand [24]. DC-SIGN recognizes mannose-containing glycoconjugates [25] 
and fucose-containing blood-group antigens, such as Lewisx (Lex), Lewisa (Lea), and Lewisy 
(Ley) [26], in the envelope of viruses and the membranes of parasites. It was shown that DC-
SIGN binds to branched high-mannose glycans [24] with a minimum of three internal 
(α1→3, α1→6) or two terminal mannose residues [24]. The receptor multimerization 
increases the binding avidity for ligands containing repetitive sugar moieties, by forming 
multivalent interactions. Due to the multimerization, DC-SIGN prefers mannose residues with 
distinct spatial arrangements [24, 25, 27]. Ultimately, it defines the set of pathogens that are 
recognized by DC-SIGN, by promoting ligand specificity [28]. An effective binding of 
various mannose- and fucose-containing oligosaccharides is also provided by DC-SIGN 
conformational flexibility upon ligand binding [29]. Furthermore, it was shown that DC-
SIGN tetramers are organized in clusters in lipid microdomains within the membrane (lipid 
rafts), which further promote ligand binding, internalization, and signal transduction [30, 31]. 
As a common feature for endocytotic receptors, DC-SIGN releases ligands at low pH. This 
allows the separation of DC-SIGN from ligands in the endosomes and the subsequent 
recycling of the free receptor to the cell surface [32]. Important ligands for DC-SIGN are for 
example Lex containing liposaccharides (LPS) of Helicobacter pylori [33], the cell wall 
component ManLAM of Mycobacterium tuberculosis [34, 35], and the envelope glycoprotein 
gp120 of HIV-1 [20, 36].  
Apart from its function as PRR and endocytotic receptor by recognizing PAMPs on microbial 
surfaces, DC-SIGN also acts as a cell-cell adhesion molecule that binds to endogenous 
ligands such as ICAM-2 or ICAM-3. ICAM-2 binding on vascular endothelial cells 
contributes to transendothelial migration [37, 38] of the DC. Interaction with ICAM-3, 
expressed on resting T cells in the lymph nodes, stabilizes the formation of the synapse 
between the antigen-MHC class II complex and the T cell receptor, resulting in T cell 
activation [20]. DCs also interact with neutrophils via DC-SIGN-Mac1 or CEACAM-1 
interaction. Neutrophils are part of the innate immunity and mediate immediate removal of 
pathogens. The interaction with neutrophils directly at the site of an infection activates DCs 
and instructs them to guide the T cells towards a Th1 response [39]. However, the major 
function of DC-SIGN is its participation in the initiation of an immune response by pathogen 
capture [26, 40]. Pathogen binding by DC-SIGN leads to an uptake of the pathogen, DC 
maturation and initiation of the adaptive immune response. 
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DC-SIGN signaling and HIV-1 infection 
Pathogens recognized by DC-SIGN are generally internalized and immediately degraded by 
the DC. However, a variety of pathogens exploit DC-SIGN to infect their host, including 
viruses (HIV-1 [20, 36], Ebola virus [41], Hepatitis C virus (HCV) [42, 43], Dengue virus 
[44], Herpes simplex virus [45], SARS corona virus [46]), bacteria (M.tuberculosis [34, 35]), 
fungi  (Candida albicans [47]) and parasites (Leishmania [26]). These pathogens are able to 
circumvent the intracellular degradation process and use the interaction with DC-SIGN on 
DCs as initial entry port to their host. In case of HIV-1, the virus survives inside of the DCs in 
multivesicular bodies. It retains its infectiveness until the infected DC has migrated from the 
site of infection to the lymph node, where HIV-1 is efficiently transmitted to CD4+ T cells 
(Figure 2).  
 
 
Figure 2. Role of dendritic cells and DC-SIGN in HIV-1 infection, taken from [9]. The immature DC 
binds via DC-SIGN to the envelope protein gp120 on HIV-1, which has entered peripheral tissues of 
the host (mucosa, skin). The activated DC migrates via the lymph vessels to secondary lymphoid 
organs, where it encounters resting T cells. HIV-1 can evade the normal degradation processes and is 
thus able to infect CD4+/CCR5 T cells. This process is termed “infection in trans”. 
 
The pathogens exploit DC-SIGN signaling to benefit their survival and dissemination. Up to 
now, it is still speculative how ligand binding leads to the induction of signal transduction by 
DC-SIGN. However, it is known that DC-SIGN signaling can either function independently, 
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or it can modulate the responses of other PRRs such as TLRs [48]. The triggered signaling 
and the specific modulation of immune responses are tailored to the type of pathogen 
involved and can therefore differ between pathogens. Signaling by M.tuberculosis, HIV-1, 
and C.albicans activates Raf-1 by interacting with Ras-1, which induces Raf-1 
phosphorylation of the residues Y340/341 or S338 by Src kinases or Pak [49, 50] (Figure 3). 
The activation of Raf-1 mediates phosphorylation of the transcription factor NFκB subunit 65 
at residue S276. In addition, NFκB needs to be previously activated by TLR signaling. The 
active heterodimers of subunits p65 and p50 then translocate into the nucleus, where they 
bind to the promoters of target genes and initiate their transcription. The NFκB activation 
upon TLR stimulation is essential for the induction of DC-SIGN triggered immune responses. 
The activity of p65, which is the transcriptionally active component, is regulated by several 
posttranslational modifications, such as phosphorylation and acetylation. DC-SIGN-
dependent phosphorylation by Raf-1 induces the acetylation of p65, resulting in enhanced and 
sustained transcription of the IL-10 gene [51]. Thus, DC-SIGN signaling controls NFκB 
activity and modulates TLR responses. IL-10 is an immunosuppressive cytokine, but it is 
presumed that p65 acetylation also modulates pro-inflammatory genes. The net immune 
response is dependent on the entity of cytokines that are stimulated by DC-SIGN signaling, 
and this needs to be further investigated. However, almost all pathogens binding to DC-SIGN 
cause chronic infections and successfully manipulate the Th1/Th2 balance. Promoting Th2 
cell proliferation is often crucial for virulence and persistence of intracellular pathogens [52]. 
Furthermore, Gringhuis et al. have demonstrated that mannose- and fucose-presenting 
pathogens induce different TLR-induced DC-SIGN signaling pathways. Mannose containing 
pathogens, such as HIV-1 and M.tuberculosis enhance IL-10, IL-12, and IL-6 secretion, while 
fucose-containing ligands induce IL-10, but suppress IL-12 and IL-6 secretion [53]. 
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Figure 3. Signaling pathway in DCs, triggered by binding to HIV-1, C.albicans, and M.tuberculosis 
(adapted from [54]). The pathogens bind with different PAMPs to TLRs and DC-SIGN. TLR 
signaling activates NFκB, a heterodimer composed of the subunits p65 and p50. Upon activation 
NFκB translocates into the nucleus, where it binds to target DNA sequences, such as the IL-10 
promoter. DC-SIGN binding to Ras induces the activation of Raf-1 and its subsequent 
phosphorylation via src kinases or Pak. Activated Raf-1 triggers the phosphorylation of the p65 
subunit of NFκB, eliciting its acetylation. This posttranslational modification enhances NFκB activity 
and results in a prolonged IL-10 transcription.  
 
In the case of HIV-1, it was shown that its virulence requires signaling elicited by the binding 
of viral ssRNA to endosomal TLR8, as well as by the binding of gp120 to DC-SIGN. Binding 
to TLR8 activates NFκB, which then binds to proviral DNA integrated in the host genome. 
NFκB initiates transcription by RNA polymerase II (RNAPII), but an additional 
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phosphorylation of the RNAPII induced by DC-SIGN signaling is necessary to prolong the 
transcriptional activity. This modification is crucial for the transcription of full-length viral 
transcripts, and thus pivotal for HIV-1 virulence [55, 56]. In addition to this effect and the 
enhanced transcription of IL-10 via NFκB, DC-SIGN signaling also impairs dendritic cell 
maturation and T cell proliferation [57], thereby promoting systemic infection of the host. 
Furthermore, it was shown that upon HIV-1 infection DC-SIGN expression gets up-regulated, 
which further enhances the infectivity [58]. However, it is presumed that the suppression of 
the immune response by the pathogen via DC-SIGN also benefits the host, since it prevents 
an excessive immune activation, which might harm the host as well.  
 
The carbohydrate recognition domain (CRD) of DC-SIGN 
The DC-SIGN CRD was co-crystalized with different mannosides [32, 59] and 
lacto-N-fucopentaose III (LNFP III), which contains the Lex trisaccharide [32]. These studies 
revealed a shallow binding site of DC-SIGN. In this binding site, mannose complexes the 
Ca2+-ion with its 3- and 4-OH in an equatorial-equatorial manner, whereas the 3- and 4-OH of 
the LNFP III fucose complex the Ca2+-ion in an equatorial-axial manner (Figure 4). 
Therefore, the fucose is tipped in comparison to the mannose and is able to form additional 
tight van der Waals contacts with the 2-OH to Val351. The galactose moiety in the Lex motif 
contributes to the binding by forming water-bridged hydrogen bonds via the 4-OH with 
Asp367 and Glu358, and via the 6-OH with Leu371. The GlcNAc of Lex is positioned in a 
vertical manner and points towards the solvent (Figure 5). Mannose-containing 
oligosaccharides involve an extended secondary binding site lined by Phe313. This amino 
acid seems to contribute to the selectivity as well as to the affinity [32] (Figure 6). Mannose- 
and fucose-based ligands show overlapping, but distinct binding modes. These differences 
might be the reason for the different biological effects of mannose- and fucose-based ligands, 
as discussed earlier [33]. 
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Figure 4. Coordination of Ca2+ by terminal 3- and 4-OHs of fucose in LNFP III (left). Since Ca2+ 
(magenta sphere) is coordinated by one equatorial and one axial OH group, fucose is “tipped” (yellow 
carbons, right) compared to mannose, coordinating the Ca2+ by two equatorial OH groups (green 
carbons) (PDB entry 1SL5 [32], modeled by Sameh Eid). 
 
 
Figure 5. Binding mode of the resolved part of LNFP. Dashed lines show Ca2+  (magenta sphere) 
coordination by 3- and 4-OH of fucose. The galactose moiety points towards the solvent (PDB entry 
1SL5 [32], modeled by Sameh Eid). 
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Figure 6. Binding mode of the resolved part of Man4 (green carbons). Dashed lines show Ca2+ 
(magenta sphere) coordination by 3- and 4-OH of mannose. Man-2 and Man-3 are interacting with a 
secondary binding site lined by Phe313. (PDB entry 1SL4 [32], modeled by Sameh Eid). 
 
DC-SIGN antagonists  
Since a variety of pathogens use the interaction with DC-SIGN on DCs as initial entry port to 
their host, DC-SIGN is considered as a potential therapeutic target for the treatment and 
prevention of a number of infectious diseases [60].  Consequently, considerable efforts are 
made to develop DC-SIGN antagonists [23, 25, 61, 62]. These new anti-infectives would 
inhibit DC-SIGN-pathogen interaction and block the initial step in an infection and the 
pathogen dissemination.  
To date, studies have only shown in vitro data on the investigation of antagonists. Poor 
pharmacokinetic properties of carbohydrate-based antagonists make the design of 
therapeutically applicable and active compounds a challenging task. The main carbohydrate 
ligand for DC-SIGN on glycoproteins of pathogens is the high-mannose glycan 
Man9GlcNAc2, with a moderate affinity in the micromolar range (gp120, GP1, etc.) [59, 63].  
Affinities of monosaccharides such as D-mannose, L-fucose, and methyl-α-D-
mannopyranoside are generally weak with KD-values in the millimolar range [25]. Up to now, 
several approaches to enhance the affinity of ligands by generating multivalent antagonists 
were explored. Oligomannose glycodendrons successfully block DC-SIGN in a glycan array 
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assay and an ELISA based assay, with affinities in the nanomolar range [64]. Furthermore, 
oligomannoside-functionalized gold glyco-nanoparticles were able to inhibit DC-SIGN-
mediated trans-infection of T cells by HIV-1 at nanomolar concentrations [65]. Sattin et al. 
showed that a tetravalent dendron containing four copies of a linear trimannose mimic 
inhibited trans-HIV infection at low micromolar concentrations [66]. Although these 
polyvalent molecules are not suitable for a systemic administration due to their poor 
pharmacokinetic properties and toxicity, they might be administrated topically at the sites of 
infection, e.g. at mucosal surfaces.  
Binding affinities of Lewis-type structures to DC-SIGN have not been extensively determined 
so far, although they show much higher selectivity [67]. Monovalent Lex exhibits an affinity 
in the low millimolar range [61], whereas Lea shows a slightly higher relative binding affinity 
to DC-SIGN [63]. Recently, fucose-based Lex mimics, with a fucosylamide linker replacing 
the metabolically unstable α-glycosidic bond were synthesized. These exhibit similar 
affinities to Lex, but with low binding affinities to the C-type lectin Langerin [61, 67]. 
Monovalent non-carbohydrate inhibitors with IC50 values in the micromolar range were 
identified in a high-throughput fluorescence-based competition assay and were also effective 
in DC-SIGN-dependent cell adhesion assays [68]. The binding mode of these non-
carbohydrate ligands remains unknown. Furthermore, DNA aptamers against DC-SIGN were 
selected, exhibiting affinities in the nanomolar range [69]. Recently, the hydrophobic region 
lined with Phe313 was employed to improve affinity of glycomimetic DC-SIGN antagonists 
[70]. Mannopyranosides substituted with a phenyl ring exhibited an increased binding 
affinity, implying that the phenyl ring makes contributing hydrophobic interactions with the 
Phe313. Lex structures with a sialylated or sulfated 3-OH group of galactose abrogated 
binding to DC-SIGN.  Based on the crystal structure these ligand exclusions could be caused 
by steric hindrances of Phe313 and by electrostatic repulsion [32].  
Since DC-SIGN is a pathogen recognition receptor with signaling functions, DC-SIGN 
antagonists are also potential agonists that might activate the receptor upon binding. In fact, it 
might even be that antagonists activate different signaling cascades, depending on their 
structure. With no integral assay existing up to now, analysis of the exact biological effects of 
novel antagonists remains a future challenge. And although one can deduce great potential for 
the developed DC-SIGN antagonists from in vitro assays, there is still a great need for 
improving affinity, selectivity and drug-like properties of DC-SIGN antagonists, before a 
potent anti-infective can be developed.  
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Abbreviations: AA, amino acid, ABTS, 2,2’-azino-di-(3-ethylbenzthiazoline-6-sulfonic 
acid); BSA, bovine serum albumin; CHO cells, chinese hamster ovary cells; CRD; 
carbohydrate recognition domain; DC, dendritic cell; DC-SIGN, 
DC-specific ICAM-3-grabbing non-integrin; EDTA, ethylenediaminetetraacetic acid; FCS, 
fetal calf serum; IgG, immunoglobulin G; IL, interleukin; Lea, Lewisa; ss, signal peptide; OD, 
optical density; PAA, polyacrylamide; HEPES, 4-(2-hydroxyethyl)-piperazine-1-
ethanesulfonic acid; PRR, pathogen recognition receptor; SDS, sodium dodecylsulfate; SRP, 
signal recognition particles. 
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Abstract 
Proteins such as enzymes and receptors are indispensable tools in the drug discovery and 
development process. The growing number of tests necessary to proof the in vitro effect of a 
drug candidate requires high amounts of high quality proteins. In this study we investigated 
the effect of different signal peptides on the expression of recombinant human DC-SIGN in 
CHO-K1 cells. DC-SIGN is considered a potential therapeutic target for the treatment and 
prevention of various infectious diseases, such as HIV-1. However, testing the potency of 
DC-SIGN antagonists requires preparative amounts of this protein. We engineered CHO-K1 
cell lines that stably overexpress the carbohydrate recognition domain (CRD) of DC-SIGN. 
The cDNA of the DC-SIGN gene was fused to an extended Kozak sequence in combination 
with different signal peptides. The usage of the luciferase signal peptide of the copepod 
Gaussia princeps led to a drastic improvement of the protein yield, compared to the standard 
interleukin-2 signal peptide. This communication emphasizes the role of genetic refinement 
for high-level production of recombinant genes.  
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Introduction 
Quantitative amounts of highly pure and active proteins are required for the supply of proteins 
for therapeutic purposes and during the early phase of drug development, e.g. for the 
characterization of ligand-protein interactions and screening applications. Protein expression 
is commonly performed in mammalian, bacterial, yeast, or insect cells [1]. Although the 
expression of recombinant proteins in mammalian cells is less efficient and more expensive 
compared to other systems [2-4], the quality of the protein compensates for these drawbacks, 
especially when expressing human proteins with complex posttranslational modifications. 
Posttranslational modifications are limited in bacteria and yeast, and missing modifications 
can negatively influence the functionality of the protein of interest [5]. In addition, the 
expression of mammalian proteins in bacteria often leads to their accumulation as inclusion 
bodies. In vitro refolding of inclusion bodies into proteins with native conformations is a 
cumbersome and time-consuming process. Therefore, mammalian cells have become the 
system of preference for the production of human proteins for research and clinical 
applications [5]. 
Increasing the expression of recombinant proteins in the mammalian cell system has been 
either achieved by refining growth conditions or by genetic engineering of the expression 
vector, increasing both transcription and translation levels [6-9]. According to Marilyn Kozak, 
translation efficiency in eukaryotic cells can be enhanced to a great extent by using a distinct 
translation initiation code in mRNAs, called the Kozak sequence [6]. That sequence was 
found to be a consensus sequence for initiation in higher eukaryotes and can be used to 
enhance the expression of recombinant proteins. It was shown, that an adenine (A) or a 
guanine (G) in position -3 (i.e. three nucleotides upstream from the AUG codon) and a G in 
position +4 boosted the recognition efficiency of the AUG codon by the scanning ribosomes 
more than 60%. Up to three repeats of the three-nucleotide motif G(A)CC preceding the AUG 
triplet further enhances this effect.  
Recently, it was demonstrated that individual signal peptides (secretion signal, ss) show high 
variations in their secretion efficiency of proteins [10-12]. Although there is little homology 
in the overall amino acid sequence, signal peptides consist of three domains, a positively 
charged N-terminus, a hydrophobic central core and a C-terminal cleavage region [13]. 
Studies revealed that the basic N-terminal and the hydrophobic core regions are essential for 
protein translocation by mediating the interaction with signal recognition particles (SRPs). 
The physical properties of both regions influence the affinity of the signal peptide for SRPs 
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and hence the efficiency of the protein export. Zhang et al. [10] investigated the influence of 
single amino acid mutations in the commonly used human interleukin-2 signal peptide (IL-2 
ss) on the protein secretion level. They were able to augment the secretion up to 3.5 fold by 
increasing the basicity and the hydrophobicity of the IL-2 signal peptide. Knappskog et al. 
[14] demonstrated that the use of a luciferase signal peptide derived from the marine copepod 
Gaussia princeps led to a substantial increase of the expression of human endostatin. 
However, the efficiency of the signal peptide seems to be dependent on the target protein. Up 
to date, human endostatin is the only mammalian protein equipped with a Gaussia princeps 
luciferase signal peptide that has been investigated. A quantitative evaluation on absolute 
protein expression yields induced by different signal peptides has not yet been reported.  
In this study, we investigated the recombinant expression of the human 
DC-specific ICAM-3-grabbing non-integrin (DC-SIGN). DC-SIGN is a pathogen recognition 
receptor (PRR) and abundantly expressed on immature dendritic cells (DCs) [15]. The 
binding of pathogens via PRRs mediates phagocytosis, DC maturation and migration from 
peripheral tissues to draining lymph nodes. After lysosomal degradation, the processed 
antigen particles are presented to naïve T-cells, resulting in the stimulation of adaptive 
immune responses [16]. However, a variety of pathogens including HIV-1 use the interaction 
with DC-SIGN on DCs as initial entry port to their host. These pathogens are able to 
circumvent the intracellular degradation process and impair DC maturation [17, 18]. DC-
SIGN is therefore considered as a potential drug target for the treatment and prevention of a 
number of infectious diseases [19]. Consequently, considerable efforts are made to develop 
DC-SIGN antagonists [20-23]. The evaluation of such antagonists requires preparative 
amount of protein.  
In this study three constructs were investigated, in which the human DC-SIGN cDNA was 
combined with an extended Kozak sequence and different signal peptides. The constructs 
were transfected into CHO cells and after selection of stable clones the protein expression was 
quantitatively evaluated. Here, we demonstrate that the choice of the signal peptide is a 
crucial factor for enhancing protein expression in mammalian cells. The Gaussia princeps 
luciferase signal peptide was superior to the commonly used interleukin-2 signal peptide, 
which is known for its efficient secretion in vivo. Protein quality control was performed using 
a target-based binding assay, which also allows the determination of IC50 values for DC-
SIGN antagonists.  
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Material and Methods 
Cloning of DC-SIGN-CRD-IgG-Fc. The plasmid containing the full-length cDNA of DC-
SIGN was kindly provided by Daniel A. Mitchell (Glycobiology Institute, Department of 
Biochemistry, University of Oxford). Standard molecular techniques [24] were used for the 
cloning of the DC-SIGN-carbohydrate recognition domain. Three different DC-SIGN-CRD-
IgG-Fc inserts (DC-SIGN: GenBank accession no. M98457, aa residues 250-404) were 
generated, each of them containing the extended Kozak sequence and either the IL-2 ss 
(GenBank accession no. NM_000586), a modified IL-2 ss (Table 1), or a codon-usage 
optimized Gaussia princeps luciferase ss (GenBank accession no. AY015993). Overhang 
primers containing the signal peptides were used on the original plasmid (pFUSE-hIgG2-Fc2 
vector, Lucerne, Switzerland) encoding DC-SIGN-CRD-IgG-Fc. The inserts were ligated into 
the corresponding cloning site of the pcDNA3.1(+) expression vector (Invitrogen, Lucerne, 
Switzerland) using the BamH1 and EcoRV restriction sites. The N-terminal sequences of each 
construct are summarized in Table 1. 
The plasmids were transformed into chemo-competent DH5α E. coli (Novagen Lucerne, 
Switzerland). After mini-preparation and restriction control, the correctness of the inserts 
was confirmed by DNA sequencing (Microsynth, Switzerland).  
 
Cell culture. CHO-K1 cells (American Type Culture Collection No. CCL-61TM) were 
cultivated in Ham’s Nutrient Mixture F-12 supplemented with 2 mM L-glutamate 
(Invitrogen, Paisley, UK), 10% fetal calf serum (FCS, Invitrogen, Paisley, UK), 100 U/mL 
penicillin, and 100 µg/mL streptomycin (both Sigma-Aldrich, Basel, Switzerland). The cells 
were subcultivated twice a week. Cells used for protein production were not subcultured, 
but the supernatant was collected and replaced by fresh medium every six days. 
 
Production of stable cell lines. FuGENE® HD transfection reagent (Roche Applied Science, 
Rotkreuz, Switzerland) was used to transfect CHO-K1 cells according to the manufacturer’s 
instructions. To obtain stable populations, positively transfected cells were selected by 
cultivation in growth medium supplemented with 0.5 mg/ml G418 (Gibco, Invitrogen 
Lucerne, Switzerland). Clonal populations were generated using the limiting dilution 
technique. For each construct 20 clones were cultured and screened for recombinant protein 
expression. The selected cell clones were cultured in 12-well plates and after six days 
cultivation the medium was tested for the presence of DC-SIGN by immunoblot analysis. 
DC-SIGN Manuscript 1  
	
  116	
  
DC-SIGN producing clones were seeded into 150 cm2 cell culture flasks and cultivated for six 
days without medium exchange.  
 
Protein purification. Purification of the recombinant protein was achieved by applying 
conditioned medium in loading buffer I (20 mM Tris/HCl, pH 7.6, 150 mM NaCl, 0.05% 
(v/v) Tween-20TM) onto a protein A-sepharose column (BioVision, Mountain View, CA, 
USA), attached to a fast protein liquid chromatography apparatus (BioLogic (FPLC) system, 
BioRad, Reinach BL, Switzerland). The protein was eluted in elution buffer I (0.5 M acetic 
acid/ammonium acetate, pH 3.4). The collected protein was further purified on a L-fucose-
sepharose column using loading buffer II (20 mM Tris/HCl, pH 7.8, 0.5 M NaCl, 25 mM 
CaCl2) and elution buffer II (20 mM Tris/HCl, pH 7.8, 0.5 M NaCl, 2 mM EDTA). For long-
term storage, the purified protein was frozen at -80 °C 
 
SDS-PAGE analysis. Protein purity was verified by SDS-PAGE analysis on a 15% non-
reducing polyacrylamide gel according to the method of Laemmli [25]. Following gel 
electrophoresis, the gel was stained with a coomassie solution as described in [26].  
 
Immunoblot analysis. Conditioned medium of each clone was resolved on a 12% SDS-
PAGE under reducing conditions and transferred onto a nitrocellulose membrane (Bio-Rad, 
Reinach, Switzerland). The membrane was blocked with 3% bovine serum albumin (BSA, 
Sigma, Steinheim, Germany) in PBS-buffer and incubated with a monoclonal rabbit anti-DC-
SIGN-CRD primary antibody (1:5000, Sigma, Buchs, Switzerland). As secondary antibody 
an alkaline phosphatase coupled anti-rabbit IgG (Sigma, Buchs, Switzerland) was used. After 
three washing steps the membrane was developed with the NBT-BCIP solution (Fluka, 
Buchs, Switzerland). 
 
Preparation of horseradish peroxidase coupled polyacrylamide glycopolymer. 
Biotinylated Lewisa (Lea)-PAA polymer (20 µL, 1 mg/mL) was mixed with 80 µL assay 
buffer, 20 µL FCS and 80 µL streptavidin-horseradish peroxidase-conjugate (500 U/mL) and 
incubated for 2 h at 37 °C [27]. The complex was stable for several weeks when stored at 4 
°C. 
 
Lea-PAA binding assay. A polymer-based binding assay for DC-SIGN was developed based 
on the assay reported in [27]. The compounds 1, 2, and 3 were purchased from ChemDiv (San 
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Diego, CA, USA, (1, K784-1581; 2, K784-1848; 3, K593-1866). D-mannose, 
methylmannoside, L-fucose, and D-glucose were purchased from Sigma-Aldrich (Basel, 
Switzerland). Flat-bottom 96-well microtiter plates (F96 MaxiSorp, Nunc) were coated with 
100 µL/well of a 2.5 µg/mL solution of DC-SIGN-CRD-IgG-Fc in assay buffer (20 mM 
HEPES, 150 mM NaCl, 1 mM CaCl2, pH 7.4) overnight at 4 °C. The coating solution was 
discarded and the wells were blocked with 200 µL/well of 3% BSA in assay buffer for 2 h at 
4 °C. After three washing steps with assay buffer, either a dilution series of the polymer 100 
µL/well (0-3 µg/mL for EC50 determination) or a mixture of test compound for IC50 
determinations (50 µL/well, dilution series) and Lea-PAA (50 µL/well, 0.5 µg/mL) in assay 
buffer were added. The plates were incubated for 3 h at room temperature and 350 rpm and 
then washed with assay buffer. After the addition of the ABTS-substrate (100 µL/well), the 
colorimetric reaction was allowed to develop for 2 min, then stopped by the addition of 2% 
aqueous oxalic acid before the optical density (OD) was measured at 415 nm on a microplate-
reader (Spectramax 190, Molecular Devices, California, USA). The EC50 or IC50-values were 
calculated with the prism software (GraphPad Software, Inc, La Jolla, USA). The IC50 defines 
the molar concentration of the test compound that reduces the maximal specific binding of 
Lea-PAA to DC-SIGN-CRD by 50%.  
 
Results and discussion 
Generation of DC-SIGN-CRD-IgG-Fc constructs. Three different expression vectors 
(Table 1) encoding the DC-SIGN-CRD were generated by standard molecular biology 
methods [24]. The constructs were ligated into the pcDNA3.1(+) plasmid and transfected into 
CHO K1 cells. After the selection of stable clones, the effect on protein expression efficiency 
was evaluated. In the starting construct pFuse-hIgG2-Fc2 the gene of interest was 
incorporated between an IL-2 signal peptide and a human IgG2-Fc2 part. It contained a non-
extended Kozak-sequence (sequence: gcc acc atg). In the newly designed vectors, DC-SIGN-
CRD-Fc2 was provided with an extended Kozak sequence (sequence: gcc gcc acc atg g*). 
The guanine (marked *) at position +4 was inserted using a codon coding for glycine (gga), 
leading to an elongation of the proceeding signal peptides by this amino acid. Glycine was 
assumed to have no influence on the secretion process, since it is a small and uncharged 
amino acid. In this study, the commonly used IL-2 signal peptide (IL-2 ss), a modified IL-2 
signal peptide (IL-2mod ss) with increased basicity and hydrophobicity, as well as a codon-
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usage optimized Gaussia princeps luciferase signal peptide (luciferase ss) were tested for 
their secretion efficiency.  
 
Construct name Sequence 
Original IL-2 ss 
5` atg tac agg atg caa ctc ctg tct tgc att gca cta agt ctt gca ctt gtc 
acg aat tcg 3` 
 
MYRMQLLSCIALSLALVTNS 
Kozak-IL-2 ss 
5` gcc gcc acc atg gga tac agg atg caa ctc ctg tct tgc att gca cta agt 
ctt gca ctt gtc acg aat tcg 3` 
 
MGYRMQLLSCIALSLALVTNS 
Kozak-IL-2mod ss 
5` gcc gcc acc atg gga cgg* agg atg caa ctc ctc* ctg tct tgc att gca 
cta ttg* ctt gca ctt gtc acg aat tcg 3` 
 
MGR*RMQLLL*SCIALL*LALVTNS 
Kozak-luciferase ss 
5` gcc gcc acc atg gga gtg aag gtg ctg ttc gcc ctg atc tgc atc gcc 
gtc gcc gag gcc 3` 
 
MGVKVLFALICIAVAEA 
Table 1. Plasmid constructs with their N-terminal DNA- and amino acid- sequence including Kozak 
sequence and signal peptide (ss). DNA sequences corresponding to the Kozak sequence are shaded in 
grey. *Modified amino acids in the IL-2mod ss. 
 
The IL-2mod ss was designed based on the study by Zhang et al. [10]. There, they modified 
the basic and the hydrophobic region of the IL-2 ss and separately investigated their effect on 
human endostatin expression. Increasing basicity and hydrophobicity of each region enhanced 
protein expression by factor 2, compared to the parental IL-2 ss. We decided to combine the 
modified parts that exhibited the most beneficial effect on endostatin expression in one single 
signal peptide, and test its impact on DC-SIGN secretion (Table 2).  
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Table 2. Design of the IL-2mod ss, based on studies by Zhang et al. [10]. Listed are the expression 
yields (f) of the IL-2 ss 1 and IL-2 ss 2 relative to the native IL-2 ss found in [10]. IL-2 ss 1 was 
modified in the basic region, IL-2 ss 2 was modified in the hydrophobic region. IL-2mod ss is a 
combination of the two modified signal peptides 1 and 2. Polar, neutral amino acids (AA) are 
highlighted in grey, basic AA in black, hydrophobic AA are not highlighted. 
 
 
Quantification of protein expression by stably transfected CHO-K1 cells. DC-SIGN 
expression by stably transfected CHO-K1 cells was analyzed in conditioned culture medium 
via affinity purification, using protein A- and L-fucose-sepharose columns. Absolute protein 
yields were then determined by HPLC. Table 3 summarizes the absolute yields of DC-SIGN-
CRD-IgG obtained from the medium samples. The construct with an extended Kozak 
sequence and the standard IL-2 signal peptide (Kozak-IL-2 ss) showed a 3.6-fold increase in 
protein expression, compared to the original construct with a non-extended Kozak sequence 
only. This effect may either result from the beneficial effect of the extended Kozak sequence, 
or it may attribute to the non-isogenic backgrounds (pcDNA3.1(+) and pFUSE-hIgG-Fc2 
vector) and the diverging promoters (hCMV, hEF1-HTLV prom) of both constructs. 
However, for a valid comparison of the effect of the different signal peptides, we only 
compared the newly designed constructs that have the same isogenic background. The 
luciferase signal peptide proved to be most efficient, with a 2-fold increase (6.5 mg/mL) in 
protein yield compared to the IL-2 signal peptide (3.6 mg/mL). Surprisingly, we obtained a 
protein yield of only 1.2 mg/mL for the IL-2mod signal peptide, meaning a 3-fold reduction 
compared to the standard IL-2 signal peptide.  
Signal 
peptide 
f basic hydrophobic polar 
IL-2 ss 1 M Y R M Q L  L S C I A L S L A L V T N S 
IL-2 ss 1 2.2 M R R M Q L  L S C I A L S L A L V T N S 
IL-2 ss 2 2.9 M Y K M Q L L L S C I A L L L A l V T N S 
IL-2mod ss  M R R M Q L L L S C I A L L L A L V T N S 
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Table 3. DC-SIGN-CRD-IgG-Fc expression yields for stably transfected cells. Absolute protein yields 
in mg per liter culture medium, after six days of culture. 
 
Construct 
Protein yield 
in mg/L 
IL-2 ss original 1.0 
Kozak-IL-2 ss 3.6 
Kozak-IL-2mod ss 1.2 
Kozak-luciferase ss 6.5 
 
Additionally, stably expressing cell populations derived from individual cell clones were 
generated and evaluated for recombinant protein expression. We used immunoblot analysis 
and Lea-PAA binding assays to identify DC-SIGN-expressing clones (Figure 1).  
 
 
Figure 1. Lea-PAA binding assay for screening CHO-K1 single cell clones that are stably transfected 
with the Kozak-luciferase ss construct. 100 µL cell medium per cell clone was coated over night on 
96-well microtiter plates and the binding to the Lea-PAA (1 µg/mL) was measured. The strength of the 
signal correlates with the amount of DC-SIGN-CRD-Fc2 in the coated medium. Background signals 
(dark grey) are Lea-PAA binding to medium of untransfected CHO-K1 cells. The assay was performed 
in triplicates. 
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The results confirmed the expression of active protein in all generated cell lines. However, 
great differences in the extent of synthesized proteins were detectable between the individual 
clones. We used the clonal populations with the highest signals in the PAA-binding assay for 
further cultivation and analysis. Conditioned medium from each population was collected and 
purified over a protein A-sepharose column. Based on the areas under the curve of the 
respective FPLC peaks, we selected the two best-producing clones of each construct. For 
these candidates, the absolute protein yields were determined by HPLC. The obtained yields 
of the best-producing clonal populations confirmed the results for the different signal peptides 
that we had observed with the pooled clones (Table 4).  
 
Table 4. DC-SIGN-CRD-IgG-Fc expression yield for the best producing stable cell lines of each 
construct.  Absolute protein yields in mg/L. 
Construct 
Protein yield 
in mg/L 
IL-2 ss original 1.2 
Kozak-IL-2 ss 9.5 
Kozak-IL-2mod ss 1.0 
Kozak-luciferase ss 
(clone nr. 1) 
19.6 
 
Influencing the translation process by inserting an extended Kozak sequence (Kozak-IL-2 ss 
cell line) resulted in a 8-fold higher protein yield compared to the original IL-2 ss cell line. 
Furthermore, by fusing the Gaussia princeps luciferase signal peptide and the extended 
Kozak sequence an even higher protein yield was obtained. Clone 1 produced 19.5 mg DC-
SIGN per liter culture medium, which represents a two-fold augmented expression compared 
to the best Kozak-IL-2 ss clone and a 16-fold increase to the original IL-2 clone. The 
hydrophobic IL-2mod signal peptide exhibited an adverse rather than a beneficial effect on 
protein secretion. The protein quantity of the best Kozak-IL-2mod ss clone was ten times less 
than for the Kozak-IL-2 ss cell line. The reason for this might be, that the enhanced basicity 
and hydrophobicity of this signal peptide results either in a very low, or in a very high affinity 
for the SRPs. Both effects would interfere with the translocation process of the protein. 
Additionally, it might be that the signal peptide interacts with the connected protein, resulting 
in reduced secretion efficiencies. This effect is likely to vary between proteins, since the 
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strength of the intramolecular interactions depends on the structure and biophysical properties 
of the recombinant protein.  
The superior efficacy of the Gaussia princeps luciferase signal peptide is in agreement with 
the published data, where its beneficial effect on human endostatin secretion was reported 
[14]. The analysis of the amino acid sequence of the luciferase signal peptide revealed a 
higher hydrophobicity of the core region in comparison to the native IL-2 signal peptide 
(Table 5). This analysis confirmed the findings of Zhang et al. that enhanced hydrophobicity 
of the signal peptide significantly improves protein secretion. 
 
Table 5. Comparison of the amino acid (AA) sequences from the native IL-2 ss, the IL-2mod ss and 
the G. princeps luciferase ss. Polar, neutral AA are highlighted in light grey, acidic AA in darker grey, 
basic AA in black, hydrophobic AA are not highlighted. 
 basic hydrophobic polar 
IL-2 ss M Y R M Q L  L S C I A L S L A L V T N S 
IL-2 mod. ss M R R M Q L L L S C I A L L L A L V T N S 
G. luciferase ss M V K V L F A L I C I A V      A E A 
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Lea-PAA binding assay. To verify the activity of the purified DC-SIGN proteins, Lea-PAA 
binding assays were performed (Figure 2, Table 6). DC-SIGN bound the Lea-PAA with an 
EC50 value of 89 ng/ml, which confirmed the activity of the protein. L-Fucose, D-mannose, 
methylmannoside, and D-glucose inhibited the Lea-PAA binding to DC-SIGN with an IC50 
value of 5.3 mM, 9.6 mM, 8.7 mM, and 22.5 mM, respectively. These values are consistent 
with data from the literature [22]. Furthermore, non-carbohydrate inhibitors 1, 2, 3 exhibited 
strong inhibitory potencies with IC50 values in the µM range (24-127 µM). However, our 
values were higher than the reported values in the literature [21], which can be explained by 
the different assay formats and by the low solubility of these compounds. The developed 
target-based competition assay can be employed as a fast screening assay for new DC-SIGN 
antagonists.	
  
 
Figure 2. EC50 determination of DC-SIGN to the Lea-PAA and IC50 determination of D-mannose, L-
fucose and compound 3 using the Prism software. The assay was performed in triplicates. 
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Table 6: EC50 value for Lea-PAA to DC-SIGN and inhibitory potencies (IC50) of DC-SIGN ligands. 
The IC50 values were determined with the Lea-PAA binding assay as described in the material and 
methods section and compared to those reported in the literature [21, 22].  
 
 
Competitive 
binding assay 
In literature  
EC50 Lea-PAA [ng/ml] 89.6 ± 19.7  
DC-SIGN antagonists IC50 IC50 
L-fucose 5.3  ± 0.8 mM 6.7 ± 0.5 mM [22] 
D-mannose 9.6 ± 1.1 mM 13.1 ± 0.4 mM [22] 
methyl mannoside 8.7 ± 2.2 mM 12.5 ± 0.5 mM [22] 
D-glucose 22.5 ± 1.2 mM 23 ± 1 mM [22] 
1 
 
42.7 ± 5.7 µM 2.0 ± 1 µM [21] 
2 
 
127.3 ± 40.5 µM 1.6 ± 0.5 µM [21] 
3  
 
24.2 ± 5.5 µM 7.3 ± 3.5 µM [21] 
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Conclusion 
In summary, the results of this study confirmed the possibility to substantially improve the 
efficacy of mammalian expression systems by inserting an extended Kozak sequence at the 
translation start, and by choosing an appropriate signal peptide. The luciferase signal peptide 
derived from the copepod Gaussia princeps showed a superior functionality compared to the 
interleukin-2 signal peptide, with more than two-fold higher protein yield. Therefore, we can 
strongly recommend the usage of this luciferase signal peptide as an alternative to the 
commonly used interleukin-2 signal peptide.  
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Abstract  
Dentritic cells (DCs) have the function of presenting antigens to other processing cells of the 
immune system, particularly T-cells. DC-SIGN (DC-specific intramolecular adhesion 
molecule-3-grabbing non-integrin) is one of the major receptors on DCs involved in the 
uptake of pathogens and has gained increasing interest over the last decade as it is crucially 
involved in infections caused by HIV-1, Ebola virus, Mycobacterium tuberculosis, and 
various other pathogens. High-mannosylated N-glycans or L-Fuc-containing trisaccharide 
motifs such as the Lewis blood group antigens Lewisa and Lewisx, which are surface 
components of these microorganisms, mediate binding to DC-SIGN. 
Crystallographic data for DC-SIGN in complex with a Lewisx-containing pentasaccharide 
suggest that the terminal sugar residues, L-Fuc and D-galactose, are predominantly involved 
in binding. We elucidated the interaction of Lewisa as well as Lewisx bearing two different 
aglycones with DC-SIGN. Binding assays together with STD NMR analysis revealed distinct, 
substitution-dependent binding modes. Eventually, molecular modelling and mutagenesis 
studies support the assumption of a switch of the binding mode when introducing 
hydrophobic residues at the reducing end of the Lewis trisaccharides. Based on this 
information a new series of potential high- affinity DC-SIGN antagonists can be designed. 	
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1. Introduction	
  
 
Immature dendritic cells (DCs), found in peripheral tissues throughout the body, play an 
essential role in triggering the immune response as they are antigen-presenting cells.1,2 DCs 
recognize and capture a broad variety of pathogens including viruses,3 bacteria,4 and yeasts5 
by pathogen recognition receptors (PRRs). Pathogen uptake by PRRs as well as inflammatory 
cytokines and chemokines (e.g. IL-4) trigger DC differentiation and migration to the 
lymphoid organs where the mature DCs present pathogenic peptides on the major 
histocompatibility complex (MHC) to resting T cells. 
 
Dendritic cell-specific intercellular adhesion molecule-3 grabbing nonintegrin (DC-SIGN) is 
one of the main receptors on DCs for recognition and uptake of pathogens. Since its first 
discovery by Geijtenbeek et al. in 20003, DC-SIGN gained popularity, particularly because a 
variety of pathogens exploit DC-SIGN to infect their host, including HIV, Ebola virus, and 
SARS.6,7,8 The fact that different pathogens have capitalized on this infection strategy makes 
DC-SIGN an interesting target for a new class of anti-infectives.9 In a study on the binding 
and transfer of HIV in human rectal mucosa cells, DC-SIGN+ cells accounted for more than 
90% of bound viruses although they represented only 1–5% of the total mucosal mononuclear 
cells. Furthermore, anti-DC-SIGN antibodies blocked more than 90% of HIV binding.10  
 
DC-SIGN is a type II transmembrane protein with a C-terminal carbohydrate recognition 
domain (CRD). It is part of the C-type lectin family, which implies that ligand binding is 
Ca2+-dependent. The majority of pathogens bind with N-linked high-mannose 
oligosaccharides to DC-SIGN11,12, e.g. mannan structures on the gp120 envelope protein of 
HIV-1.13 Besides oligomannosides, blood group antigens, such as Lewisx (Lex, Galβ(1-
4)[Fucα(1-3)]GlcNAc) and Lewisa (Lea, Galβ(1-3)[Fucα(1-4)]GlcNAc) that are also 
commonly found on pathogens, are recognized by DC-SIGN.14-17 Lex and Lea bind to DC-
SIGN in the low millimolar range, with Lea exhibiting a slightly higher binding affinity than 
Lex.18,19 Since pathogens present these rather low-affinity sugar motives in a multimeric form 
to the DC-SIGN tetramers, high binding avidities are observed.20,21 	
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Figure 1. A) X-ray of LNFP III/CRD of DC-SIGN (PDB 1SL5).22 The equatorial 3-OH and the axial 
4-OH of L-Fuc coordinate the calcium ion. The interaction of 4-OH with Glu358 is mediated by a 
water molecule. 6-OH of D-galactose forms a H-bond with Asp367,which on its part is stabilized by 
an interaction with Lys373. B) X-ray of Man4 {Manα(1-6)[Manα(1-3)]Manα(1-6)Man}/CRD of DC-
SIGN (PDB 1SL4).14,22 The calcium ion is coordinated by the equatorial 3- and the equatorial 4-OH of 
the terminal α(1-3)-linked D-mannose. In addition, a hydrophobic contact of the terminal α(1-6)-
linked D-mannose further stabilizes the interaction. 
	
  
Crystallographic data (PDB: 1SL5)22 obtained from the CRD of DC-SIGN co-crystallized 
with lacto-N-fucopentaose III (LNFP III, Galβ(1-4)[Fucα(1-3)]GlcNAcβ(1-3)Galβ(1-4)Glc) 
suggest that the equatorial 3- and axial 4-OH of the D-Fuc moiety coordinate the calcium ion 
(Figure 1A). For the 4-OH of the D-Gal moiety a water-bridged H-bond with Glu358 is 
proposed. In addition, a H-bond of 6-OH of D-Gal to Lys373, bridged by Asp367 is 
assumed.22 For the CRD of DC-SIGN co-crystallized with oligomannosides (Man4 and 
GlcNAc2Man3) a comparable docking mode was obtained. There the equatorial 3- and 4-OH 
of the α(1-3)-linked mannose moiety complex the calcium ion (Figure 1B). In addition, Man4 
(PDB 1SL4) addresses a second binding site lined by Phe313, contributing to selectivity as 
well as affinity.14,22 Only recently, Bernardi et al. took advantage of this additional 
hydrophobic contact for their design of glycomimetic DC-SIGN antagonists.23,24 
 
In our program directed to the identification of high-affinity DC-SIGN antagonists, a large 
library of carbohydrates and mimetics thereof was screened. One interesting finding was the 
unexpectedly improved affinity discovered for Lex and Lea antigens with aromatic aglycones 
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(→3,4) compared to the corresponding methyl glycosides (→1,2). When these derivatives 
adopt a binding mode similar to LNFP III,22 the aglycones should point to the solvent and 
therefore not contribute to binding. To clarify whether a modified binding mode is 
responsible for the increased affinity, the binding epitopes of the Lea and Lex derivatives 1-4 
were analyzed by STD NMR and docking studies.  
 
2. Results and Discussion 
 
2.1. Binding Affinities for Lewis Structures. For the determination of the affinities of 
methyl Lex (1), methyl Lea (2), phenyl Lex (3) and phenyl Lea (4) (Table 1) a cell-free 
competitive binding was developed. It is based on the competition of a biotinylated 
polyacrylamide glycopolymer (Lea-polyacrylamide, Lea-PAA) and the ligand of interest for 
the CRD of DC-SIGN. A soluble recombinant protein consisting of the DC-SIGN CRD-Fc 
(amino acid residues 250-404) was expressed in CHO-K1 cells and purified by affinity 
chromatography (protein A- and L-fucose-sepharose column). For the determination of IC50 
values, a microtiter plate coated with DC-SIGN CRD-Fc was incubated with biotinylated 
Galβ(1-3)[Fucα(1-4)]GlcNAcβ-polyacrylamide (Lea-PAA) polymer conjugated to 
streptavidin-horseradish peroxidase and the DC-SIGN antagonist in a serial dilution. The 
assay was performed in duplicates and repeated three times for each compound. To ensure 
comparability of different ligands, the reference compound L-fucose was tested in parallel on 
each individual microtiter plate.  
 
L-Fuc and D-mannose were used as reference compounds showing IC50 values of 7.6 mM and 
9.1 mM, respectively. These affinities correlate well with published data.20 Phenyl Lex (3) 
(IC50 1.2 mM) and phenyl Lea (4) (IC50 0.9 mM) showed a two- to threefold increase in 
affinity compared to corresponding methyl derivatives [IC50 2.3 mM for methyl Lex (1) and 
2.9 mM for methyl Lea (2)]. For phenyl Lea (4), the best antagonist in this series, we also 
performed isothermal titration calorimetry (ITC) experiments. The KD of 582 µM for phenyl 
Lea (4) confirms the results of the polymer binding assay with affinity in the micromolar 
range. As observed for the majority of carbohydrate–lectin interactions,25-27 the binding is 
enthalpy driven (ΔH = - 28.0 ±2.0  kJ/mol, TΔS = - 9.5 ± 2.1 kJ/mol).  	
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When the Lex- and Lea-motifs bind comparable to LNFP III,22 only the L-Fuc and D-Gal 
moiety participate in binding, whereas the D-GlcNAc moiety as well as the aglycone point to 
the solvent. Therefore, the observed beneficial effect of the aromatic aglycone was 
unexpected. 	
  
 
Table 1. The cell-free competitive binding assay is based on the competition of a biotinylated Lea-
PAA with the antagonist of interest for the CRD of DC-SIGN. The assay was performed in duplicates 
and repeated three times for each compound. To ensure comparability of different ligands, the 
reference compound L-Fuc was tested in parallel on each individual microtiter plate. ITC experiments 
were performed at 25 °C. Thermodynamic parameters were calculated according to the equation ∆G = 
RTlnKD = ∆H - T∆S; n.d. not determined. 	
  
Ligand Competitive binding assay, IC50  
Isothermal titration 
calorimetry, KD  
D-mannose 9.1 ± 1.3 mM n.d. 
L-fucose 7.6 ± 2.6 mM n.d. 
Me Lex (methyl Galβ(1-4)[Fucα(1-3)]βGlcNAc) (1) 2.3 ± 0.1 mM n.d. 
Me Lea (methyl Galβ(1-3)[Fucα(1-4)]βGlcNAc) (2) 2.9 ± 0.5 mM n.d. 
Ph Lex (phenyl Galβ(1-4)[Fucα(1-3)]βGlcNAc) (3) 1.2 ± 0.5 mM n.d. 
Ph Lea (phenyl Galβ(1-3)[Fucα(1-4)]βGlcNAc) (4) 0.9 ± 0.3 mM  582 ± 40 µM 	
  
	
  
2.2. Saturation Transfer Difference (STD) NMR Analysis. For the interpretation of the 
unexpected higher affinities correlated with the phenyl aglycone of antagonists 3 and 4, the 
binding epitopes of the Lea and Lex derivatives were characterized by STD NMR (Figure 2A-
D), which is particularly suited for epitope mapping of ligand receptor couples with weak 
interactions.28-31 STD NMR experiments are based on spin magnetization transfer from a 
macromolecule, the protein, to a smaller binding molecule, the ligand. The saturation transfer 
proceeds through space via dipolar coupling and is therewith dependent on the distance (r-6) 
of ligand hydrogens to the protein surface.  	
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Figure 2. Binding epitopes of the Lewis antigens 1 - 4 interacting with DC-SIGN CRD-Fc determined 
by STD NMR. The contribution of each hydrogen to the STD epitope is quantified by forming the 
ratio of the signal intensities in the STD to those in the reference spectrum. These values are 
normalized to H-6 of D-Fuc (in red, 100%) to give the percentage epitope. STD values greater than 
100% represent proximity to DC-SIGN CRD-Fc closer than that of the H-6 of D-Fuc. The letter size 
used for the hydrogens expresses the proximity to the protein, i.e. the relative amount of saturation 
transfer. The STD epitope for methyl Lex (1) is consistent with recently published data with respect to 
experimental accuracy.32 Further details regarding the percentage epitope, sample preparation and 
parameters for the STD NMR measurement are available in the experimental section. 	
  
In the STD NMR analysis significantly higher STD values for the aromatic hydrogens (3 and 
4, Figure 2C&D) compared to the methyl groups (in 1 and 2, Figure 2A&B) were found. This 
clearly indicates spatial proximity of the aromatic aglycones to DC-SIGN. However, a 
comparison of the binding epitopes reveals further differences going beyond aglycones. For 
the D-GlcNAc moieties of methyl Lex (1) and Lea (2) the maximal STD values for ring 
hydrogens are smaller than for H-6 of D-Fuc (up to 75%), whereas for the phenyl derivatives 
3 and 4 the values reach up to 165%. Especially for phenyl Lea (4), and to a lesser extend for 
phenyl Lex (3), high STD values (80-220%) are equally distributed over the entire structure. 
In contrast, for methyl Lex (1), methyl Lea (2) high STD values are predominantly located on 
the L-Fuc moiety. The latter finding corresponds with X-ray data when the Lex-containing 
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LNFP III is co-crystallized with DC-SIGN,22 indicating the dominant role of the L-Fuc 
moiety in these binding epitopes.  
 
2.3. Molecular Modeling Studies. Overall, the correlation of increased affinity with the 
presence of aromatic aglycones as well as the STD NMR data suggest a spatial proximity of 
the phenyl substituents to DC-SIGN. This is in contrast to the structural information deduced 
from the co-crystallization of LNFP III with the CRD of DC-SIGN.22 For a possible solution 
of this riddle, docking studies were initiated. The crystal structure 1SL522 was used as starting 
point for the docking studies. The replacement of the internal D-Gal moiety in LNFP III by a 
methyl aglycone LNFP III → methyl Lex (1) is not expected to have a significant influence on 
its binding mode as indicated by the small STD value of the aglycone in 1 (Figure 2A). In 
addition, the proximity of the N-acetyl of the D-GlcNAc moiety to Val351 as proposed by the 
crystal structure (inter-proton distance of 2.5 Å)22 is reflected by the increased STD value.  
 
Automated docking of methyl Lex (1) positions the Lex subunit in close agreement (RMSD 
0.7Å) with its orientation in the crystal structure22 as shown in Figure 3A. In the docking pose 
of methyl Lea (2), on the other hand, the D-GlcNAc residue is flipped along its C1-O5 axis, 
thereby positioning L-Fuc moiety similar to the LNFP III crystal structure. Calcium 
coordination and H-bond network to L-Fuc are thus maintained (Figure 3B). In this new 
orientation D-Gal can establish the same characteristic H-bond to Asp367 as well. However, 
N-acetyl group of D-GlcNAc no longer forms a hydrophobic contact with Val351 but with 
Phe313 instead, with a much longer inter-proton distance of ~ 4.5 Å. This is in good 
agreement with the lower intensity of the STD NMR signal of the N-acetyl group of GlcNAc 
in methyl Lea (2, Figure 2B).  
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Figure 3. A) Docking modes of methyl Lex (1) and B) methyl Lea (2). Contacts between the N-acetyl 
groups and closest protein residues are highlighted with double-headed arrows. 	
  
A binding mode for phenyl Lex (3) where the Lex subunit adopts an analogous orientation to 
LNFP III (Figure 1A) is inconsistent with the significant saturation transfer observed for the 
aromatic protons, since the aglycone would point to the solvent with no close contacts to the 
protein (Figure 4A). The top-ranked pose from Glide XP33 induced-fit docking presents an 
alternative pose where the ligand lies “flat” on the receptor and the phenyl aglycone makes a 
close contact with a hydrophobic cavity formed by the side chains of Phe313 and Leu371 
(Figure 4B). This docking pose perfectly explains the large STD values of the aromatic 
protons of phenyl Lex (3, Figure 2C), indicating a close proximity to DC-SIGN. 
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Figure 4. A) When phenyl Lex (3) binds to DC-SIGN in a manner comparable to methyl Lex (2) 
(Figure 3A) and LNFP III (Figure 1A), the phenyl aglycone points to the solvent (black arrow), not 
exhibiting an apparent protein contact. B) The induced-fit docking pose for phenyl Lex (3) shows an 
interaction of the phenyl aglycone with the hydrophobic cleft formed by Phe313 and Leu371, 
rationalizing the strong aromatic proton signals in STD NMR. 	
  
Because of smaller overlaps of the resonances in the H-NMR spectrum of phenyl Lea (4), its 
STD NMR analysis is more detailed. The automated docking pose of phenyl Lea (Figure 5) is 
similar to phenyl Lex (3) where L-Fuc coordinates to Ca2+ via the two equatorial hydroxyl 
groups at the 2- and 3-position. In addition, H-bonds from 2-OH to both Glu354 and Asn365 
and between 3-OH and Glu347 are formed. The D-Gal moiety lies close to the primary 
binding site forming two H-bonds from 6-OH to Glu347 and from 2-OH to Ser360 (not 
shown). The phenyl aglycone occupies the same hydrophobic pocket (Phe313 and Leu371) as 
phenyl Lex (3) (Figure 4B), rationalizing the large STD values for the aromatic protons 
(Figure 2D). Moreover, D-GlcNAc also interacts via a H-bond between its 6-OH and Asp367, 
which in turn bridges this H-bond to Lys373. In the proposed orientation, the D-GlcNAc 
moiety of phenyl Lea (4) is in closer contact with the receptor compared to methyl Lea (2) 
(Figure 3B), which explains the observed larger STD values for the D-GlcNAc protons. 
Dynamic stability of this novel binding mode was confirmed by molecular dynamics 
simulation.  
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Figure 5. Binding mode of phenyl Lea (4) to DC-SIGN. Binding of the phenyl aglycone in the 
hydrophobic cleft formed by Phe313 and Leu371 and proximity of the D-GlcNAc moiety to protein 
surface coincides with the measured STD NMR values (Figure 2D). 
 
2.4. Mutagenesis Studies. To further confirm the proposed hydrophobic interaction between 
Phe313 and the aromatic aglycone, the known DC-SIGN CRD F313A22 was expressed and 
the binding affinities for methyl Lea (2) and phenyl Lea (4) were determined. Table 2 
summarizes the results of the competitive binding assay with wild type and mutant 
DC-SIGN CRD. L-Fuc was included as reference compound. The F313A mutation should not 
have an impact on binding affinity of L-Fuc since the monosaccharide is assumed to bind 
exclusively in the primary binding site.22 However, L-Fuc showed a lower IC50 value for the 
mutant protein (IC50 3.9 mM) than for the wild type (IC50 7.6 mM). This can be explained by 
the lower affinity of Lea-PAA for the F313A mutant, reflected by the EC50 value (Table 2). 
For a better comparison we state relative IC50 values (rIC50) with L-Fuc as reference 
(Table 2). 
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Table 2. Results of the competitive binding assay for L-Fuc, methyl Lea (2), and phenyl Lea (4) with 
wild type and mutant DC-SIGN. The observed differences in the absolute inhibitory potencies 
between wild type and mutant are due to different binding affinities to Lea-PAA reflected by a higher 
EC50 value (half maximal effective concentration) in case of the mutant protein. The rIC50 values of 
methyl Lea (2) and phenyl Lea (4) with L-Fuc as reference were determined by dividing the respective 
IC50 values by the IC50 of L-Fuc; a value below 1 resembles higher affinity than L-Fuc. Detailed 
information on protein expression and competitive binding assay is given in the experimental section.	
  	
  
Ligand DC-SIGN  wild type 
DC-SIGN  
F313A mutant 
EC50 Lea-PAA 66.9 ± 0.3 ng/ml 111.2 ± 0.2 ng/ml 
rIC50 L-Fuc 1 1 
rIC50 methyl Lea (2) 0.38 0.46 
rIC50 phenyl Lea (4) 0.12 0.43 
Factor of 2 to 4 3.2  1.1  	
  
In Figure 6, inhibition curves for methyl Lea (2) and phenyl Lea (4) with wild type and mutant 
DC-SIGN CRD-Fc are shown. Graph A visualizes the aforementioned difference in binding 
affinity of methyl Lea (2) and phenyl Lea (4) to wild type DC-SIGN (factor 3.2). In contrast, 
both compounds exhibited near identical binding affinities (factor 1.1, Figure 6B) for the 
F131A mutant, which indicates the omission of the beneficial hydrophobic contact of Phe313 
with the phenyl aglycone. 	
  	
  
A 	
   B 	
  
Figure 6. Inhibition curves for methyl Lea (2) and phenyl Lea (4) obtained from the competitive 
binding assay, with (A) wild type DC-SIGN and (B) F313A mutant.	
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3. Conclusion 
 
STD NMR spectroscopy and molecular modeling supplemented with a protein mutation study 
were used to rationalize diverging binding modes of Lea and Lex antigens to DC-SIGN 
induced by the nature of the aglycone. The originally found improved binding affinity of 
phenyl Lex (3) and phenyl Lea (4) indicated a contribution of the phenyl aglycone to binding, 
presumably by a hydrophobic contact with the protein. Strong STD NMR values further 
confirmed this assumption. Docking and MD studies finally revealed a novel favorably 
interaction of the phenyl aglycone with a hydrophobic pocket formed by Phe313 and Leu371. 
With a single-point mutation of the DC-SIGN CRD the proposed interactions of the phenyl 
aglycone of 4 with Phe313 could be verified.  
 
Here, we report an interesting example, illustrating how flexible binding modes on shallow 
protein surfaces can be, especially when the starting affinity is low, a situation often present 
in carbohydrate-lectin interactions. Therefore, improved affinities induced by structural 
modifications should be carefully analyzed regarding possible reorientations of binding 
modes. STD NMR experiments28,29 represent an excellent tool for this endeavor. Based on the 
new binding mode of phenyl Lex (3) and phenyl Lea (4), the interaction within the 
hydrophobic pocket formed by Phe313 and Leu371 provides a promising rational for the 
design of more potent DC-SIGN antagonists.  
 
Our study demonstrates the value of this additional interaction with the hydrophobic cleft 
formed by Phe313 and Leu371, which in fact leads to a switch in the binding mode for Lea 
and Lex upon introduction of an aromatic aglycone. Making use of this interaction is 
therewith a promising rational for the design of more potent DC-SIGN antagonists and was 
already approached with a series of glycomimetics by Bernardi et al., recently.24 
	
  
	
  
4. Experimental section 
 
4.1. Ligands. Methyl Lex (1) and methyl Lea (2) were purchased from Toronto Research 
Chemicals Inc. Phenyl Lex (3) and phenyl Lea (4) were prepared according to ref 34. 
 
4.2. Cloning of DC-SIGN CRD-IgG(Fc). Plasmids containing the full-length cDNA of DC-
SIGN were kindly provided by Daniel A. Mitchell (Glycobiology Institute, Department of 
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Biochemistry, University of Oxford). Standard molecular techniques35 were used for the 
cloning of the carbohydrate recognition domain of DC-SIGN (DC-SIGN CRD; aa residues 
250-404, GenBank accession no. M98457). The DC-SIGN CRD encoding insert was 
amplified by PCR using specific forward and reverse primers containing the restriction sites 
EcoRI and NcoI (New England BioLabs, Allschwil, Switzerland), respectively. The insert was 
ligated into the corresponding cloning site of the pFUSE-hIgG2-Fc2 expression vector 
(Invivogen, Toulouse, France). The construct was amplified in chemocompetent DH5α E. coli 
(Novagen, Lucerne, Switzerland). After plasmid minipreparation and restriction control, the 
construct correctness was confirmed by DNA sequencing. 
 
4.3. Expression and purification of DC-SIGN CRD-Fc. CHO-K1 cells (American Type 
Culture Collection No. CCL-61TM) were cultivated in Ham’s Nutrient Mixture F-12 
(Invitrogen, Paisley, UK) supplemented with 2 mM L-glutamate, 10% fetal calf serum (FCS, 
Invitrogen, Paisley, UK), 100 U/mL penicillin, and 100 µg/mL streptomycin (Sigma-Aldrich, 
Basel, Switzerland). The cells were cultivated as monolayers in tissue culture flasks (Nunc, 
Roskilde, Denmark). The CHO-K1 cells were transfected with the DC-SIGN CRD expression 
vector using the FuGENE® HD transfection reagent (Roche Applied Science, Rotkreuz, 
Switzerland) following to the instructions of the supplier. Stably transfected CHO-K1 cells 
were selected by treatment with ZeocinTM (0.5 µg/ml, Invitrogen, Paisley, UK) and single 
clones were obtained by limiting dilution. For DC-SIGN CRD-Fc production the cells were 
cultivated as described above and the culture medium, containing the secreted DC-
SIGN CRD-Fc chimera was harvested weekly, adjusted to pH 7.6 and sterile filtrated 
(conditioned medium). 
The purification of the recombinant protein was achieved by applying conditioned medium on 
a protein A-sepharose column (BioVision, Mountain View, CA, USA) attached to a fast 
protein liquid chromatography apparatus (BioLogic (FPLC) system, BioRad, Reinach BL, 
Switzerland), which was previously equilibrated with loading buffer I (20 mM Tris/HCl, pH 
7.6, 150 mM NaCl, 0.05% (v/v) Tween-20TM). The protein was eluted with elution buffer I 
(0.5 M acetic acid/ammonium acetate, pH 3.4). The collected protein was further purified on a 
L-Fuc-sepharose column (prepared in house) using loading buffer II (20 mM Tris/HCl, pH 
7.8, 0.5 M NaCl, 25 mM CaCl2) and elution buffer II (20 mM Tris/HCl, pH 7.8, 0.5 M NaCl, 
2 mM EDTA). For long-term storage, the protein was frozen at -80 °C.  
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4.4. Cloning of the F313A DC-SIGN CRD mutant. The PCR overlap extension method36 
was used for the substitution of the codon TTC against CGC at cDNA bp 968-970, resulting 
in the mutation of phenyl alanine 313 to an alanine. In a first step, two overlapping DNA 
fragments were generated separately, both using wild type DC-SIGN cDNA as template (PCR 
1: primer fw: 5` g gaa ttc cat atg gaa cgc ctg tgc cac ccc 3` and primer F313A rv: 5`tcc aga agt 
aac cgc gcg acc tgg atg gga 3`; PCR 2: primer F313A fw: 5`aag tcc cat cca ggt cgc gcg gtt act 
tct 3` and primer rv: 5` cgc gga tcc tta cta cgc agg agg ggg gtt tgg g 3`). The two internal 
primers contained a mismatch for the site-directed base substitution (bold). In a second step, 
both overlapping DNA fragments were elongated to the full-length gene, containing the single 
point mutation. The NdeI and BamHI (New England BioLabs, Allschwil, Switzerland) treated 
insert was ligated into the corresponding cloning site of the expression vector pET-3a. After 
E.coli DH5α transformation, plasmid minipreparation, the mutation was confirmed by DNA 
sequencing. Finally, for protein expression the construct was transformed into BL21 E.coli 
(Novagen, Lucerne, Switzerland).  
 
4.5. Expression and purification of F313A DC-SIGN CRD mutant. Protein expression 
was carried out in TB medium (terrific broth) containing 100 µg/mL ampicillin (Applichem, 
Darmstadt, Germany). The bacteria were cultured at 37 °C until an OD600 of 1.0 was reached. 
The expression was induced by the addition of isopropyl-β-D-thiogalactoside (IPTG, 
Applichem, Darmstadt, Germany) at the final concentration of 0.4 mM. The cells were further 
cultivated for 12 h, prior to harvesting by centrifugation at 4000 rpm for 20 min at 4 °C. For 
bacterial lysis, the pellet was dissolved in 20 mM Tris-HCl buffer, pH 7.8, 0.5 M NaCl, 
containing 1 mg/mL lysozym (Sigma, Buchs, Switzerland) and incubated for 30 min at 4 °C 
under shaking. The inclusion bodies were solubilized by addition of β-mercaptoethanol (0.01 
% v/v), urea (8 M), and brief sonication followed by gentle rotation for 30 min at 4 °C. The 
mixture was centrifuged at 22000 rpm for 1 h at 4°C and the supernatant was diluted by slow 
addition of the fivefold volume loading buffer II. The mixture was dialyzed against 6 volumes 
of loading buffer II with 6 buffer exchanges. After dialysis, insoluble precipitate was removed 
by centrifugation at 22000 rpm for 1 h at 4°C. The protein was purified using a L-Fuc-
sepharose column as described above. 
Protein purity was confirmed by standard SDS-PAGE analysis37 followed by Coomassie 
Brilliant Blue G-250 staining (Bio-Rad laboratories, Hercules, CA, USA). Protein 
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concentration was determined either by the Bradford method (Bio-Rad laboratories, Hercules, 
CA, USA) or with HPLC38.  
 
4.6. Competitive binding assay. Biotinylated Lea-PAA polymer (20 µL, 1 mg/mL, 
GlycoTech, Gaithersburg, MD, USA) was mixed with 80 µL assay buffer (20 mM HEPES, 
150 mM NaCl, 10 mM CaCl2, pH 7.4), 20 µL FCS and 80 µL streptavidin-horseradish 
peroxidase-conjugate (500 U/mL, Roche, Mannheim, Germany) and incubated for 2 h at 37 
°C. The complex was stable for several weeks when stored at 4 °C. 
Flat-bottom 96-well microtiter plates (F96 MaxiSorp, Nunc) were coated with 100 µL/well of 
a 2.5 µg/mL solution of DC-SIGN CRD-Fc protein in assay buffer overnight at 4 °C in a 
humidified chamber. The coating solution was discarded and the wells were blocked with 200 
µL/well of 3% bovine serum albumin (BSA, Sigma-Aldrich, Buchs, Germany) in assay buffer 
for 2 h at 4 °C. After three washing steps with assay buffer (150 µL/well), a serial dilution of 
the test compound (25 µL/well) in assay buffer and streptavidin-peroxidase coupled Lea-PAA 
(25 µL/well, 0.25 µg/mL final concentration) were added. Subsequent to an incubation of 3 h 
at room temperature and 350 rpm the plate was carefully washed four times with 200 µL/well 
assay buffer. Lea-PAA binding was detected by addition of 100 µL/well of ABTS-substrate 
(2,2’-azino-bis-(3-ethylbenzthiazoline-6-sulfonic acid, Invitrogen, Paisley, UK). The 
colorimetric reaction was allowed to develop for 2 min, then stopped by the addition of 2% 
aqueous oxalic acid before the optical density (OD) was measured at 415 nm on a microplate-
reader (Spectramax 190, Molecular Devices, Ca, USA). The IC50-values were calculated 
using the Prism software (GraphPad Software, Inc, La Jolla, USA). The IC50 (half maximal 
inhibitory concentration) defines the molar concentration of the test compound that reduces 
the maximal specific binding of carbohydrate-polymer to DC-SIGN-CRD-Fc by 50%.  
For EC50 determination (half maximal effective concentration) of the Lea-PAA, the assay was 
performed as described above with a serial dilution of Lea-PAA (0-3 µg/mL) in absence of 
antagonist. 
 
4.7. Isothermal titration calorimetry. ITC experiments were performed at 298 K and a 
reference power of 10 µcal/sec under constant stirring speed of 307 rpm using a MicroCal 
VP-ITC instrument (MicroCal, Northampton, MA). The concentration of DC-SIGN CRD-Fc 
was determined by HPLC-UV against a standard curve of BSA at 210 nm 38 after extensive 
dialysis against 10 mM HEPES, 150 mM NaCl, 10 mM CaCl2, pH 7.4. The ligand was 
diluted in the dialysat. Injections of 3-5 µl ligand solutions were added from a syringe at an 
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interval of 5 min into the sample cell solution containing DC-SIGN CRD-Fc (cell volume 
1.45 ml). Control experiments were performed, where identical ligand solutions were injected 
into buffer without protein, and showed insignificant heat of dilution. The experimental data 
were fitted to a theoretical titration curve (one site binding model) using Origin software 
(version 7, MicroCal). The quantity c=Mt(0)/KD with Mt(0) as initial macromolecule 
concentration, is of importance in titration microcalorimetry.39 The experiments were 
performed with c values below 1. The stoichiometry was fixed to 1 (concentration expressed 
in terms of binding site) to allow reliable determination of KD and ∆H.40, 41 Thermodynamic 
parameters were calculated from the equation 1,  
  
€ 
ΔG° = ΔH° − TΔS° = −RTlnKA = RTlnKD  (eq. 1) 
where ∆G°, ∆H°, and ∆S° are the changes in free energy, enthalpy, and entropy of binding, 
respectively. T is the absolute temperature, and R = 8.314 J/mol/K. 
 
4.8. STD NMR. Experiments were performed on a Bruker 11.7 T spectrometer with an 
Avance III console at a temperature of 298 K. Shigemi NMR tubes with a sample volume of 
250 µL were used for the measurements. Each sample contained 20-30 µM DC-SIGN CRD-
Fc (dimer) and 1-2 mM ligand. A d-Tris buffer was used as solvent containing 20 mM d-
TRIS (98% Cambridge Isotope Libraries), 4 mM CaCl2 and 150 mM NaCl in D2O (99.8% 
Sigma-Aldrich) adjusted to a pH of 8.1 with HCl. 
 
Using a pulse sequence modified from Meyer et al.28 allows simultaneous saturation of the 
protein at two frequencies which leads to a more intense STD epitope. The cosine modulated 
E-Burp-1 pulse42 for the on resonance spectrum was centered at 1555 Hz and resulted in two 
sidebands at 0 and 3110 Hz with a power of 53 dB .43 The duration of each of the 40 E-Burp-1 
pulses used to saturate the protein was 50 ms with a 1ms recovery between the pulses. 
Off-resonance excitation was set to 26000 Hz. STD NMR experiments were performed 
applying a Watergate solvent suppression. Specific parameters were determined via 
preliminary experiments including negative control experiments with only ligand-containing 
sample to avoid artifacts from direct excitation. Scaling each STD signal on an off-resonance 
reference spectrum resulted in a relative binding epitope (approximate values).30 Ligand 
resonances were assigned by using 2D NMR and 1D selective TOCSY experiments. Not all 
protons could be assigned doubtlessly, due to solvent suppression and partial signal overlap. 
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Detailed conditions: STD NMR of methyl-bearing compounds: 2 mM ligand with 20 µM 
DC-SIGN CRD-Fc, STD NMR of phenyl Lea: 1 mM ligand with 20 µM DC-SIGN CRD-Fc, 
STD NMR of phenyl Lex: 1 mM with 30 µM DC-SIGN CRD-Fc; number of scans was 
typically 14k for on-resonance spectra and 512 for off-resonance spectra. 
Experiments with different saturation times were performed for phenyl Lea. These data 
indicate an overall consistent epitope at either saturation times of 0.7, 1, 2, and 3 s and 
exclude misinterpretation due to T1 bias for different proton species. 
 
4.9. Docking studies. All ligands were manually built using Maestro, and optimized using 
standard procedures. Model for DC-SIGN in complex with LNFP III was downloaded from 
the Protein Data Bank (code: 1SL5). Hydrogens were added and water molecules were 
removed using Maestro Protein Preparation Wizard. Partial charges were calculated from 
OPLS2005 force field while protonation states and oxidation states for metals were assigned 
by Epik 44 Orientation of added hydrogens was sampled for optimal H-bond formation and 
the model was then refined by minimization within RMSD of 0.3Å. 
GlideXP33 was used for docking of novel ligands to DC-SIGN. To account for the possibility 
of side chain re-organization upon ligand binding the Induced-Fit Docking (IFD) 
methodology was employed 45. The binding site was defined to include residues within 5 Å 
radius around the co-crystallized ligand LNFP III in the prepared complex. In the initial 
stages of IFD protocol amino acids within 5 Å radius around any found pose were considered 
as flexible, and their side chain conformations were optimized. Up to 50 poses were retained 
for each calculation within an energy window of 40 kcal/mol to allow for larger diversity in 
output poses. Prioritization was done by Standard Precision (SP) 46 scoring function in the 
initial soft-docking stage followed by more rigorous Extra Precision (XP)47 scoring in the 
redocking stage. Output poses were then visually inspected for agreement with STD NMR 
experiment, and those showing considerable discrepancy were disregarded. Stability of the 
proposed modes was assessed using molecular dynamics.	
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Competitive binding assay results 
Nr.	
   Structure	
   IC50	
  	
  (binding	
  assay,	
  Lea-­‐PAA)	
   rIC50	
   Refe-­rence	
  
AV33	
  
(Ph	
  Lea)	
  
	
  
0.28	
  mM/16.12.09	
  0.14	
  mM/11.02.10	
  0.46	
  mM/16.04.10	
  0.7	
  mM/20.04.10	
  0.75	
  mM/22.04.10	
  0.77	
  mM/23.04.10	
  1.39	
  mM/22.06.10	
  	
  1.13	
  mM/24.06.10	
  0.71	
  mM/25.06.10	
  0.95	
  mM/21.07.10	
  1.3	
  mM/23.07.10	
  1.2	
  mM/24.11.10	
  1.1	
  mM/29.03.11	
  0.82	
  mM/30.03.11	
  0.67	
  mM/31.03.11	
  1.2	
  mM/01.04.11	
  0.64	
  mM/16.06.11	
  0.73	
  mM/17.06.11	
  0.99	
  mM/07.07.11	
  
1	
  1	
  1	
  1	
  1	
  1	
  1	
  1	
  1	
  1	
  1	
  1	
  1	
  1	
  1	
  1	
  1	
  1	
  1	
  
	
  
Me	
  Lea	
  (Toronto	
  Research	
  Chemicals,	
  Canada)	
  
	
  
2.45	
  mM/16.12.10	
  2.69	
  mM/24.06.10	
  1.96	
  mM/25.06.10	
  3.48	
  mM/19.10.10	
  
8.75	
  3.7	
  2.7	
  3.6	
  
Ph	
  Lea	
  Ph	
  Lea	
  	
  Ph	
  Lea	
  Ph	
  Lea	
  
Lea	
  
	
  
2.8	
  mM/17.07.09	
   6.08,	
  relative	
  to	
  mean	
  value	
  of	
  AV33	
  results:	
  0.46	
  mM	
  
Ph	
  Lea	
  
BW558	
  
(Ph	
  Lex)	
  
	
  
0.87	
  mM/16.12.09	
  0.29	
  mM/11.02.10	
  1.62	
  mM/14.10.10	
   3.1	
  2.1	
   Ph	
  Lea	
  Ph	
  Lea	
  
Me	
  Lex	
  (Toronto	
  Research	
  Chemicals,	
  Canada)	
  
	
  
2.4	
  mM/24.06.10	
  2.2	
  mM/25.06.10	
   3.4	
  3.1	
   Ph	
  Lea	
  Ph	
  Lea	
  
OOO
NHAc
O
OHO
O
HO
HOOH
OH
HO OH
HO
OH
OOO
NHAc
OMe
OHO
O
HO
HOOH
OH
HO OH
HO
OH
OOO
AcNH
OHO
O
HO
HOOH
OH
HO OH
HO
OH OH
OO
O
O
O
HOOH
OH
AcNH
OH
OH
HO
HO
HO
O
OO
O
O
O
HOOH
OH
NHAc
OMe
OH
OH
HO
HO
HO
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Lex	
  
	
  
3.8	
  mM/17.07.09	
   8.1,	
  relative	
  to	
  mean	
  value	
  of	
  AV33	
  results:	
  0.46	
  mM	
  
Ph	
  Lea	
  
L-­fucose	
  
	
  
15.5	
  mM/10.10.08	
  10.8	
  mM/12.01.09	
  9.7	
  mM/20.02.09	
  6.2	
  mM/07.05.09	
  3.5	
  mM/08.05.09	
  13.9	
  mM/25.05.09	
  11.0	
  mM/09.02.10	
  11.4	
  mM/14.04.10	
  4.10	
  mM/15.04.10	
  4.86	
  mM/16.04.10	
  8.75	
  mM/20.04.10	
  5.4	
  mM/23.04.10	
  6.1	
  mM/23.04.10	
  9.58	
  mM/21.07.10	
  
	
  	
  	
  	
  	
  	
  	
  	
  	
  10.5	
  12.5	
  7.2	
  
	
  	
  	
  	
  	
  	
  	
  	
  	
  Ph	
  Lea	
  Ph	
  Lea	
  Ph	
  Lea	
  
L-­fucose	
  
	
  
4.06	
  mM/10.10.08	
  3.98	
  mM/10.03.09	
  3.0	
  mM/13.03.09	
  2.0	
  mM/30.06.10	
  2.5	
  mM/30.06.10	
  vs.	
  trimannose-­‐biotin-­‐PAA	
  
m.	
  v.:	
  3.68	
  ±	
  0.59	
   Ph	
  Lea	
  
L-­fucose	
  
	
  
0.94	
  mM/09.06.10	
  1.10	
  mM/30.06.10	
  1.01	
  mM/30.06.10	
  vs.	
  mannose-­‐biotin-­‐PAA	
  
	
   	
  
D-­
mannose	
  
	
  
7.7	
  mM/15.04.10	
  8.23	
  mM/21.04.10	
  10.31	
  mM/23.04.10	
  10.28	
  mM/18.08.10	
  
	
   	
  
D-­
mannose	
  
	
  
1.7	
  mM/09.06.10	
  1.27	
  mM/30.06.10	
  2.1	
  mM/18.08.10	
  vs.	
  mannose-­‐biotin-­‐PAA	
  
	
   	
  
D-­
mannose	
  
	
  
2.72	
  mM/30.06.10	
  2.58	
  mM/30.06.10	
  2.5	
  mM/18.08.10	
  vs.	
  trimannose-­‐biotin-­‐PAA	
  
	
   	
  
Me	
  α-­D-­
mannosid
e	
  
	
  
10.3	
  mM/12.01.09	
  6.8	
  mM/24.06.10	
  7.1	
  mM/25.06.10	
   	
  9.6	
  10	
   	
  Ph	
  Lea	
  Ph	
  Lea	
  
D-­glucose	
   	
   21.6	
  mM/24.06.10	
  23.3	
  mM/25.06.10	
   30.4	
  32.8	
   Ph	
  Lea	
  Ph	
  Lea	
  
OO
O
O
O
HOOH
OH
AcNH
OH
OH
HO
HO
HO
OH
O
HOOH
OH
OH
O
HOOH
OH
OH
O
HOOH
OH
OH
O
HO
HO
HO
OH
OH
O
HO
HO
HO
OH
OH
O
HO
HO
HO
OH
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O
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KM	
  65	
  
KM	
  80	
  
	
  
0.79	
  mM/11.02.10	
  1.67	
  mM/22.04.10	
  1.69	
  mM/23.04.10	
  1.69	
  mM/22.06.10	
  1.35	
  mM/24.06.10	
  2.45	
  mM/21.07.10	
  2.5	
  mM/	
  23.07.10	
  
5.7	
  2.2	
  2.2	
  1.2	
  1.2	
  2.5	
  1.9	
  
Ph	
  Lea	
  Ph	
  Lea	
  Ph	
  Lea	
  Ph	
  Lea	
  Ph	
  Lea	
  Ph	
  Lea	
  Ph	
  Lea	
  
KM	
  73	
  
	
  
0.84	
  mM/11.02.10	
  1.39	
  mM/22.04.10	
  1.79	
  mM/23.04.10	
  1.4	
  mM/24.06.10	
  2.56	
  mM/21.07.10	
  
6	
  1.84	
  2.3	
  1.2	
  2.7	
  
Ph	
  Lea	
  Ph	
  Lea	
  Ph	
  Lea	
  
KM	
  106	
  
	
  
1.9	
  mM/22.04.10	
  2.36	
  mM/23.04.10	
  3.14	
  mM/22.06.10	
  2.15	
  mM/24.06.10	
  3.75	
  mM/21.07.10	
  
2.5	
  3.0	
  2.3	
  1.9	
  3.9	
  
Ph	
  Lea	
  Ph	
  Lea	
  Ph	
  Lea	
  Ph	
  Lea	
  Ph	
  Lea	
  
KM	
  149	
  
	
  
1.8	
  mM/22.06.10	
  1.6	
  mM/22.06.10	
  2.37	
  mM/21.07.10	
  2.65	
  mM/	
  23.07.10	
  	
  
1.3	
  1.6	
  2.5	
  2.0	
  
Ph	
  Lea	
  Ph	
  Lea	
  Ph	
  Lea	
  Ph	
  Lea	
  
KM	
  151	
  
	
  
4.25	
  mM/22.06.10	
  2.25	
  mM/24.06.10	
  3.35	
  mM/21.07.10	
  2.95	
  mM/	
  23.07.10	
  
3.1	
  2	
  3.5	
  2.3	
  
Ph	
  Lea	
  Ph	
  Lea	
  Ph	
  Lea	
  Ph	
  Lea	
  
KM	
  153	
  
	
  
5.6	
  mM/22.06.10	
  3.7	
  mM/24.06.10	
  4.79	
  mM/21.07.10	
   5.6	
  3.6	
  5.0	
   Ph	
  Lea	
  Ph	
  Lea	
  Ph	
  Lea	
  
KM	
  166	
  
	
  
2.73	
  mM/21.07.10	
  2.34	
  mM/	
  23.07.10	
  1.35	
  mM/07.07.11	
   2.9	
  1.8	
  1.35	
   Ph	
  Lea	
  Ph	
  Lea	
  
KM	
  244	
  
	
  
0.98	
  mM/30.03.11	
  1.22	
  mM/17.06.11	
  	
   1.2	
  1.6	
   Ph	
  Lea	
  Ph	
  Lea	
  
KM	
  232	
  
	
  
1.84	
  mM/30.03.11	
  0.29	
  mM/16.06.11	
  1.33	
  mM/07.07.11	
   2.24	
  0.45	
  1.33	
   Ph	
  Lea	
  Ph	
  Lea	
  Ph	
  Lea	
  
KM	
  256	
  
	
  
1.2	
  mM/30.03.11	
  0.36	
  mM/16.06.11	
  1.34	
  mM/07.07.11	
   1.45	
  0.56	
  1.34	
   Ph	
  Lea	
  Ph	
  Lea	
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Chemical Formula: C24H34FNO13
Exact Mass: 563.20
Molecular Weight: 563.52
m/z: 563.20 (100.0%), 564.20 
(26.3%), 565.21 (6.1%), 566.21 
(1.0%)
Chemical Formula: C18H24FNO7
Exact Mass: 385.15
Molecular Weight: 385.38
m/z: 385.15 (100.0%), 386.16 
(20.0%), 387.16 (3.3%)
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(20.4%), 403.16 (1.9%), 403.15 (1.7%)
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KM	
  280	
  
	
   	
  
0.36	
  mM/16.06.11	
  0.63	
  mM/17.06.11	
  	
   0.56	
  0.86	
   Ph	
  Lea	
  Ph	
  Lea	
  
KM	
  277	
  
	
  
1.05	
  mM/16.06.11	
  1.2	
  	
  mM/17.06.11	
   1.64	
  1.64	
   Ph	
  Lea	
  Ph	
  Lea	
  
AV124	
  
	
  
No	
  inhibition	
   	
   	
  
AV137	
  
	
  
	
  no	
  inhibition!	
  	
   	
   	
  
AV144	
  
	
  
	
  low	
  solubility!	
  low	
  inhibition	
  starting	
  at	
  approx.	
  5	
  mM!	
  
	
   	
  
AV176	
  
	
  
1.02	
  mM/	
  25.08.10	
  1.76	
  mM/	
  25.10.10	
   	
   	
  
AV33b	
  
	
  
3.14	
  mM/	
  25.08.10	
  2.79	
  mM/	
  25.10.10	
   	
   	
  
AV257	
  
	
  
1.01	
  mM/	
  01.04.11	
   0.84	
   Ph	
  Lea	
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AV278	
  
	
  
3.89	
  mM/	
  01.04.11	
   3.24	
   Ph	
  Lea	
  
AV267	
  
	
  
0.97	
  mM/	
  31.03.11	
   1.44	
   Ph	
  Lea	
  
AV270	
  
	
  
1.99	
  mM/	
  31.03.11	
   2.97	
   Ph	
  Lea	
  
AV256	
  
	
  
2.54	
  mM/	
  31.03.11	
   3.79	
   Ph	
  Lea	
  
GMI-­1084	
  
(Glyco-­	
  
Mimetics)	
  
	
  
0.76	
  mM/07.05.09	
  
0.45	
  mM/08.05.09	
  
0.93	
  mM/29.05.09	
   	
   	
  
K784-­
1848	
  (Kiessling)	
  
	
  
17.09	
  µM/27.08.09	
  
26.37	
  µM	
  /15.09.09	
  
28.33	
  µM	
  /17.09.09	
   	
   	
  
K784-­
1581	
  (Kiessling)	
  
	
  
49.34	
  µM	
  /27.08.09	
  
39.45	
  µM	
  /15.09.09	
  
39.25	
  µM	
  /17.09.09	
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K593-­
1866	
  (Kiessling)	
  
	
  
80.51	
  µM	
  /27.08.09	
  
149.3	
  µM	
  /15.09.09	
  
152.1	
  µM	
  /17.09.09	
   	
   	
  
K584-­
1572	
  (Kiessling)	
  
	
  
n.d./27.8.09	
  
178.1	
  µM	
  /15.09.09	
  
261.7	
  µM	
  /17.09.09	
   	
   	
  
TK05	
  
	
  
17.02.09	
  
no	
  inhibition	
  up	
  to	
  
1	
  mM	
  vs.	
  trimannose	
  PPA	
  
	
   	
  
TK14	
  
	
  
17.02.09	
  
no	
  inhibition	
  up	
  to	
  
1	
  mM	
  vs.	
  trimannose	
  PPA	
  
	
   	
  
TK15	
  
	
  
17.02.09	
  12.03.09	
  
no	
  inhibition	
  up	
  to	
  
1	
  mM	
  vs.	
  trimannose	
  PPA	
  
	
   	
  
TK17	
  
	
  
17.02.09	
  
no	
  inhibition	
  up	
  to	
  
1	
  mM	
  vs.	
  trimannose	
  PPA	
  
	
   	
  
TK22	
  
	
  
12.03.09	
  
no	
  inhibition	
  up	
  to	
  
1	
  mM	
  vs.	
  trimannose	
  PPA	
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TK28	
  
	
  
17.02.09	
  
no	
  inhibition	
  up	
  to	
  
1	
  mM	
  vs.	
  trimannose	
  PPA	
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